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ABSTRACT 
Neurite outgrowth is an important process for the establishment of synaptic connections 
during development, as well as neuronal regeneration in neuropathological conditions or 
injury. With growing concerns over neurodegenerative diseases attributed to impairment 
of neurite outgrowth e.g. dementia and Alzheimer’s disease, identification of alternative 
therapeutics has become paramount. One way to prevent and/or delay the onset of such 
diseases is by discovering alternative therapeutic molecules from functional foods. One 
such candidate is the edible mushroom (higher Basidiomycetes). In this study, eight 
culinary-medicinal mushrooms were evaluated for neurite outgrowth stimulatory effects 
by using neuroblastoma-2a (N2a) cells as an in vitro model. The mushroom extracts 
were also subjected to in vitro neuro- and embryotoxicity tests using N2a and 3T3 
fibroblasts cell lines. The preliminary results showed that the aqueous extract of 
Pleurotus giganteus significantly (p < 0.05) promoted neurite outgrowth in N2a cells by 
33.4 ± 4.6%. The IC50 values obtained from tetrazolium (MTT), neutral red uptake 
(NRU) and lactate dehydrogenase (LDH) release assays showed no toxic effects 
following 24 hours exposure of N2a and 3T3 cells to the mushroom extract. The 
basidiocarps of P. giganteus were then analysed for various nutritional attributes. The 
mushroom composed of protein (15.4–19.2 g/100 g), polysaccharides, phenolics, and 
flavonoids as well as vitamins B1, B2, and B3. The antioxidant properties of the 
aqueous and ethanol extracts of P. giganteus were investigated. The results indicated 
that the aqueous extract of P. giganteus exhibited scavenging of 2,2-diphenyl-1-
picrylhyd-razyl (DPPH) radical with an IC50 value of 21.46 ± 6.95 mg/mL. Based on the 
ferric reducing antioxidant power (FRAP) assay, the reducing power of the mushroom 
extracts was in the range of 1.17–3.88 µM FeSO·7H2O/g mushroom and the ethanol 
extract showed lipid peroxidation inhibitory activity of 49.58–49.80%. The efficacy of 
the chemical constituents of P. giganteus (linoleic acid, oleic acid, cinnamic acid, 
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caffeic acid, p-coumaric acid, succinic acid, benzoic acid, and uridine) for neurite 
outgrowth activity was investigated. Uridine (100 µM) increased the number of neurite 
bearing cells by 43.1 ± 0.5%, which was about 1.8-fold higher than NGF (50 ng/mL)-
treated cells. In this study, we demonstrated that uridine of P. giganteus (1.80 ± 0.03
 
g/100g mushroom extract) increased the phosphorylation of extracellular-signal 
regulated kinases (ERKs) and protein kinase B (Akt); simultaneously promoting neurite 
outgrowth in N2a cells. Neurite outgrowth stimulatory activity was inhibited by the 
inactivation of mitogen-activated protein kinase (MEK)/ERKs and Akt signaling with 
specific inhibitors. Further, phosphorylation of the mammalian target of rapamycin 
(mTOR) was also increased. MEK/ERK and PI3K-Akt-mTOR further induced 
phosphorylation of cAMP-response element binding protein (CREB) and expression of 
growth associated protein 43 (GAP43), tubulin alpha 4a (TUBA4A), and tubulin beta 1 
(TUBb1); all of which promoted neurite outgrowth of N2a cells. In conclusion, these 
findings demonstrated that P. giganteus may enhance neurite outgrowth and one of the 
key bioactive molecule responsible for neurite outgrowth is uridine. 
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ABSTRAK 
Pengunjuran neurit merupakan satu proses yang penting untuk penubuhan sambungan 
sinaptik semasa perkembangan, dan regenerasi sel saraf (neuron) selepas keadaan 
neuropatologi ataupun kecederaan. Memandangkan penyakit neurodegenerasi yang 
berkaitan dengan kemerosotan pengunjuran neurit (demensia dan penyakit Alzheimer’s) 
semakin ketara, pengenalpastian cara perubatan alternatif menjadi lebih penting. Satu 
cara untuk menghindari dan/atau melewatkan permulaan penyakit tersebut ialah melalui 
penemuan  molekul terapeutik alternatif daripada makan fungsian. Satu calon makan 
fungsian ialah cendawan (Basidiomysit tinggi). Dalam kajian ini, sekoleksi cendawan 
masakan-ubatan telah dinilai dari segi aktiviti perangsangan pengunjuran neurit atas sel 
neuroblastoma-2a (N2a). Ekstrak cendawan juga dinilai secara in vitro dari segi 
ketoksikan saraf dan embrio. Hasil awalan menunjukkan bahawa ekstrak akueus 
Pleurotus giganteus meningkatkan pengunjuran neurit sel N2a secara signifikan (p < 
0.05) sebanyak 33.4 ± 4.6%. Nilai perencatan pada 50% kepekatan (IC50) yang didapati 
daripada asai tetrazolium (MTT), pengambilan neutral red (NRU) dan pembebasan 
laktat dehidrogenase (LDH) menunjukkan ketidakhadiran kesan toksik selepas 
pendedahan sel N2a dan 3T3 fibroblas kepada ekstrak cendawan selama 24 jam. 
Komposisi nutrisi basidiokarp (tubuh buah) P. giganteus juga dianalisa. Cendawan ini 
didapati tinggi dari segi kandungan proteinnya (154–192 g/kg), begitu juga polisakarida, 
fenolik, flavonoid, vitamin B1, B2, dan B3. Sifat antioksidaan ekstrak akueus dan etanol 
P. giganteus turut dikaji. Ekstrak akueus P. giganteus menunjukkan pemulungan radikel 
2,2-diphenyl-1-picrylhyd-razyl (DPPH) pada kepekatan IC50 21.46 ± 6.95 mg/mL. 
Kuasa antioksidaan penurunan ferik ekstrak cendawan adalah dalam lingkungan 1.17–
3.88 µM FeSO·7H2O/g cendawan dan ekstrak etanol menunjukkan aktiviti perencatan 
pengoksidaan lipid sebanyak 49.58–49.80%. Keberkesanan juzuk kimia daripada P. 
giganteus (asid linoleik, asid oleik, asid cinnamic, asid kafeik, asid p-coumaric, asid 
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succinic, asid benzoik dan uridin) dalam pengunjuran neurit turut dikaji. Uridin (100 
µM) meningkatkan peratusan sel yang mengandungi neurit sebanyak 43.1 ± 0.5%, dan 
ini adalah kira-kira 1.8 kali ganda daripada sel yang dirawat dengan NGF (50 ng/mL). 
Dalam kajian ini, uridin daripada P. giganteus (1.796 ± 0.032
 
g/100g ekstrak cendawan) 
meningkatkan pemfosforilan kinase yang dikawalselia oleh isyarat luaran sel (ERKs) 
dan protein kinase B (Akt); dan pada masa yang sama ia menggalakkan pengunjuran 
neurit pada N2a. Penyahaktifan protein kinase yang diaktifkan oleh mitogen 
(MEK)/ERKs dan Akt dengan perencat khusus merencatkan aktiviti stimulasi 
pengunjuran neurit. Tambahan pula, pemfosforilan sasaran mamalia rapamycin (mTOR) 
juga meningkat. MEK/ERK dan PI3K-Akt-mTOR mendorong  pemfosforilan protein 
pengikat elemen tindak balas cAMP dan membawa kepada pengungkapan protein yang 
berkaitan dengan pertumbuhan 43 (GAP 43), tubulin alfa 4a (TUBA4A), dan tubulin 
beta 1(TUBb1); semua ini menggalakkan pengunjuran neurite sel N2a. Secara 
keseluruhannya, kajian ini mencadangkan bahawa P. giganteus mungkin dapat 
meningkatkan kesihatan otak dan persembahan kognitif; dan salah satu molekul bioaktif 
yang memainkan peranan yang penting dalam aktivi pengunjuran neurit ialah uridin.   
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CHAPTER I 
 
1.1 INTRODUCTION 
Many non-communicable diseases (NCDs) are neglected despite causing a considerable 
health burden. One of the NCDs identified is neurodegenerative diseases, such as 
Alzheimer’s disease (AD) and dementia (Lopez et al., 2014). The economic cost of 
neurodegenerative disease is enormous, and is expected to grow rapidly as more people 
live longer. Worldwide, it was estimated that the global medical cost and cost of care 
for dementia, of which AD is the major ailment, was USD 604 billion in 2013. The 
amount is about 1% of the world gross domestic product (Housden et al., 2014). The 
pathological hallmarks of neurological diseases are characterised by impairment of 
neurite outgrowth due to amyloidogenic processing and subsequent β-amyloid cascade, 
neuroinflammation, and free radical generation.  
Current drug therapy for neurodegenerative diseases is ineffective with many 
side effects and it only provides a short term delay in the progression of the disease. 
Further, the drug development pipeline is drying up and the number of innovative drugs 
reaching the market has lagged behind the growing need for such drugs. It is therefore 
of utmost importance to find appropriate solutions to prevent, or perhaps impede, the 
development of neurodegenerative diseases associated with impaired neuritogenesis.  
An alternative approach to prevent or treat such diseases is by complementary 
health approaches, such as dietary supplementations and functional foods. Functional 
food is food that has a potentially positive effect on health beyond basic nutrition. 
Examples of functional food are oatmeal, for its high soluble fibre that can help lower 
cholesterol levels; and orange juice fortified with calcium for bone health. In general, 
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functional food is considered to offer additional benefits that may reduce the risk of 
disease or promote optimal health. Turmeric, green tea, and gingko are the examples of 
functional food that demonstrate therapeutic effects on brain by exerting 
neuroprotective and antioxidant effects. 
Can mushrooms be functional food for brain? Mushrooms have long been 
celebrated as a source of powerful nutrients. It is not new that the polysaccharides found 
in mushrooms are exotic and a broad array of them has been shown to be effective 
immuno-modulating agents (Wasser, 2002). Several compounds isolated from 
mushrooms have been shown to promote neurite outgrowth, for example hericenones 
and erinacines from the lion’s mane mushroom, Hericium erinaceus (Bull.: Fr.) Pers 
(Kawagishi et al., 1991; Phan, Lee, et al., 2014). Other mushrooms found to have 
neurite outgrowth stimulatory activities are Ganoderma lucidum (Fr) P. Karst, Lignosus 
rhinocerotis (Cooke) Ryvarden, Ganoderma neo-japonicum (Fr) P. Karst, and 
Cordyceps militaris (L.:Fr.) Link (Phan, David, Naidu, Wong, & Sabaratnam, 2014).  
The ability of natural product to potentiate neurite outgrowth in vitro is 
considered as the first line screening criteria in order to be regarded as a preventive 
agent for neurodegenerative diseases. Screening of novel natural products that can 
induce neurite outgrowth has routinely been performed in a neuronal cell culture-based 
system. To discover potential neurite outgrowth agents, various neuronal cell models 
originating from mouse, rat or even human were utilised. The goal of this project was to 
identify new potential edible and medicinal mushroom(s) that induce neurite outgrowth. 
Taking the advantage of the tractability and simplicity of the brain neuroblastoma cell 
(N2a) line as a neuronal cell model, it was used to screen mushroom extracts and their 
molecules for potential neurite outgrowth activity.  
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1.2 RESEARCH OBJECTIVES 
The mushroom extracts selected for the screening were Pleurotus giganteus (Berk.) 
Karunarathna & K.D. Hyde, Ganoderma lucidum, Hericium erinaceus, Cordyceps 
militaris, Lignosus rhinocerotis, Pleurotus pulmonarius (Fr.) Quél, Ganoderma neo-
japonicum, and Grifola frondosa (Dicks.: Fr.) S.F. Gray. The screen was performed on 
the premise that the mushrooms were able to enhance neurite outgrowth activity of 
differentiating N2a cells. The activity was deemed effective if the neurite outgrowth 
stimulatory effect of the extracts was significantly higher than that induced by nerve 
growth factor (NGF) which was the positive control. The objectives of this project were 
to: 
a) screen and identify the potential edible and medicinal mushrooms for their 
neurite outgrowth activity and to perform in vitro neuro- and embryo-toxicity  of 
the mushroom extracts 
b) investigate the nutritional composition such as the total polysaccharides, 
phenolics, and flavonoids of the selected mushroom and its antioxidant activity 
c) evaluate the neurite outgrowth  stimulatory activity of the extracts of the selected 
mushroom and its chemical constituents  
d) elucidate the signaling pathways of neuritogenesis induced by the selected 
mushroom extract and its chemical constituents; and to investigate the 
expression of selected neuronal biomarker proteins  
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CHAPTER II 
LITERATURE REVIEW  
2.1 NEURITE OUTGROWTH  
The structural and functional unit which is the core element of the nervous system is 
the neuron or nerve cell. Neurons, unlike any other cells, do not undergo cell division 
(mitosis) and when they die, they are not replaced by new ones. A large number of 
neurons are generated in early development and the excess numbers are cut down in a 
process called selection pruning, leaving only a sufficient number to last a life time. 
Unlike other body cells, neurons in the central nervous system (CNS) are only able to 
undergo mitosis to generate new cells during development and no new neurons are 
formed at post-development stage (Bhardwaj et al., 2006).  
Neurite outgrowth is a process that occurs following the differentiation of 
precursor cells to a terminal neuronal phenotype (Radio & Mundy, 2008). During the 
early stage, the cells develop broad, sheet-like extensions (lamellipodia) which 
subsequently condense into short processes tipped with growth cones (Craig & Banker, 
1994). The processes increase in length and complexity as the cells mature, and they 
become polarized by developing a single long axon and several shorter dendrites as 
shown in Figure 2.1. The axon grows rapidly in length and acquires axonal 
characteristics. The remaining neurites elongate more slowly and develop into dendrites 
several days after the formation of the axon (Figure 2.1).  
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Figure 2.1: Diagram of a sequential event in neurite outgrowth illustrating a cell 
body with lamellipodia, the development of minor processes (tipped with a growth 
cone), and transformation of the processes into an axon and dendrites (Radio & 
Mundy, 2008).  
 
Neurite outgrowth is essential for neuronal path finding and the establishment of 
synaptic connections during development (Figure 2.2A). It is also an important aspect of 
neuronal plasticity and neuronal regeneration that occurs after injury or in 
neurodegenerative conditions (Figure 2.2B). As neurons mature and differentiae, they 
lose some of their ability to produce neurite, which results in the incapability of neurite 
regeneration. Thus, finding preventative measures that promote neurite outgrowth and 
gaining a thorough understanding of the underlying mechanisms regulating neurite 
outgrowth may facilitate in a health developmental process and for therapeutic 
management of axonal/neuronal damage.   
 
 
 
 
 
Cell body Nucleus 
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Figure 2.2: The importance of neurite outgrowth in (A) Development stage for 
neuronal path finding and synaptic connections; and (B) Neuronal repair after 
injury and regeneration after neuropathological conditions  
 
2.2 NEURITE OUTGROWTH IN DEVELOPMENT  
Neuron formation and neurite outgrowth take place during development. By studying 
neurodevelopment, we can learn how the human brain develops and how brain 
abnormalities, such as mental retardation and other brain disorders, can be prevented or 
treated. In the course of development, the human brain and nervous system begin to 
develop at three weeks of gestation (Zhang, Wernig, Duncan, Brüstle, & Thomson, 
2001). By four weeks, the major regions of the human brain can be recognised in 
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primitive form, including the forebrain, midbrain, hindbrain, and optic vesicle from 
which eyes develop. Irregular ridges, or convolutions, can be seen clearly by six months 
of gestation. 
The mature nervous system contains a vast array of cell types, which can be 
divided into two main categories: (1) the neurons, primarily responsible for signaling, 
and (2) glial cells, the supporting cells in the nervous system (Grosche & Reichenbach, 
2013). Neurons of the cerebral cortex are generated in the ventricular zone of the neural 
tube. Once the neurons have left the cell cycle, the neurons migrate out of the 
ventricular zone on glial to form the cortical plate (Mahmoudzadeh et al., 2013), which 
is the gray matter of the cortex. On the cortical plate, neurons become organised into 
well defined layers. An important step called the “initial wiring” takes place after that. 
Brain wiring involves the outgrowth of neurons or axons in long distances to find and 
connect with appropriate partners (Chedotal & Richards, 2010).  
Therefore, neurite outgrowth during development is a series of precisely 
orchestrated events and having said that, stimulation is essential for fine tuning of brain 
connections. Consumption of certain nutrients can influence brain functions, even when 
the nutrients are not being used to correct malnutrition syndromes (Wachs, Georgieff, 
Cusick, & McEwen, 2014). Supplemental docosahexaenoic acid (DHA), an omega-3 
fatty acid, is reported to improve cognition in humans (Wurtman, 2014). It also 
enhances the levels of membrane phosphatides and of specific proteins in synaptic 
membrane and the density of hippocampal dendritic spines; thus it may enhance 
synaptogenesis (Wurtman, Cansev, Sakamoto, & Ulus, 2009).  
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2.3 NEURITE OUTGROWTH IN NEURODEGENERATIVE DISEASES 
AND NEUROREGENERATION 
Life expectancy of humankind had increased to 50-60 years at the beginning of 20
th
 
century due to improved medicinal, dietary and sanitation conditions. It is however,  
foreseen that society will witness an elevated life expectancy of 80-90 years by 21
st
 
century (Candore et al., 2006; Troen, 2003).  With the increased lifespan of the world’s 
population, it is estimated that approximately 80 million people will suffer from 
dementia by 2040, whereby AD will account for almost 60% of dementia cases 
(Bharadwaj, Martins, & Macreadie, 2010).   
Impairment  in neurite outgrowth will lead to neurodegenerative diseases 
including dementia, AD and Parkinson’s disease (PD) (Martorana et al., 2012). As 
discussed, the principal morphological characteristics of neuritogenesis are branching of 
neurites followed by elongation of axons and dendritic arborisation (Kiryushko, 
Berezin, & Bock, 2004; More et al., 2012). It is believed that pathogenesis of the 
nervous system may lead to neurite retraction, and AD has been described as a disease 
of synaptic failure due to brain tissue damage and lack of neurite outgrowth 
(Wasilewska-Sampaio et al., 2005). Therefore, it has been suggested that reconstruction 
of the neuronal and synaptic networks in the brains of those suffering from AD, is 
necessary for the recovery of brain functions (Figure 2.3).  
 
 
 
 
 
 
 
9 
 
 
 
Figure 2.3: The diagram shows the neurons in the non AD condition brain 
transporting electrical messages to other parts of the body using chemical 
transmitters (a); whereas, in AD brain (b), the brain tissues are damaged and some 
messages do not transmit due to lack of neurite outgrowth activity.  
 
The term ‘neuroregeneration’ describes the sprouting and outgrowth of injured 
or damaged axons over longer distances and the process is time-consuming, usually 
taking weeks to months to produce functional improvements (Krieger, 2013). It was 
once believed that nerve regeneration in the mammalian central nervous system (CNS) 
was not possible (Filli & Schwab, 2012). However, it has become apparent recently that 
damaged neurons do regenerate under the presence of stimulatory substances such as 
nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) (Allen, 
Watson, Shoemark, Barua, & Patel, 2013), lithium (Leeds et al., 2014), and thyroid 
hormones (Bhumika & Darras, 2014). Peripheral nerve regeneration on the other hand 
is, believed to be reversible with many neurotrophic factors shown to promote neurite 
Cells within the brain (neurons) transport electrical 
impulses to other parts of the body using chemical 
transmitters (neurotransmitters). 
In AD, areas of the brain tissue are damaged and 
some impulses do not get transmitted, resulting in 
the symptoms of the diseases. 
a 
b 
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outgrowth by improving the microenvironment required for nerve regeneration (Allodi, 
Udina, & Navarro, 2012). Promoters of neurite regrowth are being identified and 
provide possible therapies to stimulate regeneration. These neuritogenic substances hold 
the promise of therapeutic efficacy in the treatment of neuronal injuries by the virtue of 
their ability to stimulate outgrowth of neurites from neuronal cells.  
 
2.4 MEASUREMENTS OF NEURITE OUTGROWTH 
The characterisation of neurite outgrowth is an area of intense interest, since this 
cellular process is essential for interconnection of neuronal cell bodies in 
neuropathological disorders, neuronal injury, and regeneration (Payne et al., 2014). 
Major efforts in the nervous system drug discovery research are focused on the 
identification of compounds that affect neurite outgrowth and/or retraction. However, 
the study of neurites is held back by difficulties associated with isolating and purifying 
them (Helmstaedter, Briggman, & Denk, 2011). One of the common practices for 
measuring neurite outgrowth is by manual microscopic examination of individual cells 
(Laketa, Simpson, Bechtel, Wiemann, & Pepperkok, 2007).  Another way of assessment 
is by the measurement of total fluorescence from a labelled neuronal cell population 
using a fluorescence plate reader (Popova & Jacobsson, 2014). The disadvantage of 
these methods includes the labour intensiveness and subjectivity. Consequently, 
innovative methods have been actively developed by researchers to compensate the lack 
of informality and reproducible methodology for neurite quantification.  
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2.4.1 Semi quantitative method 
Assessment of neurite outgrowth in a semi-quantitative fashion does not involve a 
calibrated measurement of neurite length. Rather, scoring is based on the presence of 
processes emitting from a cell (Radio & Mundy, 2008). These methods are often 
preferred as they do not require sophisticated equipment and software for analysis. 
Observations can be made directly from the microscope or from photomicrographs, thus 
making these methods rather time saving and simple to perform. However, semi-
quantitative methods can be bias and subjective. In general, the endpoint semi-
quantitative assessment is the number of cells exhibiting neurites (neurite bearing cells), 
and the length of a process that qualifies as a neurite is defined as being equal to or 
greater than one to two times the diameter of the cell body (Das, Freudenrich, & 
Mundy, 2004).  
 
2.4.2 Quantitative method 
Quantitative assessment of neurite outgrowth provides a calibrated measure of neurite 
length, including the length of the longest neurite, total neurite length, or the average 
neurite length (Radio & Mundy, 2008). Scoring by the length of the longest neurite is 
considered the most common practice as it is relatively easy to demarcate from 
photomicrographs. In some instances, neurite outgrowth can be scored and ranked by 
counting the number of neurites as well as the number of branch points per neurite. 
Figure 2.4 summarises the morphologic features used to quantify neurite outgrowth. For 
quantitative analysis of neurite outgrowth, images are often associated with a scale to be 
calibrated to the length of the original neurites, in microns, for example. Further, 
cultures are generally grown under a low cell density to avoid overlap of processes. 
Measurements can be performed on cultures that have been fixed with 1% 
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glutaraldehyde in 0.1 M phosphate buffer (Bearer, Swick, O’Riordan, & Cheng, 1999) 
or 90% (v/v) methanol in phosphate buffered saline (PBS) (Sachana, Flaskos, Alexaki, 
Glynn, & Hargreaves, 2001). Staining can be done with Coomassie brilliant blue before 
being examined (De Girolamo, Hargreaves, & Billett, 2001). Nevertheless, analysis of 
live cultures using phase contrast can be performed without manipulating the cells, 
thereby decreasing time and costs associated with fixation (Radio & Mundy, 2008). As 
compared to semi-quantitative assessment, these methods are time-consuming and are 
always performed with microscopic imaging system (semi- or fully-automated), to 
facilitate data acquisition.   
 Assessment by describing the longest neurite, which is sometimes designated as 
the axon, has been done in PC12 cell line  (Das et al., 2004). For primary cultures, 
neurite length of the rat cerebellar granule cells was measured as the distance between 
the centre of the cell soma and the tip of its longest neurite (Bearer et al., 1999). A few 
requirements had to be met: (1) the neurite must emerge from an isolated cell and not a 
clump of cells, and (2) the neurite must not be in contact with other neurites. 
Measurement of the longest neurite has also been carried out in the embryonic rat locus 
coeruleus, a collection of neurons in the pons (Dey, Mactutus, Booze, & Snow, 2006). 
Meanwhile, measurement of the total neurite length (sum of the lengths of all neurites 
emanating from a cell) requires more effort and is often carried out using automated 
analyses. Total neurite length has been assessed in PC12 cell line (Das & Barone, 
1999).  In another study which employed a primary culture of immature γ-aminobutyric 
acidergic (GABAergic) interneurons, the total neurite length was measured by drawing 
all visible processes with a Scion software (Vutskits, Gascon, Tassonyi, & Kiss, 2006).  
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Figure 2.4: Quantitative assessment of neurite outgrowth (Radio & Mundy, 2008). 
Primary neurites are processes originating directly from the cell body (labelled as 
1-5). The longest neurite is labelled as 1. Secondary neurites (labelled as 6) 
originate from primary neurites. Branch points (circled) indicate branching of 
neurites. The total neurite length is the sum of the lengths of all primary and 
secondary neurites (total neurite length = 1+2+3+4+5+6). 
  
2.4.3 Biochemical marker 
A variety of biochemical markers have been used to quantify neurite outgrowth. One of 
the advantages of using biochemical markers is that they correlate to neuronal 
differentiation and the increase of neurite extension.  Biochemical measures, such as 
immunoblotting and ELISA, provide a higher throughput screening, as compared to 
morphological analysis.  
6 
6 
Cell body 
Nucleus 
 
 
14 
 
Phosphorylated microtubule-associated protein, tau was found in axons and 
dendrites of cortical neurons at all developmental stages and it is present at a higher 
level during neurite outgrowth (Brion, Octave, & Couck, 1994). Further, 
phosphorylated tau disappears during the period of neurite stabilisation and 
synaptogenesis. These suggest that tau protein can be used as a biomarker to study 
neurite outgrowth. GAP-43 is a growth-associated protein with a well-known role in 
growth cone formation, axonal elongation, and plasticity (Benowitz & Routtenberg, 
1997). A rise in GAP-43 protein and mRNA levels expressed by 
developing cerebellar granule neurons in vitro during neuritogenesis further provided 
evidence of the role of GAP-43 in neurite outgrowth (Przyborski & Cambray-Deakin, 
1994). 
Proteins associated with neurons like the cytoskeleton (neurofilaments) have 
been used for the visualization of axons and dendrites. Neurofilaments belong to the 
class of intermediate filaments and are one of the most abundant structural proteins in 
axons, playing a role in axonal calibre regulation, neuronal differentiation and axonal 
outgrowth and regeneration (Perrot, Berges, Bocquet, & Eyer, 2008). Nitric oxide 
(NOR4)-induced neurite outgrowth was shown to be accompanied by an increase of the 
expression of neurofilament 200 kDa subunit (NF200) protein, an axonal marker 
(Yamazaki, Chiba, & Mohri, 2005). Neurofilament protein levels were also shown to 
increase upon somatostatin-induced neurite outgrowth in a primary culture, i.e. rat 
cerebellar granule cells (Taniwaki & Schwartz, 1995). Besides,  a correlation between 
diazinon- and cypermethrin-induced reduction in neurite outgrowth and the decrease in 
the level of neurofilament protein has also been demonstrated in N2a cells (Flaskos et 
al., 2007).  
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2.5 IN VITRO CELL LINE MODEL FOR NEURITE OUTGROWTH  
Cell culture is a general term applied to define the removal of cells from a tissue and 
their subsequent growth in a favourable artificial environment (Sharma, Haber, & 
Settleman, 2010).  Primary culture is a culture derived directly from a tissue; therefore, 
it best resembles the natural tissue. However, a primary culture often has a limited 
growth potential and life span (Kretz, Marticke, Happold, Schmeer, & Isenmann, 2007). 
A cell line, on the other hand, is a population of immortal cells that are used for 
biological research, as they do not require to be isolated from the host’s tissue every 
time cells are needed (Poulos, Dodson, & Hausman, 2010). Cell lines have a number of 
advantages that make them useful as in vitro models (Radio & Mundy, 2008). First, cell 
lines provide a clonal and homogenous population of cells. Secondly, they are relatively 
easy to acquire as compared to the primary culture, and can be stored indefinitely in 
liquid nitrogen (Maqsood, Matin, Bahrami, & Ghasroldasht, 2013). The protocol to 
maintain cell line is well established and is easy to follow using standard tissue culture 
plastic and media. Most importantly, the cells represent an unlimited self-replicating 
source that can be continuously subcultured (passaged) to provide large numbers of 
cells in a short period of time (Burdall, Hanby, Lansdown, & Speirs, 2003).A vast 
variety of neuronal cell lines are available and many have been used as in vitro models 
to examine neurite outgrowth. Table 2.1 lists the most commonly used cell lines for 
neurite outgrowth study and describe the associated phenotype and agents used to 
induce neurite outgrowth.  
 
 
16 
 
Table 2.1 Different cell lines used for the measurement of neurite outgrowth in vitro 
Cell line Source Phenotype Inducing agents References 
N2a Mouse neuroblastoma Adrenegic, cholinergic, 
dopaminergic 
Dibutyryl cyclic AMP, serum removal, 
retinoic acid 
Chiang, Cheng, Chen, Liang, 
& Yen (2014) 
PC12 Rat 
pheochromocytoma  
Adrenegic, cholinergic, 
dopaminergic  
Nerve growth factor Eik et al., (2012) 
B50 Rat neuroblastoma Cholinergic Dibutyryl cyclic AMP, 
Serum removal 
Ibegbu, McBean, Fyfe, & 
Mullaney (2013) 
NB2a Mouse neuroblastoma Adrenegic, cholinergic, 
dopaminergic 
Dibutyryl cyclic AMP, 
retinoic acid 
Vural & Tuğlu (2011) 
N1E-115 Mouse neuroblastoma Adrenegic, dopaminergic Dimethyl sulfoxide, prostaglandin E1 (PGE1), 
serum removal 
Kotake et al., (2014) 
SH-SY5Y Human neuroblastoma Adrenegic, cholinergic, 
dopaminergic 
Retinoic acid, dibutyryl cyclic AMP, nerve 
growth factor 
Wu et al., (2009) 
SK-N-SH Human neuroblastoma Dopaminergic Retinoic acid, nerve growth factor Olajide, Velagapudi, Okorji, 
Sarker, & Fiebich (2014) 
IMR-32 Human neuroblastoma Aminergic, cholinergic 5-Bromo-deoxyuridine (BrdUr), nerve growth 
factor 
Tong et al., (2013) 
LA-N-5 Human neuroblastoma Cholinergic Retinoic acid Hill & Robertson (1998) 
NT2 Human embryonal 
carcinoma 
Cholinergic Retinoic acid Tegenge, Roloff, & Bicker 
(2011) 
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Different experimental protocols have been employed to investigate the effects 
of chemical on neurite outgrowth in cell lines. There are two common practices: (1) 
cells are treated with the chemical of interest at the same time differentiation is being 
induced; and (2) cells are pre-treated with the inducing factor prior to exposure to the 
chemical of interest. The first method exposes the cells with the inducing factor and 
chemical simultaneously. This allows the examination of both initiation of neuronal 
differentiation and later events such as neurite outgrowth and extension. A classic 
example is the induction of NGF-differentiated PC12 cells, whereby the cells are co-
treated with NGF (the inducing agent) and substances of interest, after which neurite 
outgrowth is observed after a designated time (Eik et al., 2012). As compared to the first 
method, the second method focuses on neurite initiation, rather than neurite 
differentiation. By adapting this protocol, the chemical effects can be examined in cells 
which have already bore neurites. An example of this procedure is the N2a cell model. 
The cells are cultured in a complete medium, after which they are re-plated in a serum-
free condition with the option of adding the inducing factors (dibutyryl cyclic AMP or 
retinoic acid) (Wang et al., 2011). The cells which have already been differentiated to 
the neuronal phenotype, will elaborate neurites in an accelerated manner when treated 
with neuritogenic substances.  
 
2.6  NEURITOGENIC SUBSTANCES THAT STIMULATE NEURITE 
OUTGROWTH 
2.6.1 Neurotrophic factors 
Neurotrophic factors (neurotrophins) such as nerve growth factor (NGF) play an 
important role in the maintenance of nervous system. They play an integral part in the 
regulation of development, assembling of neuron-target cell interaction, function and 
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survival of neurons. Insufficient neurotrophins is believed to result in an array of 
dysfunctions of the nervous system, which may cause dementia, AD and PD (Allen et 
al., 2013). However, polypeptides like NGF in therapy are unfavourable as they are 
unable to cross the blood brain barrier. Therefore, finding small molecules that show 
neurotrophic properties and/or enhancing the action of endogenous neurotrophic factors, 
is important.  
 
 
 
 
Figure 2.5: X-ray crystal structures of the NGF and its receptor, TrkA. The 
extracellular region of the Trk receptors can be sub-divided (by amino acid 
sequence) into different domains (d1–d3 is a leucine-rich, cysteine-rich (LR&CR) 
region). Domains 4 (d4) and 5 (d5) are immunoglobulin-like domains. d5, the 
domain closest to the membrane, binds the NGF directly (Allen et al., 2013).  
 
NGF 
NGF-TrKA 
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Besides NGF, the members of the neurotrophin family of growth factors include 
brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3) and neurotrophin 4 
(NT4) These are all survival factors, essential for the appropriate development and 
subsequent survival and maintenance of specific subsets of neurons into adulthood. The 
mature neurotrophins each bind to their specific tyrosine kinase receptor. NGF binds to 
TrkA (Figure 2.5), BDNF and NT4 bind to TrkB, and NT3 binds to TrkC (Nagahara et 
al., 2009).  
The use of growth factors such as NGF and BDNF has been proposed. Several 
in vitro and in vivo studies revealed the importance of NGF for its ability to enhance the 
survival of primary basal forebrain cholinergic neurones and to increase the activity of 
the enzyme choline acetyltransferase (ChAT) (Liu, Lamb, Chou, Liu, & Li, 2007). 
Intracerebroventricular (ICV) administration of NGF in aged rats was shown to prevent 
and reverse the cholinergic deficits of AD (Fischer et al., 1987). The concept of NGF 
protein administration as an AD therapeutic was extended into the first ICV infusion of 
NGF into early onset AD patients (Olson et al., 1992). The patient’s verbal episodic 
memory was improved after a month. However, ICV infusion of NGF caused weight 
loss. Other routes of NGF administration have been explored, for example the implant 
of NGF-transfected fibroblasts into the basal forebrain of primates (Smith, Roberts, 
Gage, & Tuszynski, 1999). Nasal administration and olfactory bulb injection of radio 
labelled NGF to the cholinergic basal forebrain has also been explored (Lauer et al., 
2000). The NGF therapy was then successfully translated to a Phase I clinical trial in 
2001 (Tuszynski et al., 2005). As reported, the Evaluation of the Mini-Mental Status 
Examination and Alzheimer Disease Assessment Scale-Cognitive subcomponent 
suggested improvement in the rate of cognitive decline. To date, it is reported that a 
Phase II multi-centre clinical trial in approximately 50 patients with mild to moderate 
AD, will be conducted in the United States.  
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2.6.2 Neuritogenic substances from plants 
There has been a recent upsurge of interest in exploring health food to promote neurite 
outgrowth and improve the overall brain and cognition health (Gunawardena, 
Shanmugam, et al., 2014). The polyphenol entities found in the vegetables, fruits and 
nuts were shown to inhibit neuro-inflammation by preventing amyloid precursor protein 
(APP) signaling and amyloid beta (Aβ) aggregation which is thought to be the culprit of 
causing AD (Essa et al., 2012). The effect of daily consumption of wild blueberry juice 
in a sample of nine older adults with early memory changes was investigated (Krikorian 
et al., 2010). Improvement in the “paired associate learning” and “word list recall” was 
detected after 12 weeks of consumption of the wild blueberry juice. Blueberries were 
reported to contain a high level of poly-phenolic compounds, most prominently 
anthocyanins (Chen, Xin, Yuan, Su, & Liu, 2014). Anthocyanins have been associated 
with increased neuronal signaling in brain and they were shown to facilitate glucose 
disposal which ultimately help to mitigate neurodegeneration. Resveratrol (trans-3,4’,5-
trihydroxystilbene) is a non-flavonoid poly-phenol found abundantly in grapes. 
Importantly, it was reported that ICV injection of resveratrol reduced neuronal loss in 
the hippocampus and prevented learning impairment in the p25 transgenic AD mouse 
model (Vingtdeux, Dreses-Werringloer, Zhao, Davies, & Marambaud, 2008). A variety 
of phyto-chemical approaches to delay and/or prevent the onset of age-associated 
neurodegenerative diseases are being investigated, some of which include the 
galantamine from Narcissus sp., lemon balm (Melissa officinalis), and periwinkle 
(Vinca minor). Table 2.2 summarises the different medicinal plants which hold the 
potential in stimulating neurite outgrowth and reducing the occurrence or prevent 
neurodegenerative diseases.  
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Table 2.2: Medicinal plants with neurite outgrowth stimulatory activity and their bioactive compounds (More et al., 2012) 
Plant Compound Dosage Biological effects References 
Panax ginseng Ginsenoside Rb1 40 mg Neuritogenesis in rats Gao et al., (2010) 
 Ginsenoside Rg1 10 mM Survival of dopaminergic neurons Radad et al., (2004) 
Curcuma longa Curcumin 10-20 µM/ 0.2 mg 
Neurite outgrowth in PC12 cells, 
neuritogenesis in mouse 
 
Liao et al., (2012) 
Withania somnifera Withanoside IV and VI 1 µM 
Axon and dendritic extension in rat 
cortical neurons 
Tohda, Kuboyama, & Komatsu 
(2005) 
Camellia sinensis  
Epigallocatechin gallate 
(EGCG) 
0.1-1 µM Neurite outgrowth in PC12 cells 
Gundimeda, McNeill, 
Schiffman, Hinton, & 
Gopalakrishna (2010) 
Picrorhiza 
scrophulariiflora 
Picroside I & II 60 μM 
Potentiating NGF induced neurite 
outgrowth in PC12D cells 
P. Li, Matsunaga, Yamakuni, 
& Ohizumi (2000) 
Rehmannia glutinosa Catalpol 
5, 15 and 50 mg, 100 
μM 
Increase in the number of mouse 
tyrosine hydroxylase positive cells 
Xu et al., (2010) 
Citrus depressa Nobiletin 100 μM Neurite outgrowth in PC12 cells Nagase et al., (2005) 
Sargassum 
macrocarpum 
Sargaquinoic acid 1.25–100 ng 
Potentiating NGF induced neurite 
outgrowth in PC12D cells 
Tsang & Kamei (2004) 
Tripterygium wilfordii Tripchlorolide 10
−10
 M 
Neurite outgrowth & survival of 
dopaminergic neurons 
F.-Q. Li et al., (2003) 
Scutellaria 
baicalensis 
Baicalein 5 μg; 50 and 200 mg 
Neurite outgrowth in PC12 
cells/Increase and survival of rat TH-
positive cells 
Mu et al., (2009) 
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2.7 MEDICINAL MUSHROOMS FOR NEURITE OUTGROWTH 
 
Mushroom offers great potential as a poly-pharmaceutic drug because of the complexity 
of chemical contents and different variety of bioactivities. Available evidence suggests 
that mushrooms exhibit anti-oxidants, anti-tumour, anti-virus, anti-cancer, anti-
inflammatory, immunomodulating, anti-microbial and anti-diabetic activities (Roupas, 
Keogh, Noakes, Margetts, & Taylor, 2012). Mushrooms with anti-inflammatory 
properties can be used as functional foods to suppress inflammation which contributes 
to many age-related chronic diseases (Gunawardena, Bennett, et al., 2014). Contrary to 
plant and herbal medicine which is widely explored and relatively more advanced, the 
brain and cognition health effects of mushrooms are in early stages of research.  
 
2.7.1 Sarcodon cyrneus Maas Geest and Sarcodon scabrosus (Fr.) P. Karst 
 
Sarcodon spp., also called “bitter tooth”, are widely distributed in Europe, North 
America and Asia (Figure 2.6a). Sarcodon mushrooms are considered inedible due to 
their bitter taste. Cyrneines A (1) and B (2) (Figure 2.7) isolated from Sarcodon cyrneus 
Maas Geest stimulated neurite outgrowth in PC12 cells at 100 μM with no cytotoxicity 
as indicated by lactate dehydrogenase (LDH) analysis (Marcotullio, Pagiott, et al., 
2006) (Table 2.3). Later, it was shown that both cyrneines A and B promoted NGF 
production in 1321N1 cells (Marcotullio et al., 2007). Neurite outgrowth activity was 
also observed in NG108-15 cells, a hybrid neuronal cell line derived from mouse 
neuroblastoma and rat glioma (Yutaro Obara, Hoshino, Marcotullio, Pagiotti, & 
Nakahata, 2007). On the other hand, cyrneines C (3) and D (4) failed to induce neurite 
outgrowth. In addition, glaucopine C (5), isolated from the hexane extract of Sarcodon 
glaucopus (Marcotullio, Pagiotti, et al., 2006), did not significantly promote neurite 
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outgrowth in PC12 cells but induced NGF gene expression in a lesser extent when 
compared to cyrneines A and B. It seemed that the presence of the hydroxyl 
cycloheptadienyl carbaldehyde system in cyrneines could be important for 
neuritogenesis (Marcotullio et al., 2007). In other words, minor differences in functional 
groups on cyathane structures in cyrneines A, B, C and D can influence the responses in 
neuronal cells. Figure 2.7 shows the chemical structures of different cyrneines (1-5). 
 
 
 
Figure 2.6: (a) The basidiocarps of wild Sarcodon cyrneus and its taxonomy. (b) 
The basidiocarps of wild Sarcodon scabrosus and its taxonomy. Source: 
http://www.mycobank.org/  
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Scabronine A (6) (Table 2.3) isolated from Sarcodon scabrosus (Figure 2.6b) showed 
potent inductive activity of NGF synthesis in 1321N1 human astrocytoma cells (Ohta et 
al., 1998). Further investigation led to the isolation of novel cyathane diterpenoids 
named scabronines B-F (7-11) (Kita, Takaya, & Oshima, 1998), G (12) (Obara et al., 
1999), K (13) and L (14) (Shi, Liu, Gao, & Zhang, 2011). However, only scabronines B, 
C, E and G (Figure 7) showed NGF-synthesis stimulating activity. It appeared that the 
presence of the α,β-unsaturated aldehyde system in the seven-membered ring could be 
crucial for the bioactivity. Recently, the first synthesis of scabronine G in an optically 
pure form, has been reported and the neurite outgrowth activity was comparable to NGF 
and natural scabronine G (Waters, Tian, Li, & Danishefsky, 2005). Meanwhile, 
scabronine G-methyl-ester (15) synthesised from scabronine G also potently promoted 
the secretion of NGF and interleukin-6 (IL-6), another major neurotrophic factor 
released from astrocytes. Most recently, secoscabronine M (16), a hemiacetal cyathane 
diterpenoid was isolated from S. scabrosus but neuritogenesis was not reported for this 
compound. Figure 2.7 shows the structures of scabronines and secoscabronines (6-16) 
isolated from S. scabrosus. 
 
Table 2.3: The effects of Sarcodon cyrneus, S. glaucopus, S. scabrosus; and their 
chemical constituents with neurite outgrowth activity 
No Mushroom Compound In vitro 
study  
Neurite 
outgrowth 
activity 
References 
1 Sarcodon 
cyrneus 
Cyrneine A  PC12; 
NG108-
15; 
1321N1  
Neurite 
outgrowth 
 
NGF  
Marcotullio, Pagiott, 
et al., (2006); Yutaro 
Obara et al., (2007) 
2  Cyrneine B PC12 Neurite 
outgrowth 
; NGF  
 
Marcotullio et al., 
(2007); Marcotullio, 
Pagiott, et al., (2006) 
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No Mushroom Compound In vitro 
study  
Neurite 
outgrowth 
activity 
References 
3 Sarcodon 
cyrneus 
Cyrneine C PC12 - Marcotullio et al., 
(2007) 
4 Cyrneine D  PC12 - Marcotullio et al., 
(2007) 
5 Sarcodon 
glaucopus 
Glaucopine C PC12 NGF gene 
expression 
 
Marcotullio et al., 
(2007); Marcotullio, 
Pagiotti, et al., (2006) 
6 Sarcodon 
scabrosus 
Scabronine A 1321N1  Neurite 
outgrowth 
 
Ohta et al., (1998) 
8 Scabronine C Rat 
astroglial 
cells 
NGF  Kita et al., (1998) 
9 Scabronine D Rat 
astroglial 
cells 
- Kita et al., (1998) 
10 Scabronine E Rat 
astroglial 
cells 
NGF  Kita et al., (1998) 
11 Scabronine F Rat 
astroglial 
cells 
- Kita et al., (1998) 
12 Scabronine G 1321N1  Neurite 
outgrowth 
 
Y Obara et al., 
(1999); Waters et al., 
(2005) 
13 Scabronine G-
methyl ester 
PC12 NGF and  
IL-6  
Y Obara, Kobayashi, 
Ohta, Ohizumi, & 
Nakahata (2001) 
14 Scabronine K PC12 - Shi et al., (2011) 
15 Scabronine L PC12 - Shi et al., (2011) 
16 Secoscabronine 
M 
- - Shi, Zhang, Pescitelli, 
& Gao (2012) 
 
Note: -: No effect on neurite outgrowth; NGF: nerve growth factor; : 
Promoted/increased 
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Figure 2.7: Cyrneines A (1), B (2), C (3) and D (4) from Sarcodon cyrneus; and 
glaucopine C (5), isolated from the hexane extract of Sarcodon glaucopus. 
Scabronines A-G (6-12), K (13), L (14), scabronine G-methyl-ester (15), and 
secoscabronine M (16), isolated from Sarcodon scabrosus. 
 
2.7.2 Hericium erinaceus (Bull.: Fr.) Pers. 
 
Hericium erinaceus is also called the lion’s mane mushroom, monkey’s head 
mushroom, hedgehog mushroom, satyr’s beard, pom pom, bearded tooth, and 
Yamabushitake. The basidiocarp is often white to creamy white in colour and with 
icicle-like projections (Figure 2.8). 
  
(12) (13) 
(14) 
(15) (16) 
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Figure 2.8: The basidiocarps of Hericium erinaceus and its taxonomy. Source: 
Mushroom Research Centre, University of Malaya, 2014. 
 
There is a possible use of Hericium erinaceus (Bull.: Fr.) Pers. in the treatment 
of neurological disorders and dementia as reported by Kawagishi and Zhuang (2008). In 
a study by Wong et al., (2007) , the extracts of H. erinaceus basidiocarp and mycelium 
induced neurite outgrowth of neuronal cells NG108-15 in vitro. Besides, ethanol extract 
of H. erinaceus promoted the neurite outgrowth of PC12 cells, enhanced NGF mRNA 
expression and secretion of NGF from 1321N1 human astrocytoma cells (Mori et al., 
2008). Further, in vivo functional recovery of axonotmetic peroneal nerve injury in 
Sprague-Dawley rats was assessed by walking-track analysis and toe-spreading reflex 
(Wong et al., 2009). The peroneal functional index (PFI) and toe-spreading reflex 
improved more rapidly in the group treated with daily administration of H. erinaceus 
extract. These data suggested that H. erinaceus could promote the regeneration of nerve 
injury in the early stage of recovery (Wong et al., 2010).   
Although preliminary, it was demonstrated that the H. erinaceus extract exerted 
neurotrophic action and improved the myelination process in the rat brain without 
affecting nerve cell growth and toxicity (Moldavan et al., 2007). There was an attempt 
to isolate a polysaccharide from the mycelium of H. erinaceus and the polysaccharide 
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(molar ratio of 1.5: 1.7: 1.2: 0.6: 0.9; glucose: galactose: xylose: mannose: fructose) 
promoted neurite outgrowth in PC12 cells in vitro (Park et al., 2002).  
Hericenones (benzyl alcohol derivatives) were isolated from the fruiting bodies 
of H. erinaceus (Table 2.4). Hericenones A (17) and B (18) (Figure 2.9) were first 
reported in 1990 but no neurite outgrowth activity was reported (Kawagishi, Ando, & 
Mizuno, 1990). Hericenones C (19), D (20), E (21), F (22), G (23), and H (24) exhibited 
stimulating activity for the biosynthesis of NGF in vitro (Kawagishi & Ando, 1993; 
Kawagishi et al., 1991). Hericenone E isolated from H. erinaceus cultivated under 
tropical conditions in Malaysia was able to stimulate NGF secretion which was two-fold 
higher than that of the positive control (50 ng/mL of NGF) (Phan, Lee, et al., 2014). 
Hericenone E also increased the phosphorylation of extracellular-signal regulated 
kinases (ERKs) and protein kinase B (Akt) responsible for neurite outgrowth activity. 
On the other hand, diterpenoid derivatives (named erinacines) were isolated from the 
mycelium of H. erinaceus (Figure 2.9). Erinacines A-I (25-33) significantly induced the 
synthesis of nerve growth factor (NGF) in vitro (Kawagishi, Shimada, Sakamoto, 
Bordner, & Kojima, 1996; Kawagishi et al., 1994; Kawagishi, Simada, et al., 1996; Lee 
et al., 2000) and in vivo (Shimbo, Kawagishi, & Yokogoshi, 2005). Isolation of new 
compounds from this mushroom continued with the discovery of erinacines J (34), K 
(35), P-R (36-38), as well as erinacol (39), a novel cyathadien-14β-ol ( Kawagishi, 
Masui, Tokuyama, & Nakamura, 2006; Kenmoku, Sassa, & Kato, 2000; Kenmoku, 
Shimai, Toyomasu, Kato, & Sassa, 2002; Kenmoku, Tanaka, Okada, Kato, & Sassa, 
2004; Ma, Zhou, Li, & Li, 2008; Ma et al., 2010). Structures of hericenones (17-24) and 
erinacines (25-39) can be found in Figure 2.9. 
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Table 2.4: List of hericenones and erinacines in Hericium erinaceus, some of which showed neurite outgrowth activity 
No Mushroom 
component 
Compound In vitro study  Neurite outgrowth activity Reference 
17 F Hericenone A - -   Kawagishi et al., (1990) 
18 F Hericenone B - -  Kawagishi et al., (1990) 
19 F Hericenone C Mouse astroglial cells NGF   Kawagishi et al., (1991) 
20 F Hericenone D  Mouse astroglial cells NGF  Kawagishi et al., (1991) 
21 F Hericenone E Mouse astroglial cells NGF   Kawagishi et al., (1991) 
22 F Hericenone F Mouse astroglial cells NGF   Kawagishi & Ando (1993) 
23 F Hericenone G Mouse astroglial cells NGF   Kawagishi & Ando (1993) 
24 F Hericenone H Mouse astroglial cells NGF   Kawagishi & Ando (1993) 
25 M Erinacine A Mouse astroglial cells 
Rat (in vivo) 
NGF ;  
Catecholamine  in the CNS of rats 
Kawagishi et al., (1994); Shimbo et 
al,. (2005) 
26 M Erinacine B Mouse astroglial cells NGF  Kawagishi et al., (1994) 
27 M Erinacine C Mouse astroglial cells NGF  Kawagishi et al., (1994) 
28 M Erinacine D Mouse astroglial cells NGF  Kawagishi et al., (1996) 
29 M Erinacine E Mouse astroglial cells NGF  Kawagishi et al., (1996) 
30 M Erinacine F Mouse astroglial cells NGF Kawagishi et al., (1996) 
31 M Erinacine G Mouse astroglial cells NGF  Kawagishi et al., (1996) 
32 M Erinacine H Rat astroglial cells NGF  Lee et al., (2000) 
33 M Erinacine I Rat astroglial cells NGF  Lee et al., (2000) 
34 M Erinacine J MRSA - Kawagishi et al., (2006) 
35 M Erinacine K MRSA - Kawagishi et al., (2006) 
36 M Erinacine P - Biosynthesis of erinacines Kenmoku et al., (2000) 
37 M Erinacine Q - Biosynthesis of erinacine C Kenmoku et al., (2002) 
38 M Erinacine R - - Ma et al., (2010) 
Ma et al., (2008) 
39 M Erinacol - Biosynthesis of erinacine Q Kenmoku et al., (2004) 
Note: F: fruiting body; M: mycelium; -: none; NGF: nerve growth factor; CNS: central nervous system; MRSA: Methicillin-resistant Staphylococcus aureus  
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(19) R = palmtoyl 
(20) R = stearoyl 
(21) R = linoleoyl 
 
 
(22) R = palmtoyl 
(23) R = stearoyl 
(24) R = linoleoyl 
 
 
 
 
(17) (18) 
(25) (26) (27) 
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(36) R = CHO 
(37) R = CH2OH 
    
(28) (29) (30) 
(31) (32) (33) 
(34) (35) 
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Figure 2.9: Hericenones A-H (17-24); erinacine A-K (25-35), P-R (36-38) and 
erinacol (39) isolated from H. erinaceus. 
 
2.7.3 Ganoderma lucidum (Fr) P. Karst, Dictyophora indusiata (Vent.) Desv., and 
Grifola frondosa (Dicks.: Fr.) S.F. Gray 
 
Ganoderma lucidum (Ling Zhi), a famous medicinal mushroom, is used widely in 
traditional Chinese medicine. The basidiocarp is corky, almost flat, red-varnished, and 
kidney shaped (Figure 2.10a).  Cheung et al., (2000) reported that G. lucidum extract 
reduced PC12 cell proliferation and induced neuronal differentiation and neurite 
outgrowth via the activation of MAP kinases and cAMP-response element binding 
protein (CREB) signaling pathways. In addition, a lipophilic fraction of G. lucidum (125 
and 500 mg/L) was also shown to induce neurite outgrowth of PC12 cells (Zhang et al., 
2005).  
Dictyophora indusiata is a famous edible mushroom used in Chinese cuisine and 
medicine (Figure 2.10b).  It is called the “Queen of the mushrooms’’, bamboo 
mushroom and Kinugasatake in Japanese. Two eudesmane-type sesquiterpenes, 
dictyophorines A (40) and B (41) (Figure 2.11), were isolated from the mushroom and 
were found to promote NGF synthesis by astroglial cells (Kawagishi et al., 1997). It was 
shown that NGF secreted into the medium in the presence of 3.3 mM of dictyophorines 
A was four times higher than the negative control. Grifola frondosa (hen of the woods, 
dancing mushroom, Maitake) is a mushroom with manifold curled or spoon-shaped 
(38) (39) 
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gray-brown caps (Figure 2.10c). It also has a tuber-like sclerotium. 
Lysophosphatidylethanolamine (LPE) isolated from G. frondosa was found to induce 
neurite outgrowth and it upregulated the neurofilament M expression in cultured PC12 
cells (Nishina et al., 2006). The study also showed suppressive effect of G. frondosa on 
serum deprivation-induced apoptosis of the PC12 cells. 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 2.10: Basidiocarps of (a) Ganoderma lucidum, (b) Dictyophora indusiata, and 
(c) Grifola frondosa. Source: http://www.mycobank.org/  
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Figure 2.11: Dictyophorines A (40) and B (41), isolated from Dictyophora indusiata. 
 
2.7.4 Tremella fuciformis Berk, Tricholoma sp., and Termitomyces albuminosus 
(Berk.) R. Heim 
 
Tremella fuciformis is also known as Yin Er, white jelly fungus, silver ear mushroom, 
and snow mushroom (Figure 2.12a). It has a white, frond-like, and 
gelatinous basidiocarp. The aqueous extract of T. fuciformis not only promoted the 
neurite outgrowth of PC12 cells, but significantly reversed the scopolamine- and 
trimethyltin-induced memory deficit in rats, as revealed by the Morris water maze test 
and choline acetyltransferase (ChAT) immunohistochemistry (Kim et al., 2007; Park et 
al., 2012). Tricholoma is mycorrhizal, and it has a gilled cap and fleshy stem (Figure 
2.12b). Neuritogenic compounds named tricholomalides A-C (42-44) (Figure 2.13) 
were also isolated from Tricholoma sp. and neurite outgrowth in PC-12 cells was 
significantly induced at concentrations of 100 µM (Tsukamoto et al., 2003). 
Termitomyces albuminosus is a wild and edible mushroom with long stem, and it often 
emerges from a termite nest (Figure 2.12c). The cerebrosides named termitomycesphins 
A-D (45-48) (Qi, Ojika, & Sakagami, 2000),  E-F (49-50) (Qi, Ojika, & Sakagami, 
2001), and  G-H (51-52) (Qu et al., 2012) (Figure 2.13) were identified to potentiate 
neuritogenesis in PC12 cells. It is interesting that termitomycesphin with a 16-carbon-
chain fatty acid (A, C, and G) showed higher neuritogenic activity than that of 
(40) (41) 
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termitomycesphin with an 18-carbon-chain fatty acid (B, D, and H), suggesting that the 
chain length of the fatty acyl moiety played a determining role in neuritogenesis.  
 
 
 
 
 
 
Figure 2.12: Basidiocarps of (a) Tremella fuciformis, (b) Tricholoma sp., and (c) 
Termitomyces albuminosus. Source: http://www.mycobank.org/ 
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No Termitomycesphin C7-C9(C19) n 
45 A OH
 
16 
46 B 18 
47 C 
OH  
16 
48 D 18 
49 E OH
 
16 
50 F 18 
 
 
 
Figure 2.13: Tricholomalides A-C (42-44) and termitomycesphins (45-52) isolated 
from Tremella fuciformis and Termitomyces albuminosus; respectively.  
 
(42) (43) (44) 
(51) n = 16 
(52) n = 18 
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2.7.5 Lignosus rhinocerotis (Cooke) Ryvarden, Ganoderma neo-japonicum (Fr) P. 
Karst, and Cordyceps militaris (L.:Fr.) Link 
 
 Known as the tiger’s milk mushroom, Lignosus rhinocerotis poses underground tuber-
like sclerotium and has a solitary basidiocarp (Figure 2.14a). Aqueous extract of L. 
rhinocerotis sclerotium (Eik et al., 2012) and  L. rhinocerotis mycelium (John, Wong, 
Naidu, & Sabaratnam, 2013) exhibited neurite outgrowth activity in PC12 cells. 
Ganoderma neo-japonicum (Figure 2.14b) grows on dead hardwoods or bamboos. The 
indigenous people in Malaysia drink the water infusion of this wild as a tonic to 
strengthen their body. Ganoderma neo-japonicum was shown to induce neuronal 
differentiation and stimulate neurite outgrowth of PC12 cells (Seow et al., 2013). 
Meanwhile, 5-20 µg/mL of methanol extract of Cordyceps militaris (Figure 2.14c) was 
found to increase primary neurite sprouting and choline acetyltransferase expression in 
differentiated N2a cells (Lee et al., 2011). Administration of C. militaris also restored 
the scopolamine-induced memory deficit in rat.  
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Figure 2.14: Basidiocarps of (a) Lignosus rhinocerotis, (b) Ganoderma neo-
japonicum, and (c) Cordyceps militaris. Source: http://www.mycobank.org/ 
 
2.8 PLEUROTUS GIGANTEUS (BERK.) KARUNARATHNA & K.D. HYDE 
 
Pleurotus giganteus (Berk.) Karunarathna & K.D. Hyde (Figure 2.15) is a saprobe and 
one of the largest edible mushrooms which grows on the ground. It is solitary or can be 
found in groups, often around stumps, wood, dead roots, in the open and in lowland, 
and mountain forest up to 3000 masl (Mortimer et al., 2012). Pleurotus giganteus is 
gaining popularity for its organoleptic properties and commercial prospects. 
Consumption of this wild mushroom has long been a tradition in the indigenous villages 
in Peninsular Malaysia (Lee, Chang, & Noraswati, 2009). A variety of P. giganteus 
from China is now being cultivated in Malaysia and the common commercial name in 
Malay language for P. giganteus is “Seri Pagi” (morning glory). In China, P. giganteus 
is widely referred as “Zhudugu” (swine’s stomach) (Deng et al.,2006).  
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Figure 2.15: The basidiocarps of Pleurotus giganteus. 
 
In mushroom biology, species boundaries are always indistinct and many 
mushrooms are subsumed under erroneous names (Hallenberg, Nilsson, & Robledo, 
2012). The “Panus-Pleurotus-Lentinus” confusion of this mushroom has long existed 
and has resulted in the perplexity of nomenclature and taxonomy of these three species. 
Briefly, Panus giganteus (Polyporaceae, Polyporales) is characterised by its unbranched 
skeletal hyphae that usually grows on buried woody substrates (Corner, 1981). While 
Pegler has merged Panus as a subgenus within Lentinus, Corner, on the other hand 
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grouped the genus Panus to species with skeletal hyphae and separated those species 
with ligative hyphae in Lentinus. Hence, Lentinus giganteus is regarded as synonym for 
Panus giganteus and Lentinus giganteus should be used if recommendation of Pegler is 
ever adopted. However, Karunarathna and colleagues have revisited this issue and 
concluded that Panus/Lentinus giganteus should be unified and positioned in Pleurotus 
as supported by molecular evidences (Karunarathna et al., 2011).  
Studies on P. giganteus include domestication and cultivation of the mushroom 
(Klomklung, Karunarathna, Chukeatirote, & Hyde, 2012). Accordingly, the optimal 
growth of P. giganteus was reported to be obtained on soybean agar within a pH range 
of 5.0-6.5 and the optimal temperature of 30°C (Klomklung, Karunarathna, Hyde, & 
Chukeatirote, 2014). In a recent study on the liver protective activity of P. giganteus,  
rats were injected intraperitoneally with thioacetamide (TAA) thrice a week and were 
orally administered with freeze-dried basidiocarps of P. giganteus daily for two months 
(Wong et al., 2012). After 60 days, the rats administered with P. giganteus showed 
lower liver body weight ratio, restored levels of serum liver biomarkers and oxidative 
stress parameters comparable to treatment with the standard drug i.e. silymarin. Gross 
necropsy and histopathological examination further confirmed that P. giganteus was 
able to prevent or reduce the severity of TAA-induced liver injury in rats. 
Pleurotus giganteus also exhibited anti-Candida activity (Phan et al., 2013). In 
the study, Candida albicans WM1172, C. albicans ATCC90028, C. dubliniensis, C. 
glabrata CBS138, C. glabrata ATCC90030, C. krusei ATCC6258, C. pseudotropicalis, 
and C. tropicalis WM30 were used. The minimum inhibitory concentration (MIC) of 
the ethyl acetate extract and its fractions against all the tested yeasts were determined. 
The MIC values for all the Candida spp. tested, ranged from 2.0 ± 1.0 to 10.3 ± 2.5 
µg/mL for fraction A; and 9.3 ± 2.3 to 34.3 ± 10.8 µg/mL for fraction B.  Constituents 
of both the fractions from ethyl acetate extract were elucidated by using gas 
 
 
42 
 
chromatography mass spectrometry (GCMS). As a result, 12 compounds were identified 
in both the fractions:, i.e. methyl palmitate, ethyl palmitate, methyl linoleate, methyl 
oleate, methyl stearate, and ethyl oleate, palmitic acid and oleic acid, ergosterol, 
ergosta-5,7,9 (11),22-tetraen-3β-ol, ergost-5,8(14)-dien-3-ol, and γ-ergostenol. 
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 CHAPTER III 
IDENTIFICATION OF MUSHROOMS WITH NEURITE OUTGROWTH 
STIMULATORY EFFECTS USING DIFFERENTIATING NEUROBLASTOMA-
2A CELLS  
 
3.1  INTRODUCTION 
Neurite outgrowth is an important event in neuronal path finding and the establishment 
of synaptic connections during development (Bernd, 2008; Fornasiero, Bonanomi, 
Benfenati, & Valtorta, 2010). It is also essential in neuronal plasticity, neuronal 
regeneration after injury (Loers & Schachner, 2007) and neurodegenerative conditions 
such as Alzheimer’s and Parkinson’s diseases (Shulman & Jager, 2009). Therefore, 
treatments aiming at promoting neurite outgrowth and preserving the neurite network 
and synaptic connections are needed.  
The potential use of culinary-medicinal mushrooms in neurodegenerative 
diseases is being explored (Sabaratnam, Wong, Naidu, & David, 2011). On-going 
research shows that Hericium erinaceus (Bull.: Fr) Pers. (monkey’s head mushroom, 
lion’s mane mushroom and Yamabushitake) (Wong et al., 2007) and Lignosus 
rhinocerotis (Cooke) Ryvarden (tiger milk mushroom) (Eik et al., 2012; Seow et al., 
2013) exhibit neurite outgrowth stimulatory effects in NG108-15 and PC12 cell lines. 
This observation raised a question with respect to the neurodevelopmental effects, if 
any, of culinary-medicinal mushrooms.  Congenital diseases are present in 2–3% of 
human newborns (Genschow et al., 2004). About 20% of the birth defects are due to 
genetic anomaly and 10% are caused by environmental factors during pregnancy (Seiler 
& Spielmann, 2011). Therefore, toxicological safety assessments of food, chemicals and 
drugs to evaluate the effects on reproductive health and for embryotoxicity have become 
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important requirements. Thus, the aims of the present study were (a) to evaluate neurite 
outgrowth stimulatory effects of selected culinary-medicinal mushrooms using 
neuroblastoma-2a (N2a) cells and (b) to assess the neuro- and embryotoxicity of the 
mushroom extracts using N2a and embryonic 3T3 fibroblasts.    
 
3.2 MATERIALS AND MEETHODS  
3.2.1 Mushrooms 
The mushrooms were authenticated by experts in the Mushroom Research Centre, 
University of Malaya and voucher specimens were deposited in the University of 
Malaya (Table 3.1). Fresh basidiocarps of Ganoderma lucidum (Fr) P. Karst (KLU-M 
1233) and H. erinaceus (KLU-M 1232) were obtained from Ganofarm Sdn 
Bhd. Pleurotus giganteus (KLU-M 1227) was provided by Nas Agro Farm and Dong 
Foong Biotech. Freeze dried powder of Cordyceps militaris (L.:Fr.) Link and L. 
rhinocerotis were purchased from BioFact Life and Ligno Biotech Sdn Bhd, 
respectively. Pleurotus pulmonarius (Fr.) Quél. fruiting bodies (KLU-M 
1309) and Gingko biloba extracts were obtained from Reishilab Sdn Bhd, Selangor. 
Wild Ganoderma neo-japonicum Imazeki 1939 (KLU-M 1231) was collected from a 
forest in Ulu Grik, Perak, Malaysia. Grifola frondosa (Dicks.: Fr.) S.F. Gray (KLU-M 
1229) imported from Japan was obtained from supermarkets in Selangor, 
Malaysia. Lycium barbarum (wolfberry), a traditional Chinese medicine was purchased 
from a Chinese medicine shop in Selangor, Malaysia. Curcumin was purchased 
(NatXtra, Synthite Co., India). 
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Table 3.1: Mushrooms used in this study, their common names, medicinal and culinary nature 
Mushroom 
species 
Voucher 
number 
Common names Local names (in 
Malay) 
Part used Edible/ 
culinary 
Wild/ 
cultivated 
Medicinal 
properties 
References 
Pleurotus 
giganteus 
(Panus 
giganteus) 
KLU-M 
1227 
Zhudugu, cow’s 
stomach 
mushroom 
Cendawan  seri pagi 
(morning glory), 
perut lembu (cow’s 
stomach)  
Fruiting 
body 
Culinary Cultivated Antioxidant, 
neurite 
outgrowth 
simulation 
Phan, Wong, David, 
Naidu, & Sabaratnam  
(2012);  Wong et al., 
(2012) 
Pleurotus 
pulmonarius 
(Pleurotus 
sajor-caju) 
KLU-M 
1309 
Grey oyster 
mushroom 
Cendawan tiram 
kelabu (grey oyster) 
Fruiting 
body 
Culinary Cultivated Antioxidant, anti-
diabetic 
Kanagasabapathy, 
Malek, Kuppusamy, & 
Vikineswary, (2011) 
Lignosus 
rhinocerotis 
Ligno 
Biotech 
Sdn Bhd 
Tiger milk 
mushroom  
Cendawan susu 
rimau 
(tiger’s milk) 
Sclerotium 
and 
mycelium 
Non-
culinary 
but edible 
Cultivated Anticancer, 
neurite outgrowth 
stimulation 
Eik et al., (2012);  Lee, 
Tan, Fung, Tan, & Ng 
(2012) 
Hericium 
erinaceus 
KLU-M 
1232 
Monkey’s head 
mushroom, lion’s 
mane mushroom, 
Yamabushitake 
Cendawan bunga 
kubis 
(cauliflower) 
Fruiting 
body 
Culinary Cultivated Anti-ulcer, 
neurite outgrowth 
stimulation 
Wong, Sabaratnam, 
Abdullah, Kuppusamy, 
& Naidu, (2009); Wong 
et al., (2010); Wong et 
al., (2009, 2007) 
Ganoderma 
lucidum 
KLU-M 
1233 
Lingzhi, reishi Cendawan merah 
(red mushroom) 
Fruiting 
body 
Non-
culinary 
but edible 
Cultivated Anticancer, 
neuroprotection 
Zhou et al., (2010) 
Ganoderma 
neo-
japonicum 
KLU-M 
1231 
Purple reishi Cendawan senduk 
(cobra mushroom) 
Fruiting 
body 
Non-
culinary 
but edible 
Wild Antioxidant, 
neurite outgrowth 
stimulation 
Lin, Lin, Chen, Ujiie, & 
Takada, (1995) 
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Mushroom 
species 
Voucher 
number 
Common names Local names (in 
Malay) 
Part used Edible/ 
culinary 
Wild/ 
cultivated 
Medicinal 
properties 
References 
Cordyceps 
militaris 
Purchased 
from 
BioFact 
Life Sdn 
Bhd 
Winter worm 
summer grass, 
caterpillar fungus 
- Fruiting 
body 
(ascocarp) 
Non-
culinary 
but edible 
Cultivated Anti-
inflammatory, 
anticancer, relief 
respiratory 
disorders 
Lee et al., (2011) 
Grifola 
frondosa 
KLU- M 
1229 
Maitake, hen of 
the woods 
Cendawan maitake Fruiting 
body 
Culinary Cultivated Anti-
inflammatory, 
anti-cholesterol, 
neurite outgrowth 
stimulation 
Nishina et al., (2006) 
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3.2.2 Cell culture  
Mouse neuroblastoma cells (N2a, ATCC CCL-131) and mouse embryonic fibroblast 
cells (BALB/c 3T3, ATCC clone A31) were purchased from American Type Culture 
Collection (ATCC; MD, USA). N2a cells were cultured in Eagle’s minimum essential 
medium (MEM) with L-glutamine (PAA) supplemented with 10% (v/v) heat-
inactivated foetal bovine serum (PAA), 100 U/ml penicillin, and 100 µg/ml 
streptomycin. 3T3 fibroblasts were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) with L-glutamine (high glucose at 4.5 g/l) supplemented with 10% FBS. All 
the cells were maintained at 37°C and 5% CO2 in a humidified atmosphere. N2a cells 
were subcultured at 3 – 4 days intervals while 3T3 cells were routinely passaged every 2 
– 3 days. For preservation, the cells were frozen at -70°C liquid nitrogen in complete 
medium supplemented with 5% (v/v) dimethyl sulfoxide (DMSO; Sigma) as a 
cryoprotecting agent. 
 
3.2.3 Preparation of mushroom extracts 
The fresh fruiting bodies of P. giganteus, P. pulmonarius, H. erinaceus, and G. 
frondosa were sliced, frozen and then freeze-dried for two days. The freeze-dried 
fruiting bodies were then ground to powder and kept at 4 - 8°C. For aqueous extraction, 
the freeze dried powder was soaked in distilled water (1:20, w/v) at room temperature 
and at 200 rpm in a shaker for 24 h. The mixture was then double boiled in water bath 
for 30 min, cooled and then filtered (Whatman No. 4). The resulting aqueous extracts 
were freeze-dried and kept at -20°C prior to use. The process was repeated for the 
freeze-dried powder of C. militaris and L. rhinocerotis sclerotia. For ethanol extraction, 
the freeze dried powder was soaked in 95% ethanol at room temperature for three days 
and the process was repeated three times. The solvent was then evaporated using a 
rotary evaporator (Eyela N-1000, USA) to give a brownish viscous extract.  
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3.2.4 Neurite outgrowth assay  
N2a cells were seeded in a 24-well culture plate at an initial density of 5,000 cells per 
well containing complete growth medium (1 ml/well) and incubated overnight. 
Concentrations of NGF ranging from 5 - 100 ng/ml (w/v) were tested to determine the 
optimum concentration that stimulates maximum neurite outgrowth. The optimum 
concentration was then used as a positive control throughout the subsequent assays. 
Aqueous and ethanol mushroom extracts were stocked at 10 mg/ml and were 
subsequently dissolved in sterile distilled water or dimethyl sulfoxide (DMSO), to the 
appropriate concentrations. The final concentration of DMSO in the assays was 0.1 - 
0.25%. To induce cell differentiation, the complete medium was carefully replaced with 
5% serum medium before exposure to mushroom extracts at 10 - 50 µg/ml. Cells with 
medium only served as a negative control. All the cells were incubated for 48 h at 37°C, 
95% air and 5% CO2 to observe neuritogenic activity, if any. Curcumin, G. biloba and 
L. barbarum extracts were also tested to compare the neurite outgrowth activities with 
those of mushroom extracts. 
 
3.2.5 Quantification of neurite bearing cells 
Five random fields (100 – 200 cells/well) were examined in each well by using a phase 
contrast microscope (20× magnifications) equipped with QImaging Go-3 camera 
(QImaging, Canada). Neurite length was measured in at least 30 cells in randomly 
chosen fields by using image processor system Image-Pro Insight (Media Cybernetics, 
MD). The number of neurite outgrowths, defined as axon-like extensions that were 
double or more than the length of the cell body diameter was recorded. The percentage 
of neurite bearing cells (%) is the number of neurite bearing cells divided by the total 
number of cells in a field and then multiplied by 100%. At least three independent 
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experiments were conducted and results were expressed as mean ± standard deviation 
(S.D). 
 
3.2.6. Fluorescence immunocytochemistry study 
The axon-like extensions were confirmed as neurite outgrowth by immunofluorescence 
staining. N2a cells were seeded in 12-well µ-dishes (ibidi, Martinsried, Germany) and 
were exposed to treatments for 48 h. The cells were fixed with 4% paraformaldehyde in 
phosphate buffered saline (PBS) (pH 7) for 20 min. After two washes with PBS, the 
cells were incubated with rabbit anti-neurofilament 200 polyclonal antibody (1:80 in 
10% sheep serum as blocking buffer) for 1 h. The cells were washed and then incubated 
in a mixture of fluorescein isothiocyanate (FITC)-conjugated secondary antibody and 
sheep anti-rabbit IgG (1:160) in blocking buffer) for 2 h at room temperature in the 
dark. The cells were then washed three times. 4'-6-diamidino-2- phenylindole (DAPI) 
was used to counter stain the nuclei. Images were observed under a fluorescent 
microscope (Nikon Eclipse 80i microscope).  
 
3.2.7 Evaluation of embryo- and/or neurotoxic effects of mushroom extracts 
3.2.7.1  MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay 
N2a and 3T3 cells (1 × 10
4
) per well were seeded in 96-well plates. After incubation for 
24 h, different concentrations of mushroom extracts (0 – 5 mg/ml) dissolved in phenol 
red free culture medium were added to each well. The samples were incubated for 24 h 
at 37°C under humidified atmosphere of 5% CO2 and 20 µl MTT (5 mg/ml) was added 
to each well. The crystal dyes taken up by the cells were then dissolved with DMSO. 
Absorbance was measured at 570 nm in a microplate reader (Tecan, Austria) using 630 
nm as a reference wavelength. All measurements were done in triplicates, and at least 
three independent experiments were carried out. To calculate IC50 values which 
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estimated the concentration of mushroom extract that caused 50% inhibition of 
proliferation (viability) in N2a and 3T3 cells, Probit analysis was conducted using SPSS 
17.0 (SPSS Science Inc., Chicago, IL).  
 
3.2.7.2   Neutral red uptake assay 
Neutral red medium (40 µg/ml) was prepared fresh before use by diluting the neutral 
red stock (4 mg/ml) with phenol red free culture medium. Neutral red medium was 
centrifuged at 1800 rpm for 10 min to remove any precipitated dye crystals before use. 
After cell seeding and treatment (0 – 5 mg/ml), the medium was discarded and replaced 
with equal amount of neutral red medium to each well of the plate. The plate was then 
incubated for 2 h. The neutral red medium was then removed and the cells were washed 
quickly with adequate amount of PBS. A total of 100 µl of neutral red solubilising 
solution (1% acetic acid in 50% ethanol) was added to each well and allowed to stand 
for 10 minutes at room temperature until the neutral red extracted from the cells reached 
a homogeneous solution. The absorbance at a wavelength of 540 nm with 690 nm of 
background absorbance was spectrophotometrically measured (Tecan, Austria). The 
experiment was repeated at least three different times. 
 
3.2.7.3   Lactate dehydrogenase (LDH) release assay 
After cell seeding and treatment with mushroom extracts (0 – 5 mg/ml), the culture 
plates were centrifuged at 1500 rpm for 5 minutes and 50 µl of supernatant was then 
transferred to a new plate for LDH analysis according to manufacturer instruction 
(Sigma). To each well, 100 µl of LDH mixture solution comprising of LDH assay 
substrate, dye and cofactor was added and incubated at room temperature for 30 min. 
The reaction was stopped by adding 10 µl of HCl (1 N) to each well. Absorbance was 
measured spectrophotometrically at 490 nm with background absorbance at 690 nm. 
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Triton X-100 (0.5%, Scharlau) was used as a positive control and was thus set to 0% 
viability representing a 100% cell death. 
 
3.2.8 Statistical Analysis 
All the experimental data are expressed as mean ± standard deviation (S.D). Statistical 
differences between groups were analysed and calculated by one-way analysis of 
variance (ANOVA) from at least three independent experiments. This was followed by 
Duncan's multiple range tests. P < 0.05 was considered to be significant between 
groups.  
 
3.3 RESULTS  
3.3.1 Determination of the optimum NGF concentration in neurite outgrowth of 
differentiating N2a cells 
Nerve growth factor induced neurite outgrowth of N2a cells in a dose-dependent 
manner (Figure 3.1). After 48 h, the percentage of neurite bearing cells increased 
significantly (p < 0.05)  to 26.1 ± 1.8% in N2a cells treated with 50 ng/ml NGF when 
compared to negative control (7.6 ± 2.5 %). At 60 ng/ml of NGF, the percentage of 
neurite bearing cells significantly decreased to 12.2 ± 2.1% (p < 0.05). Based on these 
findings, the optimised concentration of NGF of 50 ng/ml was selected as a positive 
control in the following studies unless otherwise stated. 
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Figure 3.1: The effects of different NGF concentrations (5 – 100 ng/ml) on 
stimulation of neurite outgrowth using differentiating N2a cells as an in vitro 
model. The results shown represent the mean ± SD; n = 3. Means not sharing a 
common letter were significantly different at p < 0.05. 
 
3.3.2 Neurite outgrowth of differentiating N2a cells promoted by different 
mushroom extracts 
 
The yield of extracts from the mushrooms are summarised in Table 3.2. The positive 
control (NGF) recorded 26.4 ± 3.6% of neurite-bearing cells (Figure 3.2). The 
percentage of neurite bearing cells after treatment with aqueous extracts of G. lucidum 
(38.4 ± 4.2%), L. rhinocerotis (38.1 ± 2.6%), and ethanol extract of C. militaris (35.8 ± 
3.4%) were significantly higher (p < 0.01) than NGF control by approximately 1.45-, 
1.44- and 1.35-fold, respectively. Aqueous extracts of G. frondosa (33.7 ± 1.5%) and P. 
giganteus (33.4 ± 4.6%) were also shown to induce significantly (p < 0.05) higher 
neurite bearing cells compared to the NGF control. Meanwhile, the aqueous extracts of 
L. rhinocerotis mycelium, H. erinaceus, G. neo- japonicum, P. pulmonarius, as well as 
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ethanol extracts of H. erinaceus, P. pulmonarius and P. giganteus showed varied neurite 
outgrowth stimulatory effects with average neurite bearing cells ranging from 26.4 ± 
5.4% to 29.6 ± 2.2%. Further, these extracts showed no significant difference when 
compared to NGF control. Among the plant extracts tested, wolfberry extract did not 
show any neurite outgrowth activity. The percentage of neurite bearing cells obtained 
after treatment with 20 µg/ml of ethanol extract of G. biloba (30.3 ± 2.5%) was higher 
than curcumin treated cells which yielded 26.4 ± 5.4% at 20 µg/ml.  
 
Table 3.2: Yield of aqueous and ethanol extracts from the mushrooms and plants 
studied 
Mushrooms Extract Yield (%, 
w/w) 
Lignosus rhinocerotis (S) Aqueous 3.56 
Lignosus rhinocerotis (M) Aqueous 4.65 
Hericium erinaceus Aqueous 8.56 
Ganoderma lucidum Aqueous 3.67 
Ganoderma neo-japonicum Aqueous 5.75 
Grifola frondosa Aqueous 3.54 
Pleurotus pulmonarius Aqueous 3.60 
Pleurotus giganteus Aqueous 6.70 
Hericium erinaceus Ethanol  4.50 
Cordyceps militaris Ethanol  3.45 
Pleurotus pulmonarius Ethanol  6.70 
Pleurotus giganteus Ethanol  5.30 
Lycium barbarum 
(wolfberry) 
Aqueous 9.76 
Gingko biloba Ethanol n.d 
 
(S) = sclerotium, (M) = mycelium. n.d. = not determined 
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Figure 3.2:  Percentage of neurite bearing cells after treatment with different concentrations of mushroom and plant extracts. 
*
 p < 0.05,  
**
 p < 
0.01 compared to the positive control (NGF). (S) = sclerotium, (M) = mycelium. 
** 
** 
* 
* ** 
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3.3.3 Mushroom extracts treatment increased neurite length in N2a 
To qualify as a “neurite”, the axon-like extension needs to be double or more than the 
cell body length of N2a. The average neurite length of NGF-stimulated cells was 78.58 
± 18.6 µm (Figure 3.3), which is approximately 4-time longer than the cell body. The 
mean diameter of N2a cell body was found to be 19.45 ± 0.72 µm. Cells treated with 
aqueous extract of G. lucidum were found to develop the longest mean neurite length 
i.e. 121.51 ± 28.6 µm (6.25-time longer than cell body), followed by aqueous extract of 
P. giganteus which recorded mean neurite length of 116.72 ± 29.5 µm (5.99-time longer 
than cell body).  
 
 
Figure 3.3: The mean neurite length of N2a cells treated with different mushroom 
extracts at 20 µg/ml. The results shown represent the mean ± SD; n = 3. Means not 
sharing a common letter were significantly different at p < 0.05.  
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3.3.4 Immunofluorescence staining of neurofilament  
Figure 3.4 shows the morphology of differentiating N2a cells with neurites after 48 h of 
treatment with 50 ng/ml NGF (a) and 20 μg/ml of aqueous extracts of  G. lucidum (b), 
L. rhinocerotis (c), P. giganteus  (d) and G. frondosa (e); as well as ethanol extract of C. 
militaris (f). Neurofilament belongs to a class of intermediate filament found in 
neuronal cells that provides specific support for axons. There is a direct relationship 
between neurite outgrowth and neurofilament expression as neurofilament protein levels 
increase with differentiation of cell lines (Flaskos, Fowler, Teurtrie, & Hargreaves, 
1999). While Plate 1A shows the phase contrast photomicrograph, Plate 1B shows the 
immunocytochemical labeling of neurons. The expression of neurofilament protein 
during neurite outgrowth was stained green while nuclei were stained blue.  
 
3.3.5 The cytotoxic effects of mushroom extracts on 3T3 and N2a cells  
Table 3.3 shows the results of cytotoxicity screening of mushroom and plant extracts to 
N2a cells and 3T3 fibroblasts. The cytotoxicity determination are expressed as IC50 
values, which is the concentration resulting in 50% inhibition of cell growth and 
proliferation after 24 h exposure. All the extracts of mushrooms and plants did not show 
cytotoxic effects to the two tested cell lines (IC50 ≥ 1 mg/ml in all cases). Three 
cytotoxicity assessments were used in this experiment, which include MTT, NR uptake 
assay and LDH release assay. Interestingly, IC50 determined by NRU test and LDH test 
was higher than that of MTT. In a general term, the ethanol extracts showed lower IC50 
too.  
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Figure 3.4: (A) Phase contrast photomicrographs showing the effects of (a) NGF, 
(b) G. lucidum, (c) L. rhinocerotis, (d) P. giganteus, (e) G. frondosa, and (f) C. 
militaris on the morphology of differentiating N2a cells after 48 h. Untreated cells 
serve as control (g) and only contained 5% FBS as vehicle. (B) 
Immunocytochemical staining of neurofilament in N2a cells. DAPI stains nuclei 
blue, while anti-neurofilament 200 kD labeled with FITC stains neuronal cells 
green. Arrows indicate neurite outgrowth. Photomicrographs of representative 
microscope fields were taken with a 20× objective. Scale bar represents 20 μm. 
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Table 3.3: Cytotoxic effects of extracts of mushrooms and plants assessed by different cytotoxicity assays- MTT, NRU and LDH release 
Mushroom/Plant Species Extracts  Neuroblastoma 2a cells  3T3 Embryonic Fibroblast 
IC50 (mg/ml) after 24 h IC50 (mg/ml) after 24 h 
MTT NRU LDH MTT NRU LDH 
Culinary/medicinal 
mushroom 
Pleurotus giganteus  Aqueous 4.07 ± 0.67
e
 6.95 ± 1.00
g
 - 2.16 ± 0.05
c
 2.67 ± 0.47
d
 -  
Pleurotus pulmonarius Aqueous 2.85 ± 0.06cd 2.13 ± 0.87cdef - 1.75 ± 0.14bc 2.60 ± 0.55d - 
Lignosus rhinocerotis 
(sclerotium) 
Aqueous 3.27 ± 0.77d 2.72 ± 0.65ef - 5.63 ± 0.06e 5.93 ± 0.05f - 
Lignosus rhinocerotis 
(mycelium) 
Aqueous 2.43 ± 0.12c 1.75 ± 0.18abc - 5.23 ± 0.17e 5.60 ± 0.1f - 
Hericium erinaceus Aqueous 2.60 ± 0.52cd 2.85 ± 0.56e - 3.43 ± 0.29d 3.53 ± 0.06e - 
Ganoderma  lucidum Aqueous 1.35 ± 0.03a 1.52 ± 0.17ab 2.20 ± 0.52ab 1.19 ± 0.06ab 1.35 ± 0.02ab 1.50 ± 0.08a 
Ganoderma neo-
japonicum 
Aqueous 
 
Aqueous 
1.17 ± 0.006
a
 1.11 ± 0.03
a
 2.00 ± 0.53
ab
 1.47 ± 0.37
ab
 1.78 ± 0.56
bc
 1. 58 ± 0.44
a
 
Grifola frondosa 2.72 ± 0.08
cd
 4.60 ± 1.10
f
 - 6.67 ± 0.87
f
 7.60 ± 0.1
g
 - 
Pleurotus giganteus Ethanol 2.43 ± 0.10
c
 2.81 ± 0.15
e
 5.8 ± 0.10
c
 1.66 ± 0.56
bc
 1.96 ± 0.42
c
 1.73 ± 0.48
a
 
Pleurotus pulmonarius Ethanol 2.30 ± 0.72bc 2.64 ± 0.16def 2.53 ± 0.96bc 1.27 ± 0.06ab 1.48 ± 0.05abc 1.67 ± 0.12a 
Hericium erinaceus Ethanol 2.47 ± 0.50c 1.61 ± 0.51ab 2.10 ± 0.72ab 1.31 ± 0.03ab 1.84 ± 0.57bc 1.47 ± 0.31a 
Cordyceps  militaris Ethanol 1.65 ± 0.015ab 1.81 ± 0.10abcd 2.37 ± 0.21b 1.02 ± 0.08a 1.10 ± 0.02a 1.40 ± 0.29a 
Plants Lycium barbarum Aqueous 4.37 ± 1.00
e 6.96 ± 0.73g - 8.40 ± 0.72g 7.86 ± 0.06g - 
Gingko biloba  Ethanol 1.56 ± 0.08
ab
 1.66 ± 0.11
ab
 1.43 ± 0.39
a
 1.56 ± 0.58
abc
 1.37 ± 0.07
ab
 1.78 ± 0.07
a
 
Curcumin Compound 1.13 ± 0.01
a
 1.15 ± 0.01
a
 1.30 ± 0.16
a
 1.16 ± 0.06
ab
 1.23 ± 0.03
ab
 1.60 ± 0.22
a
 
The data represent the mean ± SD of three determinations. Means not sharing a common letter were significantly different at p < 0.05.
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3.4 DISCUSSIONS 
 
Eight species of medicinal mushrooms were investigated and categorised into two 
groups: culinary and non-culinary. The former group represents mushrooms that can be 
used for culinary purposes like preparing meal and cooking, especially from the 
basidiocarps. This group (culinary-medicinal mushrooms) comprised of P. giganteus, P. 
pulmonarius, H. erinaceus, and G. frondosa. Medicinal mushrooms that do not exhibit 
culinary properties are appreciated for their pharmacological merits and are not cooked 
as a meal. The basidiocarps or sclerotia are often handpicked, ground to powder and 
subjected to various extraction methods before being used as a traditional medication 
(Tibuhwa, 2012). Lignosus rhinocerotis, G. lucidum, G. neo-japonicum, and C. militaris 
are examples of non-culinary medicinal mushrooms. 
Ganoderma lucidum (also known as Lingzhi in Chinese or Reishi in Japanese) 
has been widely investigated for its potential therapeutic benefits and longevity. The 
results showed that the aqueous extract of G. lucidum promoted neurite outgrowth in 
N2a cells with 38.4 ± 4.2% increase in neurite bearing cells. This agrees with the 
finding of Cheung et al (2000) who showed that Ganoderma extract contained NGF-like 
compounds that mediated the neuronal differentiation and elongation of rat 
pheochromocytoma (PC12) cells.  The Ganoderma neuroactive constituents that 
accounted for neurite outgrowth activity are triterpenoids, such as lucidenic acid 
(Connolly & Hill, 2003),  7-oxo-ganoderic acid Z, ganolucidic acid A,  methyl 
ganoderic acid A, ganoderic acid S1, and 4,4,14α-trimethyl-5α-chol-7,9(11)-dien-3-oxo-
24-oic acid (Zhang et al., 2011). Further, the water-soluble polysaccharides of G. 
lucidum were shown to significantly (p < 0.05) reduce neuronal cell death and apoptosis 
of rat primary cortical neurons (model of brain cerebral ischemia) induced by 
oxygen/glucose deprivation treatment (Zhou et al., 2010). Ganoderma extracts may also 
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provide mitigation to Parkinson’s disease as it was shown to prevent dopaminergic 
neuron degeneration by attenuating the pro-inflammatory response of microglial cells 
(R. Zhang et al., 2011).  
The tiger’s milk mushroom, L. rhinocerotis, has been described as the national 
treasure of Malaysia since this macrofungus is rare and is often used as folk remedy to 
treat a variety of diseases. Consistent with the previous study (Eik et al., 2012), the 
sclerotia of  L. rhinocerotis improved neurite outgrowth in N2a cells. Interestingly, in 
the present study, the sclerotial extract (38.4 ± 4.2% of neurite bearing cells) performed 
better than the mycelial extract (27.2 ± 2.9%). However, the active components in L. 
rhinocerotis that play the role in neurite outgrowth activity need further investigation. 
The protein or carbohydrate/protein complex of the cold water scerotial extract (4
o
C) is 
responsible for the antiproliferative activity against human breast and lung carcinoma 
(M. L. Lee et al., 2012).  In this study, a hot water extraction approach was employed 
and it is hypothesised that polysaccharides or triterpenoids rather than peptides are 
involved in the neurite outgrowth stimulatory activity of L. rhinocerotis. 
The medicinal properties of P. giganteus are comparatively unknown when 
compared to P. pulmonarius (grey oyster mushroom). Cordyceps militaris is a parasitic 
fungus that colonises moth larvae (Lepidoptera) and has been valued in Traditional 
Chinese Medicine for more than 2000 years. The major bioactive components in C. 
militaris include adenosine, cordycepin and polysaccharides (Yu, Wang, Huang, & 
Duh, 2006). The finding is in agreement with the work by Lee et al (2011) where 
methanol extract of C. militaris was shown to significantly reverse the scopolamine-
induced deficit in the memory of rat and improve neurite outgrowth in N2a cells. 
Similar to the results in this study, lysophosphatidylethanolamine isolated from G. 
frondosa (Maitake) was also reported to induce neuronal differentiation in PC12 cells, 
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causing up-regulation of neurofilament M expression of PC12 cells (Nishina et al., 
2006). 
It is well known that N2a cells, upon the withdrawal of serum, differentiate and 
elaborate neurites (X. Wang et al., 2011; Z. Wang et al., 2011). This well-defined 
neuronal model is often employed for studies relating to neuronal differentiation 
(Wasilewska-Sampaio et al., 2005).  It is also a popular cell line in studying 
neurotoxicity as the brain is the first target in situations such as ageing and 
neurodegenerative diseases (Radio & Mundy, 2008). NGF is the most appropriate 
positive control in neurite outgrowth assays as its role in neural development have been 
characterised extensively (Sofroniew, Howe, & Mobley, 2001). The therapeutic 
application of neurotrophins like nerve growth factor (NGF) is not possible as NGF 
cannot penetrate the blood-brain barrier. Studies indicate that lower-molecular-weight 
molecules may be a promising alternative for therapeutic intervention, for example, α-
phenyl-N-tert-butylnitron (Tsuji, Inanami, & Kuwabara, 2000). However, most of the 
experiments testing natural products have been conducted in vitro, and few studies 
evaluated these compounds in the brain in vivo. It is anticipated that mushroom extracts 
(comprising of neuroactive molecules) under certain condition (serum deprivation) 
participate in triggering NGF signals, hence activating the downstream neuronal 
responses to axonal growth (W. Zhang & Liu, 2002).  
 It is important that functional and health food remedies recommended for the 
prevention or management of diseases undergo safety assessment. Today, a number of 
natural products with potential biomedical application are being launched, although 
some could be potentially toxic when ingested at high doses or in combination with 
other medications (Maria, Lopez, Diaz, & Alba, 1997). The results indicated that at the 
concentrations tested, there were no cytotoxic effects to the cells. Notably, ethanol 
extract of C. militaris showed the lowest IC50 (p < 0.05) value against 3T3 fibroblast. 
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Similarly, curcumin although was reported beneficial in neuroprotection (F. Yang et al., 
2005), the IC50 value detected against N2a was the lowest by means of MTT, NRU and 
LDH assays. Elsewhere, in vivo toxicity evaluation of Ganoderma boninense (Pat.) was 
carried out (Sasidharan, Jinxuan, Latha, & Amutha, 2011) and a significant toxicity 
(IC50 = 640 µg/ml) against Artemia salina (brine shrimp) was demonstrated after 24 h. 
However, Ganoderma extract is granted safe on short-term exposure. Conversely, in 
vivo toxicity profiling of total triterpene fraction from G. lucidum against Swiss albino 
mice showed that ganoderma triterpenes did not possess significant toxicity (Smina, 
Mathew, Janardhanan, & Devasagayam, 2011) and administration of G. lucidum β–
glucan (2000 mg/kg body weight/day) to Sprague Dawley rats did not cause 
toxicological abnormality (S. N. Chen et al., 2011). Mutagenicity studies by means of 
Salmonella typhimurium also did not reveal any genotoxicity. Meanwhile, sub-acute 
toxicity study of the sclerotial powder of L. rhinocerotis by using rat model showed no 
treatment-related toxicity at 1000 mg/kg (Shien, Hong, Yee, Pailoor, & Mui, 2011). 
 More than one cytotoxicity assay namely MTT, NRU, and LDH release assay 
was chosen in this study to determine the in vitro cell viability in order to increase the 
reliability of the results obtained and also to avoid over- or underestimation of the 
mushroom or plant toxicity. The mechanisms of each of the chosen assays are different. 
While MTT is based on the enzymatic conversion of MTT in the mitochondria, NRU 
assay is based on the dye uptake capability by lysosomes (Weyermann, Lochmann, & 
Zimmer, 2005). Both served as colorimetric assays, whereby viable and uninjured cells 
stain blue and red, for MTT and NRU assays, respectively. LDH release assay, on the 
other hand is based on the release of the enzyme into the culture medium after the 
disruption of cell membrane (Fotakis & Timbrell, 2006).  It is noteworthy that the 
toxicity profiles detected by the three different assays generally followed a similar trend 
although some results were not in agreement. For instance, no IC50 values were 
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recorded for some mushroom extracts by using LDH assays, suggesting that LDH may 
be the least sensitive method among the three.  
 
3.5 CONCLUSION 
 
The extracts of G. lucidum, L. rhinocerotis, P. giganteus, G. frondosa and C. militaris 
showed potential in promoting neurite outgrowth of differentiating N2a cells. The 
synergism of the various active entities in these mushroom extracts may be responsible 
for the neurite outgrowth activity. This study also showed the absence of embryotoxic 
and neurototoxic effects of the various mushroom extracts in 3T3 and N2a cells, 
respectively. Pleurotus giganteus was selected for further study since the study has 
shown for the first time its neurite outgrowth activity which was 33.4 ± 4.6% of neurite 
bearing cells. The mushroom extract also triggered mean N2a neurite length of 116.72 ± 
29.5 µm. Further, P. giganteus was less studied when compared to the other mushrooms 
for its neuritogenic properties. Coming from a Pleurotus genus, this mushroom is edible 
and culinary; therefore, it would be interesting to diversify what is on the table and to 
develop P. giganteus as a functional food which may serve as a brain food.  
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CHAPTER IV 
NUTRITIONAL COMPOSITION AND ANTIOXIDANT ACTIVITY OF 
PLEUROTUS GIGANTEUS, A POTENT NEURONAL-HEALTH PROMOTING 
MUSHROOM 
 
4.1  INTRODUCTION 
Age-related neurodegenerative diseases such as Alzheimer’s involved a programmed 
apoptotic neuronal death triggered as a result of NGF depletion and oxidative stress 
exerted by reactive oxygen species (ROS) (Liochev, 2013). Strategies aimed at 
preventing neuronal loss and preserving and/or restoring the neurite network, are crucial 
in preventing and treating neurodegenerative diseases. Dietary intake of antioxidants, 
therefore, is important to improve the intrinsic antioxidant mechanisms (superoxide 
dismutase, catalase, and glutathione peroxide) to avoid an environment where pro-
oxidant species overwhelm antioxidant species.  
Studies have shown that there is a positive correlation between the neurite 
outgrowth stimulatory effects of a molecule and its antioxidant capacity. Curcumin is a 
natural product widely used in India since ancient days to treat various ailments. The 
high antioxidant activity has made it an effective neuroprotective and neuritogenic agent 
to prevent and/or treat multiple neurological disorders (Liao et al., 2012). Green tea 
represents a popular beverage across Asian countries. The polyphenols in green tea 
possess radical scavenging and iron chelating properties (Biasibetti et al., 2013). 
Evidence indicates that the antioxidants, e.g. catechin, epicatechin, and epigallocatechin 
gallate (EGCG) present in green tea is able to regulate APP processing, protect neurons 
from apoptosis, and stimulate neurite outgrowth via various signaling pathways (Jeon, 
Bae, Seong, & Song, 2003; Reznichenko, Amit, Youdim, & Mandel, 2005).  
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In recent times, amounts of consumed mushrooms have risen greatly. 
Mushrooms are valued not only for their nutritional properties, but their health 
properties. Recently, the phenolics in mushrooms have attracted much attention due to 
their strong antioxidant activity. The phenolics includes caffeic acid, catechin, 
chlorogenic acid, p-coumaric acid, ferulic acid, gallic acid, gentisic acid, p-
hydroxybenzoic acid, homogentisic acid, myricetin, protocatechuic acid, and pyrogallol 
(Palacios et al., 2011). Further, mushrooms (Boletus edulis, Pleurotus ostreatus, among 
others), are known to contain high concentrations of ergothioneine which was reported 
to have a high antioxidant potency (Ey, Schömig, & Taubert, 2007). 
There are ample studies available in the literature regarding the chemical 
composition of different mushroom species from all over the world. However, such 
information on P. giganteus, an edible mushroom found in China, Thailand, and Sri 
Lanka is scanty. Moreover, in this study P. giganteus has been shown to promote 
neurite outgrowth (Phan, David, Naidu, Wong, & Sabaratnam, 2013; Phan, Wong, 
David, Naidu, & Sabaratnam, 2012), it would be interesting to analyse its various 
nutritional attributes and its antioxidant properties. Besides, it is important to ensure a 
consistency of nutritional composition between the wild mushroom and the 
domesticated one. In this study, an intra-strain comparison (the domesticated wild strain 
versus the commercial strain of P. giganteus) on their various nutritional components 
including protein, carbohydrates, sugar profile, vitamins, fatty acids, and amino acids; 
was carried out. The cultivation conditions were kept constant. Besides, the phenolic 
and flavonoid contents, as well as antioxidant activities of the extracts, were evaluated. 
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4.2 MATERIALS AND METHODS 
 
4.2.1 Mushroom  
Fresh basidiocarps of P. giganteus (commercial strain KLU-M 1227) were collected 
from Nas Agro Farm and Dong Foong Biotech. Wild P. giganteus (KLU-M 1228) 
collected from Ayer Hitam Forest Reserve, Puchong, Malaysia was domesticated and 
cultivated. The mushroom identity (molecular finger-printing) was authenticated by Dr. 
Yee-Shin Tan from Mushroom Research Centre, University of Malaya. Voucher 
specimens were deposited in the Herbarium of University of Malaya, Kuala Lumpur. 
 
4.2.2 Cultivation of P. giganteus 
Pleurotus giganteus (KUM61102) was maintained on potato dextrose agar (PDA) at 4 - 
10°C and regularly subcultured. The substrate formulation for the cultivation of P. 
giganteus is similar to that for oyster mushroom cultivation, i.e. 89 - 94% (w/w) rubber 
wood sawdust, 5 - 10% (w/w) rice bran and 1% (w/w) calcium carbonate.  
Polypropylene bags are used for substrate bagging and the moisture content in the 
substrate was kept at 60% - 65%. The temperature for mycelia growth, spawn run, and 
fruiting body formation is 26 - 32°C.  Relative humidity of 70% and 80 - 90% during 
mycelia growth and fruiting; respectively, should be maintained. Direct illumination 
should be avoided as it has been reported to inhibit the fruiting body formation. A 20-
day cycle after complete colonization of the artificial log is needed for each harvest and 
about four harvests (a total yield of 280 g) can be obtained from each bag of 900 g (Nas 
Agro Farm, personal communication). 
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4.2.3 Proximate analysis of basidiocarps of P. giganteus 
The freeze-dried powder of basidiocarps of P. giganteus was analyzed for the 
nutritional components using the standard American Oil Chemists’ Society (AOCS) 
procedures (AOAC, 1995). Total fat, dietary fibre, and protein content were analyzed 
using AOAC 989.05, AOAC 985.25, and Kjeldahl method with boric acid modification; 
respectively. Carbohydrates were calculated using the formula carbohydrates (g) = 100 - 
(protein+ fat + ash). Energy was calculated using the formula energy (kcal) = 4 × 
(protein + carbohydrate) + 9 × (fat) (AOAC, 1995). 
 
4.2.4 Determination of free sugars, minerals, vitamins, fatty acids, and amino 
acids 
Free sugars and amino acids were analysed by high performance liquid chromatography 
(HPLC). Minerals were determined using inductively coupled plasma optical emission 
spectrometry ICP-OES following the AOAC 985.01 and 922.02, as well as American 
Association of Cereal Chemists (AACC 40-70) procedures. Vitamin C was determined 
by the AOAC 967.21 method. Preparation of methyl esters of long-chain fatty acids was 
carried out based on AOCS Ce-2-66 test for further analysis by gas chromatography 
(GC). Chromatography system (Agilent Technologies 6890N) equipped with an Inert 
Mass Selective Detector (Agilent Technologies 5975) (70eV direct inlet) on a HP-5ms 
(5% phenyl methyl siloxane) capillary column (30 m × 250 µm × 0.25 µm) initially set 
at 150ºC, then increased at 5ºC per min to 300ºC and held for 10 min. Helium was used 
as carrier gas at a flow rate of 1 mL per min. The total ion chromatogram obtained was 
autointegrated by chemstation and the constituents were identified by comparison with 
the accompanying mass-spectra database (Wiley 9th edition with NIST 11 Mass 
Spectral Library, USA) wherever possible. Omega-3 and Omega-6 fatty acids were 
analyzed using AOCS 1d-91 methods by capillary gas-liquid chromatography (GLC).  
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4.2.5 Preparation of P. giganteus extracts 
The aqueous and ethanol extracts were prepared as described in section 3.2.3.   
 
4.2.6 Determination of total polysaccharides in P. giganteus extracts 
The total polysaccharide content of the aqueous and ethanol extracts was determined 
using the phenol-sulphuric acid method with D-glucose as a reference (DuBois, Gilles, 
Hamilton, Rebers, & Smith, 1956). Briefly, 1 mL of 5% phenol was added to 1 mL of 
sample solution, followed by 5 mL of concentrated H2SO4. The absorbance was 
measured after 10 min at 497 nm.  
 
4.2.7 Determination of total phenolic contents (TPC) in P. giganteus extracts 
The total phenolic contents in the mushroom extracts, expressed as gallic acid 
equivalents (GAEs), were determined by the Folin–Ciocalteu method (Singleton & 
Rossi, 1965). Fifty microliter of sample was mixed with an equal volume of Folin–
Ciocalteu phenol reagent. After 3 min, 100 µL of Na2CO3 (10%) was added to the 
mixture. The reaction was kept in the dark for 90 min, after which the absorbance was 
read at 750 nm using a spectrophotometer. A calibration curve was prepared with 
different concentrations of gallic acid (0 - 100 µg/mL) as standard. TPC was expressed 
as mg GAE/ g of extract. 
 
4.2.8. Determination of total flavonoids in P. giganteus extracts 
Total flavonoids in the mushroom extract were estimated by using the aluminum 
calorimetric method (Iqbal Ismail, Chan, Adam Mariod, & Ismail, 2010). Mushroom 
extract of 150 µL was mixed with an equal volume of aluminium chloride, AlCl3 (2%). 
After 10 min, the absorbance of the supernatant was measured at 435 nm by using an 
ELISA microplate reader (Sunrise, Austria). The total flavonoid content of the 
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mushroom extract was expressed as rutin equivalents in microgram per gram extract 
(mg RE/g extract).  
 
4.2.9  Evaluation of antioxidant activity of P. giganteus extracts   
 
4.2.9.1  DPPH scavenging activity assay 
The DPPH free radical scavenging activity was determined as previously described 
(Gorinstein et al., 2005). Mushroom extracts of various concentrations (5 µL) was 
mixed with 195 µL of DPPH reagent. The reduction of the DPPH radical was 
determined by measuring the absorption at 517 nm using a microtiterplate reader 
(Tecan, Austria). The radical scavenging activity was calculated using the following 
equation: % radical scavenging activity = (Abs Blank - Abs Sample) / Abs Blank × 100%] 
where Abs Sample is the absorbance of the sample whereas Abs Blank is the absorbance of 
the DPPH solution. The antioxidant property of the extracts was expressed in terms of 
IC50 value that is the concentration to quench 50% of available DPPH content. L-
ascorbic acid (0-25μM) was used as standard and butylated hydroxytoluene (BHT) was 
used as control. 
 
4.2.9.2  FRAP (ferric reducing antioxidant power) assay 
The reducing power of mushrooms extracts was determined by the ferric reducing 
antioxidant potential (FRAP) assay as previously described (Benzie & Strain, 1999). To 
prepare FRAP reagent, 2.5 mL of FeCl3•6H2O solution (20 mM in 40 mM HCl) was 
mixed with 2.5 mL of 2,4,6-tri(2-pyridyl)-1,3,5-triazine (TPTZ) (10 mmol/L in 300 
mmol/L acetate buffer). Then, 10 µL of mushroom extract was added to 300 µL of the 
FRAP reagent after which the absorbance of the product of the reaction between Fe
2+
 
and TPTZ was measured at 593 nm against a blank for each sample. Ferrous sulfate 
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(FeSO4) of concentrations 0-20 mM was used as standard and BHT as control. The 
FRAP value was expressed as µM of FeSO4 equivalents/g mushroom.  
 
4.2.9.3  Inhibition of lipid peroxidation  
The assay was based on the thiobarbituric acid reaction method (Kuppusamy, Indran, & 
Balraj, 2002). Mushroom extracts of different concentrations (0 - 20 mg/mL) was mixed 
with 0.5 mL of egg yolk suspension and 0.5 mL of FeSO4. The mixture was incubated 
at 37 °C for an hour after which 0.5 mL of 20% trichloroacetic acid (TCA) and 1 mL of 
0.8% thiobarbituric acid (TBA) were added. The mixture was then heated in boiling 
water for 15 min and centrifuged at 3500 rpm for 20 min. The absorbance of 
thiobarbituric acid reactive substances (TBARS) present in the supernatant was 
measured at 532 nm using a microtiterplate reader (Tecan, Austria). Result was 
expressed as percentage inhibition of lipid peroxidation at extract concentration of 10 
mg/ml. BHT was used as a control in this assay. 
 
4.3 RESULTS 
 
4.3.1 Proximate analysis, determination of sugars, minerals; and vitamins in P. 
giganteus 
The proximate nutritional components of commercial P. giganteus (KLU-M 1227) and 
domesticated wild P. giganteus (KLU-M 1228) are shown in Table 4.1. The commercial 
strain presented a significantly higher (p < 0.05) carbohydrate, dietary fibre, total fat, 
and monosaturated fat content compared to the domesticated wild strain by 3.7, 2.7, 16, 
and 2.1%; respectively. Both strains showed no difference in the gross energy value and 
saturated fat contents. However, the wild strain presented a significantly higher (p < 
0.05) crude protein and polyunsaturated fat content.  
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The sugar composition of P. giganteus basidiocarps is also given in Table 4.1. 
Glucose and fructose were detected in the basidiocarps of both strains. The glucose and 
fructose content of the domesticated wild strain was approximately 47% and 26% 
higher (p < 0.05) than that of the commercial strain. For macroelements composition, 
potassium in the basidiocarps of commercial strain (13.46 ± 0.0 g kg
-1
) was significantly 
higher (p < 0.05) than the domesticated wild strain (11.71 ± 0.32 g kg
-1
). On the other 
hand, the calcium level in the domesticated wild strain (0.087 ± 0.01 g kg
-1
) was higher 
than that of the commercial strain (0.058 ± 0.0 g kg
-1
). The vitamin profiles showed 
similarity but the concentrations in the two strains were different. Vitamin C (ascorbic 
acid) in the wild strain was almost 3.9-fold higher than that of the commercial strain 
(Table 4.1). Vitamin B3 (niacin) is the most abundant vitamin found in this mushroom 
with 0.09 ± 0.10 and 0.06 ± 0.02 g kg
-1
 in the commercial and domesticated wild strain; 
respectively.  
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Table 4.1: Chemical compositions, sugars, macro-, microelements, and vitamins of 
commercial Pleurotus giganteus (KLU-M 1227) and wild P. giganteus (KLU-M 
1228) 
Parameter Pleurotus 
giganteus 
(commercial 
strain)  
Pleurotus 
giganteus  
(wild strain) 
Recommended 
daily allowance 
(RDA) 
Carbohydrate (g kg
-
1
) 
672 ± 0.00
a
 647 ± 0.00
b
 300 g 
Protein (g kg
-1
) 154 ± 0.00 
c
 192 ± 0.00 
d
 50 g 
Energy (kcal kg
-1
) 3640 ± 0.00 
e
 3640 ± 0.00 
e
 - 
Dietary fiber (g kg
-1
) 333.5 ± 0.07 
f
 324.5 ± 0.07 
g
 25 g 
Total fat (g kg
-1
) 37.0 ± 0.00 
h
 31.0 ± 0.00 
i
 65 g 
Saturated fat 9.7 ± 0.00 
j
 9.5 ± 0.00 
j
 - 
Monosaturated fat 19.7 ± 0.00 
k
 13.2 ± 0.00 
l
 - 
Polyunsaturated fat 7.8 ± 0.00 
m
 8.3 ± 0.00 
n
 - 
Trans fat ND ND - 
Cholesterol  (g kg
-1
) ND ND 300 mg 
Free sugars (g kg
-1
)    
Fructose 7.2 ± 0.2 
a
 10.6 ± 0.4 
b 
 - 
Glucose 31.4 ± 0.7 
c
 39.7 ± 0.2 
d
 - 
Sucrose ND ND - 
Lactose ND ND - 
Maltose ND ND - 
Maltotriose ND ND - 
Macroelements (g 
kg
-1
) 
   
Potassium (as K) 13.46 ± 0.00 
a
 11.71 ± 0.32
 b
 3.5 g 
Phosphorus (as P) 5.27 ± 0.39 
c
 4.01 ± 0.04 
d
 0.7 g 
Magnesium (as Mg) 0.67 ± 0.00 
e
 0.65 ± 0.00 
f
 0.4 g 
Calcium (as Ca) 0.058± 0.00 
g
 0.087 ± 0.01
h
 1.0 g 
Sodium (as Na) 0.058 ± 0.07 
g
 0.047 ± 0.00 
i
 2.4 g 
Microelements (g 
kg
-1
) 
   
Iron (as Fe) 0.019 ± 0.04 
a
 0.014 ± 0.00 
b
  18 mg 
Zinc (as Zn) 0.027 ± 0.01 
c
 0.042 ± 0.00 
d
 15 mg 
Manganese (as Mn) 0.041 ± 0.01 
e
 0.043 ± 0.00 
e
 2.0 mg 
Copper (as Cu) (mg 
kg
-1
) 
0.60 ± 0.01 
f
 0.228 ± 0.00 
f
 2.0 mg 
Selenium (as Se) 
(mg kg
-1
) 
ND ND 70 µg 
Vitamins (g kg
-1
)    
Vitamin B1 0.004 ± 0.01 
a
 0.002 ± 0.00 
b
 1.4 mg 
Vitamin B2 0.009 ± 0.00 
c
 0.009 ± 0.00 
c
 1.6 mg 
Vitamin B3 0.09 ± 0.10 
d
 0.06 ± 0.02 
e
 14 - 16 mg 
Vitamin C 0.003 ± 0.00 
a
 0.001 ± 0.01 
f
 75 - 90 mg 
Each values are expressed as mean ± SD (n = 3).  In each row, the different letters 
represent significant differences between samples (p < 0.05). ND: Not detectable. 
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4.3.2 Determination of amino acids in P. giganteus 
All the essential amino acids (threonine, valine, methionine, isoleucine, leucine, 
phenylalanine, tryptophan, lysine, histidine, and arginine) were detected in this 
mushroom with the exception of tryptophan (Table 4.2). Among the essential amino 
acids, leucine (commercial strain 20.4 ± 0.10 g kg
-1
; domesticated wild strain 19.4 ± 0.0 
g kg
-1
) was found to be the largest constituent, followed by phenylalanine, and histidine. 
The methionine, isoleucine and valine were present in small amounts ranging from 
0.31-0.80% for both the P. giganteus strains. In particular, P. giganteus had the highest 
concentration of glycine, which is categorized as the non-essential amino acid. Also, the 
wild strains exhibited higher amount of glutamine, alanine, and asparagine as compared 
to the commercial strains.  
 
4.3.3 Determination of fatty acids in P. giganteus 
Table 4.3 presents the fatty acid profile of basidiocarps of P. giganteus. Among the 
saturated fatty acids, palmitic acid (C16:0) was predominant with 3.8 ± 0.01 and 3.3 ± 
0.0 g kg
-1
 in the commercial strain and wild strain; respectively. Amongst the 
polyunsaturated fatty acids, oleic acid was the predominant fatty acid in this species. 
Oleic acid (C18: 1n9c) in the commercial strain (10.3 ± 0.06 g kg
-1
) was significant (p < 
0.05) higher than that in the wild strain (8.9 ± 0.0 g kg
-1
). Linoleic acid was also present 
in significant quantities (4.5 – 5.0 g kg-1) in P. giganteus.  The medium chain fatty acid, 
caprylic acid (C8:0) and the long chain fatty acid, stearic acid (C18:0) were also present. 
Capric, undecanoic, palmitoleic and eicosadienoic acids were detected in trace amounts 
in P. giganteus.  
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Table 4.2: Amino acid content (g kg
-1 
dry weight) of Pleurotus giganteus KLU-M 
1227 and KLU-M 1228 
Amino 
acids  
Pleurotus giganteus (commercial 
strain) 
Pleurotus giganteus (wild 
strain) 
Asp 6.9 ± 0.00 
c
 7.0 ± 0.00
c 
 
Glu 15.7 ± 0.00 
jk
 17.2 ± 0.10 
l
 
Ser 11.1 ± 0.01 
e
 11.0 ± 0.01 
e
 
His
*
 15.4 ± 0.04 
ji
 15.1 ± 0.05 
j
  
Gly 29.0 ± 0.11 
p
 29.5 ± 0.04 
p
 
Thr
*
 5.3 ± 0.01 
b
 5.2 ± 0.00 
b
 
Arg
*
 11.4 ± 0.04 
ef
  12.1 ± 0.00 
fg
  
Ala 11.1 ± 0.01 
e
  13.5 ± 0.00 
h
 
Tyr 5.8 ± 0.06 
b
 5.9 ± 0.00 
b
 
Cys ND ND 
Val
*
 8.0 ± 0.01 
d
 7.1 ± 0.00 
c
 
Met
*
 3.1 ± 0.01 
a
 3.1 ± 0.00 
a
 
Phe
*
 16.4 ± 0.09 
kl
 16.5 ± 0.00 
kl
 
Ile
*
 7.7 ± 0.02 
cd
  7.3 ± 0.00 
cd
  
Leu
*
 20.4 ± 0.10 
n
  19.4 ± 0.00 
m
 
Lys
*
 14.5 ± 0.01 
i
 12.8 ± 0.00 
gh
 
Asn 15.2 ± 0.07 
ij
  24.6 ± 0.00 
o
  
Gln ND ND 
Nva ND ND 
Trp
*
 ND ND 
Asp (Aspartate); Glu (Glutamate); Ser (Serine); His (Histidine); Gly (Glycine); Thr 
(Threonine); Arg (Arginine); Ala (Alanine); Tyr (Tyrosine); Cys (Cystine); Val 
(Valine); Met (Methionine); Phe (Phenylalanine); Ile (Isoleucine); Leu (Leucine); Lys 
(Lysine); Asn (Asparagine); Gln (Glutamine); Nva (Norvaline); Trp (Tryptophan). Each 
values are expressed as mean ± SD (n = 3).  In each row, the different letters represent 
significant differences between samples (p < 0.05). ND: Not detected. 
*
 Essential amino 
acids.  
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Tabe 4.3: Fatty acids (g kg
-1 
dry weight) detected in the basidiocarps of Pleurotus 
giganteus 
 Fatty acid Pleurotus giganteus 
(commercial strain) 
Pleurotus giganteus 
(wild strain) 
C8:0 Caprylic  1.3 ± 0.00 
a
 1.1 ± 0.00 
ab
 
C10:0 Capric 0.4 ± 0.00 
c
 0.4 ± 0.00 
c
  
C11:0 Undecanoic 0.8 ± 0.00
b
 0.8 ± 0.00
b
 
C16:0 Palmitic 3.8 ± 0.00 
d
 3.3 ± 0.00 
e
 
C16:1 Palmitoleic 0.1 ± 0.00
c
 0.1 ± 0.00 
c
 
C18:0 Strearic 1.1 ± 0.03 
ab
 0.8 ± 0.00 
b
 
C18:1n9c Oleic 
***
 10.3 ± 0.06 
g
 8.9 ± 0.00 
h
 
C18:2n6c Linoleic
 **
 5.0 ± 0.01 
f
 4.5 ± 0.00 
f
 
C20:2 Eicosadienoic 
**
 0.3 ± 0.01 
c
 0.3 ± 0.00 
c
 
C22:0 Beheric 0.1 ± 0.0 c 0.1 ± 0.00c 
C24:0 Lignoceric  0.4 ± 0.01 
c
 0.4 ± 0.00 
c
 
** 
Omega-6 PUFAs; 
*** 
Omega-9 PUFAs. Each values are expressed as mean ± SD (n = 
3).  In each row, the different letters represent significant differences between samples 
(P < 0.05).  
 
4.3.4 Determination of total polysaccharides, total phenolic, and total flavonoids 
in P. giganteus extracts 
The total polysaccharides of the commercial and wild P. giganteus were comparable. 
The aqueous extract had the highest amount of polysaccharides as shown in Table 4.4. 
Notably, the total polysaccharides in aqueous extract of the wild strains (17.91 ± 0.05%, 
w/w) was significantly (p > 0.05) higher than that of the commercial strain (14.93 ± 
0.04%). On the other hand, the total phenolic content in the ethanol extracts were 
higher. The quantity of phenolics in the mushrooms extracts was in descending order: 
commercial strain ethanol extract > wild strain ethanol extract > commercial extract 
aqueous extract > wild strain aqueous extract. There was also a significant difference (p 
< 0.05) in the total flavonoids between the basidiocarps of the commercial and wild 
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strains. The wild P. giganteus had approximately 2.09% higher flavonoids than the 
commercial strains.  
 
Table 4.4: Total polysaccharides, phenolics, and flavonoids present in the crude 
aqueous and ethanol extracts of basidiocarps of Pleurotus giganteus 
 Pleurotus giganteus 
(commercial strain) 
Pleurotus giganteus (wild 
strain) 
 Aqueous Ethanol Aqueous Ethanol 
Extraction yield 
(%, w/w) 
15.60 ± 2.20 
a
 
12.00 ± 1.00 
b
 13.77 ± 1.68 
ab
 
6.67 ± 1.06 
c
 
Total 
polysaccharides 
(%, w/w) 
14.93 ± 0.04 
a
 
11.31 ± 0.16 
b
  17.91 ± 0.05 
c
 13.72 ± 0.04 
d
 
Total phenolic 
content (mg 
GAE/g) 
12.14 ± 1.89 
a
 
24.08 ± 1.04 
b
 9.58 ± 0.18 
c
 21.61 ± 1.47 
d
 
Total flavonoids 
(mg RE/g) 
ND 2.94 ± 0.00 
a
  ND 6.14 ± 0.01
b
 
In each row, the different letters represent significant differences between samples (p < 
0.05). ND = not detected. 
 
4.3.5 Evaluation of antioxidant activity in P. giganteus extracts 
 
4.3.5.1  DPPH scavenging activity assay 
The scavenging effect of the mushroom extracts on DPPH radicals increased with 
sample concentration, depending on the extraction solvent and strain type. In general, 
the ethanol extracts showed higher scavenging activity, hence lower IC50 (mg/mL) when 
compared to the aqueous extracts (Table 4.5). The scavenging activity obtained in 
descending order was: wild strain ethanol extract > commercial strain ethanol extract > 
wild strain aqueous extract > commercial strain aqueous extract.  
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4.3.5.2  FRAP (ferric reducing antioxidant power) assay 
In the ferric reducing power assay, the reducers present in the mushroom extracts lead 
to the reduction of the Fe
3+
/ferricyanide complex to the ferrous form. The reducing 
capacity of the mushroom extract serves as an index of antioxidant activity. The 
reducing ability of the different extracts was in the range of 1.17 – 3.88 µM 
FeSO4.7H2O/ g mushroom (Table 4.5). The antioxidant activity obtained in descending 
order was: commercial strain ethanol extract ≥ wild strain ethanol extract ≥ commercial 
strain aqueous extract ≥ commercial strain aqueous extract.  
 
4.3.5.3  Inhibition of lipid peroxidation  
The study of lipid peroxidation (LPO) inhibition is based on the measurement of 
malondialdehyde (MDA) generated by the polyunsaturated fatty acid peroxides upon 
decomposition. As a result of LPO, destruction of cellular components occurs and 
brings about oxidative stress in biological systems. As shown in Table 4.5, there was no 
significant difference (p > 0.05) in terms of lipid peroxidation inhibition between the 
commercial and domesticated wild mushroom extracts. However, the ethanol extracts of 
both the strains showed significantly higher (p < 0.05) lipid peroxidation inhibitory 
ability (49.58 – 49.80%) when compared to the aqueous extracts (44.41 – 44.61%). 
Therefore, the extraction methods and solvent used instead of mushroom strains played 
a more prevailing role in lipid peroxidation inhibition.  
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Table 4.5: Antioxidant activities of the aqueous and ethanol extracts from the 
commercial strain of Pleurotus giganteus (KLU-M 1227) and the wild strain (KLU-
M 1228) 
Antioxidant 
properties 
Test method Positive 
control 
(BHT) 
Pleurotus 
giganteus  
(commercial 
strain) 
Pleurotus 
giganteus  
(wild strain) 
Aqueous Ethanol Aqueous Ethanol 
Free radical 
scavenging 
DPPH (IC50; 
mg/mL) 
0.09 ± 
0.01 
21.46 ± 
6.95 
a
 
 
11.28 ± 
3.54 
bc
 
16.18 ± 
1.76 
ab
 
 
8.10  ± 
2.15 
c
 
Reducing 
power 
FRAP (µM 
FeSO4.7H2O/ g) 
780.29 
± 13.40 
2.26 ± 
0.29 
ab
 
2.99 ± 
0.14 
b
 
2.04 ± 
0.32 
a
 
2.69 ± 
0.71 
b 
 
Lipid 
peroxidation 
inhibition 
Inhibition of lipid 
peroxidation at 
extract 
concentration of 
10 mg/mL (%) 
79.07 ± 
2.25 
44.41 ± 
1.00 
a
 
49.58 ± 
1.87 
b
 
44.61 ± 
1.42 
a
 
49.80 ± 
3.27 
b
 
In each row, the different letters represent significant differences between samples (p < 
0.05). 
 
4.3.6 Correlation between total polysaccharides, total phenolics, and antioxidant 
activities 
The TPC in the mushroom extract was positively correlated to the DPPH scavenging 
capacity (r = +0.827) and FRAP reducing power (r = +0.820). This indicated that the 
antioxidant effects increased with increasing concentrations of the total phenolics 
present in the mushroom extracts. However, a weak correlation was found between the 
lipid peroxidation inhibition activity and the TPC (r = +0.321). Nevertheless, the DPPH 
scavenging capacity, FRAP reducing power, and lipid peroxidation inhibition 
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showed a strong positive correlation (r = +0.806 to +0.820) between each antioxidant 
activity. 
 
4.4 DISCUSSION 
 
The nutritional components found in the present work are in accordance with the 
literature. A study in Italy showed that the protein content in Pleurotus ostreatus (grey 
oyster mushroom) was 1.61 ± 0.02 g/100 g (Manzi, Aguzzi, & Pizzoferrato, 2001), 
which is lower than the protein content of P. giganteus in this study. Pleurotus 
giganteus also showed a higher protein content when compared to Pleurotus sajor-caju 
(13.0-18.4 g/100 g) (Bonatti, Karnopp, Soares, & Furlan, 2004). The protein content of 
mushrooms is dependent on the strain, substrate chemical composition, pileus size, and 
cultivation time (Nunes, Maria, Paes, Júlio, & Ribeiro, 2012; Shashirekha, Rajarathnam, 
& Bano, 2005). In this study, rice bran supplementation may have increased the soluble 
protein content present in both strains as the protein content in rice bran is about 10-
15% of the total weight of the mushroom growth substrate (Fabian & Ju, 2011).  
The carbohydrate content of Pleurotus ostreatus was mainly composed of 
glucose (14.29 g kg
-1
) and mannose (10.55 g kg
-1
) (M.-Y. Kim et al., 2009). While 
fructose was not detected in P. ostreatus, 27.81 g kg
-1
 of glucose was detected in P. 
eryngii with trace amounts of ribose and xylose. Pleurotus spp. in particular are rich in 
calcium, potassium, magnesium, iron, and phosphorus (Ragunathan & Swaminathan, 
2003). Pleurotus sajor-caju, P. platypus, and P. citrinopileatus were reported to contain 
16.3 ± 0.22, 11.2 ± 0.3, and 10.3 ± 0.2 g kg
-1
 of potassium; respectively. The 
concentrations of vitamin B3 in mushrooms were highly species dependent and it varies 
from 34 to 109 mg/100 g dry weight for P. ostreatus (Cheung, 2010). Mushrooms 
contain higher vitamin B2 (riboflavin) when compared to vegetables. Some varieties of 
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Agaricus bisporus (white button mushroom) have also been reported to contain vitamin 
B2 levels as high as those found in eggs and cheese (Mattila et al., 2001). In this study, 
vitamin B1 (thiamin) was higher in the commercial strain by 1.9-fold, while vitamin B2 
level was not significantly different when compared to that of the wild strain.  
The amino acids in P. giganteus were comparable with reported literature 
values. Tanzanian wild mushrooms Lactarius sp. (milky cap), Boletus pruinatus (Matt 
Bolete mushroom) and Boletinus cavipes were reported to have leucine as high as 
15.9%, 10.6% and 8.40%; respectively (Mdachi, Nkunya, Nyigo, & Urasa, 2004). The 
fresh P. ostreatus was found to have 2.74, 1.76, and 1.43 g kg
-1
 of glutamine, 
asparagine, and arginine; respectively (Jaworska, Bernaś, Mickowska, & Bernas, 2011). 
Similar to the present study, other edible mushrooms also contained high levels of oleic 
acid  (% total fatty acid methyl esters): Auricularia polytricha (27.1), Lentinus sajor-
caju (23.5), Lentinus squarrosulus (5.8), Pleurotus djamor (28.8), P. sajor-caju (16.4), 
and Russula brevepis (39.2) (Kavishree, Hemavathy, Lokesh, Shashirekha, & 
Rajarathnam, 2008). The presence of caprylic and capric acids in mushrooms is rare. 
Calocybe gambosa (St. George's mushroom) and Clitocybe odora (Aniseed funnel 
mushroom) were reported to have 0.25 ± 0.02 and 0.03 ± 0.00% of caprylic acid; 
respectively; while Coprinus comatus (shaggy mane mushroom) registered 0.09 ± 
0.00% of capric acid (Vaz et al., 2011).     
Extraction with boiling water is used to obtain extracts with high molecular 
weight compounds, such as polysaccharides which play an important medicinal role in 
mushrooms (Ferreira, Vaz, Vasconcelos, & Martins, 2010). Low molecular weight 
compounds, such as phenolic compounds were usually from ethanol extraction (Vaz et 
al., 2011). Although flavonoid was not detected in P. sajor-caju (Kanagasabapathy et 
al., 2011), its concentration ranging from 0.24 - 0.32 mg/g was reported in P. ostreatus 
(Vamanu, 2013). Flavonoids were also present in other mushroom species like 
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Clitocybe gibba (3.56 mg chatequin/g extract) and Boletus armeniacus (8.59 mg 
chatequin/g extract) (Pereira, Barros, Martins, & Ferreira, 2012). The rubber wood 
sawdust which is rich in lignin could have been depolymerized by the lignocellulosic 
enzymes of mushrooms into phenolic units and further dimerized or polymerized, 
creating flavonoids (Dubost, Ou, & Beelman, 2007).  
DPPH radical scavenging effects of the mycelia extracts of Pleurotus spp. (P. 
citrinopileatus, P. djamor, P. eryngii, P. flabellatus, P. florida, P. ostreatus, and P. 
sajor-caju) have been reported (Mishra et al., 2013; Vamanu, 2013).  The methanol and 
hot water extracts (10 mg/mL) of P. eous were found to scavenge DPPH radical by 
85.19% and 70.21%, respectively (Sudha, Vadivukkarasi, Shree, & Lakshmanan, 2012). 
The higher DPPH scavenging ability of ethanol extracts might be due to more 
hydrogen-donating components including phenolic compounds extracted from the 
mushroom. The higher phenolic content of ethanol extracts might account for the better 
results found in reducing power as compared to the aqueous extract (Singdevsachan, 
Patra, & Thatoi, 2013). When comparing the FRAP values of P. giganteus with P. 
sajor-caju, FRAP values of aqueous extract of P. giganteus was lower than that of P. 
sajor-caju (35.06 ± 0.86 µM FeSO4.7H2O/ g mushroom) (Kanagasabapathy et al., 
2011). The higher phenolic content in the ethanol extracts might contribute to a higher 
inhibitory effect on lipid peroxidation. Pleurotus florida was reported to display 57% of 
lipid peroxidation inhibition, while P. flabellatus, P. cystidiosus, P. eryngii, and P. 
sajor-caju showed 50%, 49.8%, 48% and 43% of lipid peroxidation inhibition, 
respectively (Abdullah, Ismail, Aminudin, Shuib, & Lau, 2012). Meanwhile, P. 
ostreatus at a concentration of 10 mg/ml inhibited LPO activity in rat liver homogenate 
by 56.20% (Jayakumar, Thomas, & Geraldine, 2009).  
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4.5 CONCLUSION 
It was shown that P. giganteus markedly promoted the neurite outgrowth activity in 
differentiating N2a cells but the nutritional profile of P. giganteus is yet to be 
determined. This is the first report on the nutritional profile and chemical compositions 
of P. giganteus. The extracts of the commercial and domesticated wild strains showed 
similar nutritional profile (carbohydrate, protein, and dietary fibre), monosaccharides 
(fructose and glucose), macroelements (potassium, phosphorus, magnesium, calcium, 
and sodium), microelements (iron, zinc, manganese, and copper), and vitamins (B2, B2, 
B3, and C). The amino acid and fatty acid composition of both the strains are also 
similar. This study suggests that the high linoleic acid (4.5-5.0%) present in the 
mushroom extract could be linked to the neurite outgrowth activity as this 
polyunsaturated fatty acid was reported to induce neurite outgrowth. Further, the neurite 
outgrowth activity may be attributed to the vitamins B2 (0.009 g/kg) and B3 (0.09 g/kg) 
which were reported to be beneficial to brain as they help to carry neurotransmitters. On 
the other hand, the commercial and domesticated wild strains of P. giganteus showed 
distinctive antioxidant activities due to the differential distributions of total phenolics 
and flavonoids. The aqueous extract did not contain flavonoids and had a lower 
phenolic content, hence explaining its lower antioxidative capacity. The new data 
presented here are useful and will support future studies on the effects of P. giganteus 
supplementation in individuals at high risk of age-related disease. Further studies will 
consider the direct effect of the chemical compounds in the mushroom extract on 
differentiating N2a cells. 
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CHAPTER V 
EFFICACY OF THE CHEMICAL CONSTITUENTS OF PLEUROTUS 
GIGANTEUS EXTRACTS ON NEURITE OUTGROWTH IN N2A CELLS AND 
THE UNDERLYING MECHANISMS  
 
5.1  INTRODUCTION 
As discussed earlier, functional food plays a significant role in preventing or reducing 
the severity of lifestyle associated diseases and improve physical and mental well-being 
of consumers. Edible and medicinal mushrooms are gaining recognition as preventative 
agents for age-related diseases including neurodegenerative diseases such as AD, 
Parkinson’s disease, and dementia (Sabaratnam et al., 2011). Currently, medications are 
prescribed for mild, moderate, to severe Alzheimer’s disease to help delay or prevent 
behavioural symptoms but that too, seems to be effective for only a limited time frame. 
Trials with NGF for Alzheimer's disease had gained some degree of success but the 
high molecular weight of NGF protein reduces its ability to cross the blood-brain barrier 
(Allen et al., 2013). Considering the limitation of the above, early intervention strategy 
using mushrooms as functional food may be helpful. Edible and medicinal mushrooms 
are packed with a wide array of bioactive and nutritional components that could 
scavenge reactive oxygen species (ROS). They are able to exert neuroprotective effects 
and promote neuritogenesis as well as play a role in neuroregeneration (Roupas et al., 
2012).  
Pleurotus giganteus is one of the edible mushrooms which have been shown to 
have neurite outgrowth stimulatory effects (Chapter III). In Chapter IV, the mushroom 
extracts exhibit high antioxidant activities (Phan, David, et al., 2014). There is a need to 
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elucidate the chemical compounds which contribute to the neuritogenic properties of 
this mushroom. Therefore, the objective of this chapter was to determine the efficacy of 
the individual chemical constituents of P. giganteus in stimulating neurite outgrowth of 
N2a cells. The chemical constituents selected were linoleic acid, oleic acid, cinnamic 
acid, caffeic acid, p-coumaric acid, succinic acid, benzoic acid, and uridine based on a  
previous study (Moroney, 2012). The compound which showed the most promising 
neurite outgrowth activity will be subjected to finger printing by using HPLC for 
another round of verification. The compound will then be used for the subsequent tests 
along with the standardised extracts. In order to confirm the underlying mechanisms of 
the neurite outgrowth activity induced by the chemical compounds and the standardised 
extracts, treatment of cells with specific inhibitors was carried out followed by 
measurement of the phosphorylated kinases using enzyme-linked 
immunosorbent assays. 
 
5.2 MATERIALS AND METHODS 
 
5.2.1 General methodology 
Preparation of the aqueous and ethanol extracts of P. giganteus is given in Section 3.2.3. 
Cell culture method and neurite outgrowth assay by quantification of neurite bearing 
cells can be found in Sections 3.3.2, 3.2.4, and 3.2.5. 
 
5.2.2 Compounds detected in the basidiocarps of P. giganteus 
The compounds in the basidiocarps of P. giganteus were previously identified by 
GCMS and LCMS/MS (Moroney, 2012). Linoleic acid (5.00%) and oleic acid (10.30%) 
were present in the ethanol extract of P. giganteus; while cinnamic acid (0.1%), caffeic 
acid (1.31%), p-coumaric acid (0.07%), succinic acid (12.57%), benzoic acid (2.14), 
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and uridine (0.55%) were present in the aqueous extract. All the compounds were 
purchased from Sigma (St. Louis, MO, USA). Figure 5.1 shows the structure of the 
compounds. 
 
  
 
 
   
 
 
Figure 5.1: Compounds detected in the aqueous and ethanol extracts of P. 
giganteus. 
 
 
 
 
 
Linoleic acid Oleic acid 
Cinnamic acid 
Caffeic acid 
p-coumaric acid 
Benzoic acid Succinic acid Uridine 
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5.2.3  Neurite outgrowth assay using chromogenic method 
 
5.2.3.1  Preparation of cell suspension, treatment, coating and fixation 
N2a cells were seeded in culture flask and grown to 70% confluence. The growth media 
was replaced with 5%-serum differentiation media for 24 hours to initiate cell 
differentiation and neurite extension. The insert membrane surface of the NS220 
Neurite Outgrowth Assay Kit (Merck Millipore, Germany) was then prepared. Ten 
µg/mL of collagen Type 1 from rat tail (Sigma) which acts as an extracellular matrix 
(ECM) protein was prepared freshly with 1X phosphate buffered saline (PBS). The 
ECM protein solution (400 µL) was added to the bottom of an empty well of the 24-
well plate. The Millicell insert (Merck Millipore) provided in the assembly kit was 
placed into the well containing the ECM protein and allowed to coat the underside of 
the membrane for 2 hours at 37ºC (Figure 5.2). While membranes were being coated, 
N2a cells were detached from culture flasks and resuspended in 5%-serum media at a 
concentration of 100,000 cells per 100 µL. Following coating, the insert was removed 
from its coating solution and placed into a new well containing 600 µL of 5%-serum 
media with the mushroom extracts or compounds. Cell suspension (100 µL) was added 
onto the top of the membrane and allowed to sit at room temperature for 15 minutes to 
enable even cell distribution. The plate assembly was then transferred to a 37ºC 
incubator to allow neurites to extend on the underside of the membrane for 48 hours 
(Figure 5.2). After 48 hours, each insert was removed from its culture well and the 
liquid from the top of the membrane was gently removed. PBS (1X, 800 µL) was placed 
in the well of a 24-well assay plate and insert was allowed to sit in the PBS briefly to 
rinse. The insert was then transferred to a new well containing 400 µL of - 20ºC 
methanol and allowed to fix for 20 minutes at room temperature. Then, it was rinsed 
again briefly in 800 µL of fresh PBS.  
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5.2.3.2  Staining of neurites for visualisation and quantification 
Following fixation, the insert was placed into 400 µL of Neurite Stain Solution (Merck 
Millipore) in a new well. The neurites were allowed to stain for 15-30 minutes at room 
temperature, and then rinsed in 800 µL of fresh PBS. All the cell bodies were removed 
from the top of the membrane (particularly at the edge) by gently wiping with the cotton 
swab moistened with PBS (Figure 5.2).   
The stained neurite extensions were visualized on intact inserts in a 24-well plate using 
an inverted microscope focused on the underside of the membrane. For quantification, 
200µL drop of Neurite Stain Extraction Buffer (Merck Millipore) was added to each 
insert which was placed onto a piece of Parafilm that has been taped to a flat surface. 
The underside of the membrane was placed over the drop of Extraction Buffer so that 
the entire membrane surface is covered. The stain was allowed to extract for 5 minutes 
at room temperature. The buffer from around and inside of the insert was collected and 
placed in 96-well plate. The neurite extension was then quantified using 
spectrophotometer by reading the absorbance at 560 nm.  
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Figure 5.2: Overview of neurite outgrowth assay using chromogenic method (NS220) Neurite Outgrowth Assay Kit from Merck Millipore, 
Germany. Diagram was modified from NS220 Neurite Outgrowth Assay Kit guide book. 
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5.2.4 Quantification of uridine in P. giganteus extracts 
For quantification of uridine, uridine reference compound was accurately weighed and 
dissolved in water to prepare the standard chemical solutions (1 mg/mL). Perkin Elmer 
Series 200 liquid chromatography equipped with a Perkin Elmer Series 200 UV detector 
was used. The detector signal was recorded by the Turbochrom workstation software. 
The column used was Hypersil BDS C18 (4.6 × 250 mm) with Alltech refillable C18 
Guard column (10 × 4.6 mm) (Alltech, USA). The mobile phase consisted of methanol: 
10 mM monobasic potassium phosphate (15:85; pH 5.0) and the flow rate was 1.5 
mL/min. The calibration curve was prepared by injecting a series of uridine (Sigma) 
standard dilutions. Uridine was quantified by means of calibration curves obtained from 
standard from Sigma.   
5.2.5 Treatment with specific inhibitors  
Stock solution (10 mM) of MEK inhibitors (U0126, PD98059) and PI3K inhibitor 
(LY294002) were prepared in DMSO and stored in −20 °C in the dark. Each inhibitor 
i.e. U0126 (10 μM), PD98059 (40 μM), and LY294002 (30 μM) was then prepared by 
diluting in medium prior to use. P2Y receptor antagonists, suramin (30 μM) and 
pyridoxal phosphate-6-azophenyl-2' 4'-disulfonic acid (PPADS; 30 μM) were prepared 
in double distilled water and protected from light. Cells were either incubated with or 
without the treatment of inhibitors for one hour. All the cells were then stimulated with 
mushroom extracts and uridine for three days prior to scoring neurite bearing cells and 
ELISA tests were carried out for signaling pathway elucidation and protein synthesis.  
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5.2.6 Preparation of cell lysate 
To harvest the cells in a non-denaturing condition, the cells were rinsed with ice-cold 
PBS followed by addition of 0.5 mL of ice-cold cell lysis buffer (Cell Signaling 
Technology, Inc) with 1 mM of phenylmethylsulfonyl fluoride (PMSF) (Sigma). The 
cell lysis buffer (1X) consists of 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM 
Na2EDTA, 1 mM EGTA 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM b-
lycerophosphate, 1 mM Na3VO4, and 1 μg/ml leupeptin. The plate or flask containing 
the cells was incubated on ice for 5 mins. The cells were scraped off, sonicated on ice, 
and microcentrifuged for 10 mins at 4°C. The supernatant is the cell lysate and stored at 
−80°C in single-use aliquots. 
5.2.7 Protein quantification using Coomassie (Bradford) protein assay 
A set of protein standards (0-2000 µg/mL) was prepared by diluting the contents of one 
albumin standard (BSA) ampoule into several vials. A total of 150 µL of standard or 
cell lysate was added into microplate wells. Coomassie reagent (150 µL) was added to 
each well and mixed with plate shaker for 30 seconds. The plate was incubated for 10 
minutes at room temperature to obtain the most consistent results. The absorbance was 
measured at 595 nm on a plate reader. A standard curve was prepared by plotting the 
595 nm measurement for each BSA standard versus its concentration in µg/mL. Using 
the standard curve, the protein concentration estimate was determined for each protein 
lysates.  
5.2.8 Measurement of phosphorylated extracellular-signal regulated kinase (p-
ERK), phosphorylated protein kinase B (p-Akt), phosphorylated mitogen-activated 
protein kinase (p-MEK), phosphorylated mammalian target of rapamycin (p-
mTOR), and phosphorylated cAMP-response element binding protein (p-CREB)  
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Mushroom extracts and uridine were added to N2a cells with or without pretreatment 
with specific inhibitors. At indicated time points, the cells were harvested and cell 
lysates were prepared. The cell lysates were then incubated in microwells pre-coated 
individually with phospho-ERK (p-ERK; Thr202/Tyr204), p-Akt (Thr308), p-MEK1 
(Ser217/221), p-mTOR (Ser2448), and p-CREB (Ser133) antibodies. To increase 
sensitivity, the plate was incubated overnight at 4
o
C. The wells were then washed four 
times with washing buffer (10 mM phosphate buffer pH 7.4, 150 mM NaCl, and 0.05% 
Tween 20). Following washing, detection antibody was added (Cell Signaling 
Technology, Inc). Anti-rabbit IgG, HRP-linked antibody was then added to recognise 
the bound detection antibody. HRP substrate, which is TMB, was then added for colour 
development. Absorbance at 450 nm was recorded and the magnitude of absorbance is 
proportional to the quantity of the p-ERK, p-Akt, p-MEK1, p-mTOR, and p-CREB 
antibodies. 
5.2.9 Measurement of growth associated protein 43 (GAP-43), tubulin alpha 4A 
(TUBA4A), and tubulin beta 1 (TUBb1) 
Each dilution of standard (GAP-43, TUBA4A, and TUBb1; 100μL) and cell lysate 
samples (100μL) were added in appropriate wells (Cloud-Clone Corp., USA). The plate 
was incubated for two hours at 37
o
C. After that, the liquid of each well was removed 
carefully and washing was not required. A total of 100 μL Detection Reagent A 
working solution (Cloud-Clone Corp., USA) was added to each well and was incubated 
for one hour at 37
o
C after covering. The solution was aspirated and the wells were 
washed with 350 μL of 1× washing buffer using a multi-channel pipette; and was left to 
sit for two minutes. The remaining washing buffer was removed from all wells 
completely by snapping the plate onto an absorbent paper. The total number of wash 
was three times. Detection reagent B (100 μL) was added and incubated for 30 minutes 
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at 37
o
C. The wash process was repeated for 5 times. Substrate solution (90 μL) was 
added to each well and incubated for 15-25 minutes. Stop solution (50μL) was added 
and measurement was conducted at 450nm. The levels of GAP-43, TUBA4A, and 
TUBb1were determined from a standard curve plotted with known concentrations of the 
respective proteins.  
5.3 Results 
5.3.1 Neurite outgrowth assays (Quantification of neurite bearing cells and 
chromogenic method) 
The mean value of neurite-bearing cells in NGF treated cells (positive control) was 
22.67 ± 0.74% as shown in Figure 5.3. The aqueous and ethanol extracts of the P. 
giganteus (20 µg/mL) caused a significant (p < 0.05) increase in neurite-bearing cells by 
4.0- and 4.7-times when compared to the control cells with medium only. P-coumaric, 
cinnamic, and oleic acids (100 µM) caused no neuritogenic effects on differentiating 
N2a cells, i.e. 8.56 ± 1.51%, 10.17 ± 1.88%, 10.06 ± 1.32%; respectively. Linoleic acid 
caused 20.78 ± 2.43% of N2a cells to bear neurites. Uridine stimulated the highest (p < 
0.05) percentage of neurite-bearing cell (43.09 ± 4.88%), which was 1.9-times higher 
than that of the positive control.  
Indirect measurement (chromogenic method) was performed on N2a treated 
with mushroom extracts and compounds by using the neurite outgrowth quantification 
assay kit (Merck Millipore). The results were used to confirm the neurite outgrowth 
assay which records the neurite-bearing cells. Briefly, N2a cells after treatment were 
allowed to extend neurites for 48 hours, and then stained with Neurite Stain Solution for 
30 minutes. A total of 100 µL of Neurite Stain Extraction Buffer was used for stain 
extraction and OD562 values were recorded for each of the treatments. As shown in 
Figure 5.3, uridine had the highest neurite outgrowth score as indicated by the highest 
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OD which was 0.53 ± 0.01 absorbance units (AU).  This is in agreement with the 
counting method of neurite outgrowth, whereby the percentage of uridine-treated 
neurite bearing cell was also the highest i.e. 43.09 ± 4.88%. Overall, the neurite 
outgrowth score by using the chromogenic method in a descending order was uridine, 
NGF control, ethanol extract, aqueous extract, linoleic acid, benzoic acid, succinic acid, 
caffeic acid, cinnamic acid, p-coumaric acid, and oleic acid. The neurite bearing score 
also followed the similar descending trend:  uridine, ethanol extract, aqueous extract, 
NGF control, linoleic acid, succinic acid, benzoic acid, caffeic acid, cinnamic acid, oleic 
acid, and p-coumaric acid. Therefore, it was concluded that the two methods can be 
used at the same time, in the condition that neurite bearing score (%) must be obtained 
and that the chromogenic method might be used as a confirmatory measurement to 
compliment the neurite bearing score results. 
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Figure 5.3: The effects of mushroom extracts and compounds on neurite outgrowth of differentiating N2a cells by using (a) quantification of 
neurite bearing cells, and (b) chromogenic method at optical density 562. NGF (50 ng/mL) was used as a positive control. Values are mean ± 
SD from three independent experiments. Different letters represent significant differences between samples (p < 0.05).  
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5.3.2 Quantification of uridine in P. giganteus extracts 
Uridine (100 µM) caused the highest (p < 0.05) neurite bearing score of 43.09 ± 4.88%. 
As evidenced by the neurite outgrowth assay using chromogenic method, the neurite 
outgrowth was the highest (0.42 ± 0.01 AU) at OD 526. Therefore, the concentration of 
uridine was determined in the extracts of P. giganteus.   On the basis of the calculations 
of the external reference uridine (Sigma), aqueous extracts contained 1.80 ± 0.03% (g of 
compound per 100 g extract) of uridine (Table 5.1). On the other hand, ethanol extract 
yielded a lower (p < 0.05) amount of uridine, i.e. 1.66 ± 0.03 g/100g. The HPLC 
chromatograms of the mushroom extracts showed a clear peak representing uridine 
(Figure 5. 4). 
Table 5.1: Uridine (%, w/w) in the aqueous and ethanol extracts of P. giganteus 
 
Compounds Content (%, w/w) in extract 
Aqueous  Ethanol 
Uridine 1.80 ± 0.03
a
 1.66 ± 0.03
b
 
Note: (w/w) = g of compound per 100 g of mushroom extract.  In each line different 
letters mean significant differences at p =0.05. 
 
 
 
 
 
96 
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Figure 5.4: HPLC chromatogram of (a) Uridine reference (Lot no.:#030M1518V), 
(b) ethanol extract of P. giganteus, and (c) aqueous extract of P. giganteus. 
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5.3.3 The effects of uridine on neurite outgrowth activity of N2a cells 
Treatment with uridine significantly (p < 0.01) increased neurite outgrowth in the N2a 
cells in a dose dependent manner up to 100 µM (Figure 5.5). The percentage of neurite 
bearing cells maintained at 45-50% upon increasing the concentration of uridine from 
100 µM to 500 µM.  Uridine at 100 µM also exhibited a significantly (p < 0.01) higher 
percentage in neurite-bearing cells when compared to NGF- and extract-treated cells. 
Figure 5.6 shows the morphology of the N2a cells with neurite outgrowth at 48 h of 
treatment with uridine (100 µM) and vehicle (serum-free medium). 
  
Figure 5.5:  The effects of different concentrations of uridine (50-500 µM) on 
neurite outgrowth in differentiating N2a cells. NGF (50 ng/mL) was used as 
positive control and medium only (vechicle) with no treatment was used as control. 
Aqueous and ethanol extracts (20 µg/mL) were compared to uridine. Values are 
mean ± SD from three independent experiments. Different letters represent 
significant differences between samples (p < 0.05). 
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Figure 5.6: Phase-contrast photomicrographs of (a) uridine (100µM) induced 
neurites as indicated by arrows and (b) negative control cells treated with only 
vehicle (serum-free medium). 
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5.3.4 The effects of P2Y receptor, MAPK/ERK1/2 and PI3K/Akt signaling 
pathway inhibitors on neurite outgrowth activity of N2a cells 
Specific inhibitors of key intermediates involved in neurite outgrowth signaling 
pathways were used to explore the mechanism of neuritogenesis in differentiating N2a 
cells potentiated by uridine and mushroom extracts. It was shown that neurite outgrowth 
induced by uridine was markedly inhibited (p < 0.05) by P2Y inhibitors suramin (30 
µM) and PPADS (30 µM) (Figure 5.7). In N2a cells which were treated with aqueous 
and ethanol extracts combined with either suramin or PPADS, the decrease in the 
number of neuritic processes was significant (p < 0.05). On the contrary, both the 
inhibitors did not inhibit NGF-induced neurite outgrowth (Figure 5.7). This could be 
due to a different receptor, for example the Trk family that is responsible for binding of 
NGF, but not P2Y receptor. MAPK/ERK1/2 inhibitors U0126 and PD98059 at the 
concentrations of 10 μM and 40 μM, respectively, caused inhibition effects on N2a 
cells. The number of differentiating N2a cells with neurite lengths double the cell 
diameter decreased significantly for NGF-, extracts-, and uridine-treated cells (Figure 
5.8). Cells pretreated with the PI3K/Akt inhibitor, LY294002 showed no difference (p > 
0.05) to the negative controls, with differentiated cells bearing neurites ranging only 
from 8.9 – 10.3% (Figure 5.8). From these results, it is proposed that the P. giganteus 
extract and uridine induced neurite outgrowth on N2a cells via the activation of P2Y 
receptor. Activation of the P2Y receptor then triggered the activation of ERK1/2 and 
PI3K/AKt phosphorylation cascade.  
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NGF - + - - - + - - - + - - - 50 ng/mL 
Uridine - - + - - - + - - - + - - 100 µM 
AE - - - + - - - + - - - + - 20 µg/mL 
EE - - - - + - - - + - - - + 20 µg/mL 
Suramin - - - - - + + + + - - - - 30 µM 
PPADS - - - - - - - - - + + + + 30 µM 
 
Figure 5.7: The effects of two specific inhibitors of P2Y receptors (suramin and 
PPADS) on neurite outgrowth of differentiating N2a cells. NGF (50 ng/mL) was 
used as positive control and medium only with no treatment was used as control. 
Aqueous (AE) and ethanol extracts (AE; 20 µg/mL) were tested to compare with 
uridine treatment. Values are mean ± SD from three independent experiments. 
Different letters represent significant differences between samples (p < 0.05). 
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Figure 5.8: The effects of specific inhibitors of MEK/ERK and PI3K/Akt pathways 
(U0126 and PD98059; and LY294002, respectively) on neurite outgrowth of 
differentiating N2a cells. NGF (50 ng/mL) was used as a positive control and 
medium only with no treatment was used as control. Aqueous (AE) and ethanol 
extracts (AE; 20 µg/mL) were tested to compare with uridine treatment. Values 
are mean ± SD from three independent experiments. Different letters represent 
significant differences between samples (p < 0.05). 
α
p < 0.05 vs. NGF, 
β
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uridine, 
γ
p < 0.05 vs. AE, and 
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p < 0.05 vs. EE. 
 
 
ab 
d 
e 
f 
g 
aα a
β aγ 
abcδ 
abα 
aβ 
cγ 
abcδ abc
α 
abβ 
cγ cdδ 
0 
10 
20 
30 
40 
50 
60 
N
eu
ri
te
 b
ea
ri
n
g
 c
el
ls
 (
%
) 
NGF - + - - - + - - - + - - - + - - - 50 ng/mL 
Uridine - - + - - - + - - - + - - - + - - 100 µM 
AE - - - + - - - + - - - + - - - + - 20 µg/mL 
EE - - - - + - - - + - - - + - - - + 20 µg/mL 
U0126 - - - - - + + + + - - - - - - - - 10 µM 
PD98059 - - - - - - - - - + + + + - - - - 40 µM 
LY294002 - - - - - - - - - - - - - + + + + 30 μM 
 
 
102 
 
5.3.5 The effects of uridine on the expression of phosphorylated-(p-)ERK, p-Akt, 
p-MEK, p-mTOR, and p-CREB 
Since the uridine-induced neurite outgrowth activity was found to be mediated by P2Y, 
MAPK/ERK1/2, and PI3K/Akt pathways, the ability of uridine to activate the specific 
protein kinases responsible for the pathways was tested. The phosphorylation of the 
downstream target proteins was measured. P-ERK activity (Figure 5.9) was 
significantly (p < 0.05) enhanced by uridine when compared to the NGF-treated cells. 
The presence of the aqueous and ethanol extracts also triggered significantly (p < 0.05) 
higher phospho-p44/42 (Thr202/Tyr204) levels when compared to cells with medium 
only. Besides, uridine resulted in the highest expression of p-ERK. As expected, ERK 
phosphorylation was significantly (p < 0.05) suppressed in the presence of inhibitors 
U0126 and PD98059. N2a cells treated with uridine also exhibited a significantly higher 
(p < 0.05) Akt (Thr308) phosphorylation when compared to the NGF control (50 ng 
mL−1) (Figure 5.10). Similarly, AKT inhibitor LY294002-treated cells added with 
mushroom extracts, uridine, or NGF did not result in phosphorylation of Akt. 
Considering the above results showing that uridine significantly (p < 0.05) enhanced the 
expression of p-ERK and p-Akt, it will be crucial to evaluate whether uridine could also 
increase p-MEK and p-mTOR. Treatment of N2a cells with uridine caused a significant 
(p < 0.05) and sustained increase of phosphorylation of MEK and mTOR in dose 
dependent manner (Figure 5.11). The highest phosphorylation levels of MEK and 
mTOR (2.65±0.2 and 3.33±0.2, respectively) were observed with 500 μM uridine. 
CREB is critical for activating the transcription of genes controlled by the cAMP-
response element, and many of these genes may be involved in neuronal outgrowth and 
plasticity. Therefore, the phosphorylation of CREB was investigated. As shown in 
Figure 5.12, treatment of N2a cells with 500 μM of uridine caused approximately 2.8 
fold increase of CREB phosphorylation when compared with the vehicle group.  
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Figure 5.9: Enhancement of uridine-induced neurite outgrowth is ERK-dependent 
as evidenced by the expression of phospho-ERK1/2 (p44/p42) as detected using 
antibody specific for phospho-ERK1/2. U0126 and PD98059 are the inhibitors for 
ERK. Data are expressed as mean ± S.D. for n=3. 
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Figure 5.10: Enhancement of uridine-induced neurite outgrowth is PI3K/Akt- 
dependent as evidenced by the expression of phospho-Akt (Thr308) detected by the 
antibody specific for phospho-Akt. LY294002 is the inhibitor for PI3K/Akt.  Data 
are expressed as mean ± S.D. for n=3. 
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Figure 5.11: Enhancement of uridine-induced neurite outgrowth is MEK- and 
mTOR-dependent as evidenced by the activation of phospho-MEK (Ser217/221) 
and phospho- mTOR (Ser2448) as detected by using specific antibodies. Data are 
expressed as mean ± S.D. for n=3. *p < 0.05 represents a significantly higher value 
from the negative and NGF controls.  
 
 
 
 
 
 
a 
bc 
cd 
e* 
bc b 
d* 
f * 
bcd bcd 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
A
b
so
rb
a
n
ce
 4
5
0
n
m
 
NGF - + - - - + - - - - 50 ng/mL 
Uridine - - + - - - + - - - 100 µM 
Uridine - - - + - - - + - - 500 µM 
AE - - - - + - - - + - 20 µg/mL 
EE - - - - - - - - - + 20 µg/mL 
   p-MEK p-mTOR    Control 
 
 
 
106 
 
 
 
Figure 5.12: Enhancement of uridine-induced neurite outgrowth is MEK/ERK-
CREB and PI3 K/Akt-mTOR-CREB dependent. Activation of phospho-CREB 
(Ser133) was detected using antibody specific for phospho-CREB. Data are 
expressed as mean ± S.D. for n=3. *p < 0.05 represents a significantly higher value 
from the negative and NGF controls.  
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5.3.6 The effects of uridine on the expression of GAP-43, TUBA4A, and TUBb1 
As shown in Figure 5.13a, uridine (100 and 500 μM) significantly (p < 0.05) increased 
total GAP-43 (0.63±0.1 and 1.07±0.1 ng/mL of protein, respectively) level in a dose-
dependent manner in N2a cells. The cytoskeleton requirement in uridine-induced 
neurite outgrowth was then investigated. Tubulin a4a, the neurite outgrowth marker was 
evaluated in the presence of uridine. The up-regulation in tubulin a4a expression was 
significant (p < 0.05) when treated with 100 and 500 µM of uridine when compared to 
NGF (Figure 5.13b). Notably, concentration of 500µM uridine resulted in a 
significantly (p < 0.05) higher tubulin a4a expression when compared to the NGF-
treated cells by 2.18-fold. Moreover, aqueous extract-treated N2a cells expressed 
0.79±0.1 ng/mL of tubulin a4a, which was 1.6-fold higher than that of NGF-treated 
cells. Tubulin beta represents another important cytoskeleton component in neurite 
outgrowth. As shown in Figure 5.13c, the expression of tubulin beta b1 was 
significantly (p < 0.05) up-regulated by the aqueous extract of P. giganteus (1.56±0.3 
ng/mL of protein). Treatment with uridine (500 µM) led to an up-regulation of tubulin 
beta b1 level by 1.8-fold (2.16±0.06 ng/mL of protein) when compared to NGF-treated 
cells. 
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Figure 5.13: Uridine and mushroom extracts increased the activity of GAP-43 (a), 
Tubulin aipha 4a (b), and tubulin beta b1 (c) in N2a cells. Data are expressed as 
mean ± S.D. for n=3. *p < 0.05 represents a significantly higher value from the 
untreated and NGF-treated cells.  
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5.4 Discussion 
In this study, linoleic acid promoted neurite outgrowth of N2a cells by 20.78 ± 2.43% 
(Figure 5.3). On the other hand, oleic acid caused little or no neurite outgrowth in N2a 
cells. Extension of neurites from neuronal cell body is an important step in neuronal 
development and requires the generation of additional plasma membrane (Kamata, 
Shiraga, Tai, Kawamoto, & Gohda, 2007). Polyunsaturated fatty acids like linoleic, 
linolenic, docosahexanoic, and arachidonic acids are known to promote neurite 
extension (Darios & Davletov, 2006). This suggests that linoleic acid which was present 
in abundance in the extracts of P. giganteus may play a key role in neuritogenesis.  
Similar to our results, other studies also showed that monounsaturated fatty acids and 
saturated long-chain fatty acids like oleic, stearic and palmitic acids caused little or no 
effects in neurite outgrowth (Darios & Davletov, 2006).  
Long-chain polyunsaturated fatty acids (LCPUFA) are essential nutrients in the 
development and functioning of the central nervous system. The most abundant 
LCPUFA in the brain are docosahexaenoic acid (DHA) which is mainly derived from 
fish, and arachidonic acid (ARA) from meat and eggs (Janssen & Kiliaan, 2014). The 
desaturation and elongation of linoleic acids and alpha-linolenic acids to ARA and 
DHA; respectively, are very crucial for the infant’s brain development. Since the 
percentage of ARA decreases in the brain during prenatal development, the balance in 
the dietary ratio of linoleic acid is very crucial to maintain a healthy brain development 
in preterm infant (Enke et al., 2011). Apart from that, many studies have demonstrated 
the importance of LCPUFA as a potent neuroprotectant. Linoleic acid was found to 
protect mouse cortical neurons against glutamate excitotoxicity (Hunt, Kamboj, 
Anderson, & Anderson, 2010). Linoleic acid and its derivatives also prevented sodium 
nitroprusside-induced cell death of cultured rat cerebral cortical neurons (Yaguchi, 
Fujikawa, & Nishizaki, 2010).  
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 Nucleosides (adenosine, guanosine, uridine, and inosine) bind purinergic and/or 
pyrimidine receptors and their functions include the regulation and modulation of 
various physiological processes in the human body. Beside acting as precursors in 
nucleic acid synthesis, nucleotides were reported to enhance immune response, control 
metabolism of fatty acids, contribute to iron absorption in the gut,  and improve 
gastrointestinal tract repair after damage (Yang, Lv, Zhang, & Xia, 2012). In this study, 
uridine was found to be present in a considerably high amount (1.66-1.80 g/100g 
extract). To date, uridine has been recognised as one of the main bioactive compounds 
in Cordyceps militaris. The mycelia extract of C. militaris NBRC 9787 and C. militaris 
G81-3 were reported to contain 106.8 and 45.4 mg/kg extract of uridine (Das, Masuda, 
Sakurai, & Sakakibara, 2010). Most recently, a total of 0.20, 0.79, 1.50, 1.40, and 0.80 
mg/g extract of uridine was detected in Agrocybe aegerita, Boletus nigricans, Boletus 
fulvus, Tricholoma matsutake, and Auricularia auricular-judae; respectively (Yang et 
al., 2012). Besides, fractions F-K of the methanol extract of Gomphus clavatus 
demonstrated a high scavenging activity (63.8 –0.1 70.3%) against 1,1-diphenyl-2-
picrylhy-drazyl (DPPH) radicals. Uridine and several other compounds like nicotinic 
acid and inosine were isolated from the fractions (Makropoulou et al., 2012).  
Neurons form synapses through outgrowth of neurite throughout life. The 
numbers of neurite outgrowth and membrane synapses formed depend on the levels of 
three key nutrients in the brain, i.e. uridine, omega-3 fatty acid DHA, and choline 
(Wurtman, Cansev, Sakamoto, & Ulus, 2010). Therefore, it is thought that giving these 
compounds to patients with AD, a disease characterised by loss of neurite outgrowth 
and brain synapses, could be beneficial (Wurtman et al., 2010). Uridine is present as 
such in breast milk (Thorell, Sjöberg, & Hernell, 1996), but also as constituents of 
RNA; nucleotides (5’-UMP); and nucleotide adducts (UDP-glucose or UDP-galactose) 
(Leach, Baxter, Molitor, Ramstack, & Masor, 1995). Synthetic infant formulas are also 
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routinely fortified with uridine and uridine monophosphates. Cytidine (as cytidine 
triphosphate, CTP) and uridine (which is converted to UTP and then CTP) contribute to 
brain phosphatidylcholine and phosphatidylethanolamine synthesis via the Kennedy 
pathway (Cansev, 2006) (Figure 5.14). Uridine and cytidine circulating in our body can 
serve as the substrates to synthesise the respective nucleotides.  They act as the 
precursors of the cytidine triphosphate (CTP) needed in the phosphatidylcholine (PC) 
biosynthetic pathway (Kennedy & Weiss, 1956). The principal constituents of 
mammalian cell membranes are phosphatides, the most abundant of which is 
phosphatidylcholine (PC) (Cansev, 2006). PC biosynthesis is initiated by the 
phosphorylation of choline to form phosphocholine, which then combines with cytidine 
triphosphate (CTP) to form 5’-cytidine diphosphocholine (CDP-choline); this 
compound then reacts with diacylglycerol (DAG) to produce PC (Richardson, Watkins, 
Pierre, Ulus, & Wurtman, 2003) (Figure 5.14). Uridine or cytidine increases CTP levels, 
hence, in turn can be rate-limiting in the syntheses of PC. 
 In gerbils (Meriones unguiculatus) and humans, the primary circulating 
pyrimidine is uridine. Uridine readily penetrates the blood-brain barriers (BBB) and 
enters the brain via a high-affinity transporter yielding UTP which is then converted to 
CTP by CTP synthase (Figure 5.14).  Intracellular levels of uridine triphosphate (UTP) 
depend on the availability of free uridine. Since it seems possible that uridine would 
also enhance the production and extension of neurites, it is hypothesised that increasing 
the availability of uridine may further promote neurite outgrowth in N2a cells.  
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Figure 5.14: Phosphatidylcholine (PC) biosynthesis via the Kennedy pathway 
(Kennedy & Weiss, 1956; Richardson et al., 2003).  
In a study using PC12 cells, uridine increased the number of neurites per cell 
significantly and in a dose-dependent manner after 4 days (Pooler, Guez, Benedictus, & 
Wurtman, 2005). This increase was accompanied by an increase in neurite branching 
and the neurofilament M and neurofilament 70. Uridine treatment also increased 
intracellular levels of CTP which suggests that uridine may affect neurite outgrowth by 
enhancing phosphatidylcholine synthesis. In an in vivo study, gerbils were given 
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supplemental uridine as its monophosphate (UMP, 0.5%), DHA (300 mg/kg/day), 
and/or choline (0.1%) via diet and by gavage for 4 weeks (Holguin, Martinez, Chow, & 
Wurtman, 2008).  When uridine was co-administered with choline, phosphatides were 
increased. Uridine also further enhanced the animals’ performance on the 
neurobehavioral tests, i.e. the four-arm radial maze, T-maze, and Y-maze tests. The 
effects of dietary supplementation with uridine (as in UMP-2Na+, an additive in infant 
milk formulas) on striatal dopamine (DA) release in aged rats were also tested (L. 
Wang, Pooler, Albrecht, & Wurtman, 2005). As a result, DA release was significantly 
greater among UMP-treated rats. Besides, the levels of neurofilament-70 and 
neurofilament-M proteins (biomarkers of neurite outgrowth) were also increased 
significantly with UMP consumption. Co-supplementation of uridine with DHA also 
increased the number of dendritic spines in adult gerbil hippocampus by more than 30% 
(Sakamoto, Cansev, & Wurtman, 2007). 
Another hypothesis for uridine-induced neurite outgrowth is the involvement of 
P2Y receptor, a family of purinergic G protein-coupled receptors (Holguin et al., 2008).  
Exogenous uridine and its phosphorylated products, such as UMP, UDP, and UTP act 
as ligands for P2Y receptors which then can activate downstream protein synthesis 
related to neuronal differentiation and the promotion of brain glycogen synthesis via 
UDP- glucose (Brown, 2004). While P2X receptors recognise adenine nucleotides, P2Y 
receptors can recognise both adenine and uridine nucleotides. Members of the P2Y 
family are widely distributed throughout the body, including the brain (Wurtman et al., 
2010). To date, eight P2Y receptors of human origin (P2Y1, 2, 4, 6, 11, 12, 13, and 14) 
have been cloned and characterised (Haas, Ginsburg-Shmuel, Fischer, & Reiser, 2014; 
Wurtman et al., 2010).  
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In gerbils, a single oral dose of a uridine source, i.e., UMP (which was 
approximately 300 mg/kg of uridine), yielded a two-fold increase in brain uridine levels 
(Cansev, Watkins, van der Beek, & Wurtman, 2005). Besides, uridine can also have 
effects on the brain by activating the P2Y receptors. There are eight different 
mammalian P2Y receptor subtypes (P2Y1, 2, 4, 6, 11, 12, 13, and 14) and only P2Y2, 
P2Y4 and P2Y6 accept uridine nucleotides as ligands (Dobolyi, Juhasz, Kovacs, & 
Kardos, 2011). In this study, uridine has been shown to mediate neurite outgrowth. This 
effect was accompanied by an increase in tubulin alpha and beta synthesis. Further, 
uridine’s effect was blocked by P2Y receptor antagonists, suggesting that uridine may 
promote neurite outgrowth by uridine-mediated stimulation of a P2Y receptor-coupled 
signaling pathway. This observation is in agreement with previously reported 
neurotrophic effects of P2Y receptors. UDP and UTP have been reported previously to 
modulate noradrenaline release from cultured rat superior cervical ganglia (Boehm, 
Huck, & Illes, 1995). In addition to that, the pathway involved in UTP-evoked 
noradrenaline release was then shown to be mediated by P2Y6 receptors via activation 
of protein kinase C (Vartian et al., 2001). Uridine has been shown to excite sensory 
neurons via P2Y2 receptors  (Molliver, Cook, Carlsten, Wright, & McCleskey, 2002) 
and most recently, extracellular UDP-glucose has been reported to stimulate neurite 
outgrowth via the purinergic P2Y14 receptor (Haanes & Edvinsson, 2014).   
All eukaryotic cells possess multiple mitogen-activated protein kinases 
(MAPKs) pathways, which co-ordinate to regulate gene expression, mitosis, 
metabolism, motility, survival, apoptosis, and differentiation (Seger & Krebs, 1995). 
The conventional MAPKs comprise the extracellular signal-regulated kinases 1/2 
(ERK1/2), c-Jun amino (N)-terminal kinases 1/2/3 (JNK1/2/3), p38 isoforms (α, β, γ, 
and δ), and ERK5. By far the most extensively studied MAPKs are the ERK1/2, JNKs, 
and p38 isoforms. The Erk1/2 (p44/42) signaling pathway can be activated in response 
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to many extracellular stimuli, for example mitogens and growth factors (W. Zhang & 
Liu, 2002). Upon stimulation, a chronological protein kinase cascade is initiated. The 
three-part kinase consists of a MAP kinase kinase kinase (MAPKKK or MAP3 K), a 
MAP kinase kinase (MAPKK or MAP2 K), and a MAP kinase (MAPK). MEK1 and 
MEK2, which are MAPKKs, activate p44 and p42 through phosphorylation of 
activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Here, it was 
demonstrated that 100 µM of uridine activated the phosphorylation of ERK1/2. 
Previous studies have shown that induction of ERK activation by some medicinal 
mushrooms was consistent with their ability to stimulate neurite outgrowth and that 
treatment with specific inhibitors resulted in inhibition of neuritogenesis by G. lucidum 
(Cheung et al., 2000), G. neo-japonicum (Seow et al., 2013), and G. frondosa  (Nishina 
et al., 2006).  
Activation of phosphatidylinositol 3-kinase (PI3K) and subsequent activation of 
the downstream signaling effector, the Akt has been implicated in the neuronal survival 
and differentiation (H. S. Kim, Hong, Kim, & Han, 2011). Akt plays a critical role in 
controlling cell survival and apoptosis; and is activated by phospholipid binding and 
activation loop phosphorylation at Thr308 by pyruvate dehydrogenase lipoamide kinase 
1 (PDK1) (Bozulic & Hemmings, 2009). PI3K/Akt has been proposed as a potential 
therapeutic target in neurodegenerative diseases since activation of Akt inhibits stress-
activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) that causes oxidative 
stress during neuronal degeneration (Burke, 2007). LY294002, a specific inhibitor of 
Akt has been widely used to elucidate PI3K/Akt pathway. In this study, based on the 
results it was hypothesised that neuritogenesis potentiated by uridine was regulated by 
PI3K/Akt pathway. As a result, uridine-treated N2a cells exhibited a significantly higher 
(p<0.05) Akt (Thr308) phosphorylation when compared to NGF control (50 ng/mL). 
This is consistent with the other reported studies. Dilong extracts (Chinese medicinal 
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preparation from the earthworm species Lumbricus rubellus) were found to promote 
neuron regeneration (Chang et al., 2011). Treatment with extract of Dilong induced the 
phosphorylation of the insulin-like growth factor-I (IGF-I)-mediated PI3K/Akt pathway, 
resulting in cell proliferation and survival of RSC96 Schwann cells. Besides, 
sargaquinoic acid isolated from a marine brown alga Sargassum macrocarpum, was 
found to promote neurite outgrowth in PC12 cells and inhibition of PI3K by 
wortmannin significantly suppressed the neuritogenic activity of sargaquinoic acid 
(Tsang & Kamei, 2004). More recently, luteolin (3′,4′,5,7-tetrahydroxyflavone) isolated 
from rosemary, Rosmarinus officinalis (Lamiacea), has been reported to induce PC12 
cell differentiation (El Omri, Han, Kawada, Ben Abdrabbah, & Isoda, 2012). Luteolin 
treatment significantly enhanced acetylcholinesterase (AChE) activity and increased the 
level of total choline and acetylcholine in PC12 cells. In addition, treatment with U0126 
and LY294002 also attenuated luteolin-induced AChE activity and neurite outgrowth in 
PC12 cells, suggesting that the neuritogenic properties of luteolin was regulated by 
activation of ERK1/2 and PI3K/Akt signalings. 
The cAMP responsive element binding protein, CREB is a bZIP transcription 
factor that activates target genes through cAMP response elements. CREB is able to 
mediate signals from numerous physiological stimuli, resulting in regulation of a wide 
array of cellular responses. CREB plays a dominant regulatory role in the nervous 
system (Scott Bitner, 2012). CREB is believed to play a key role in promoting neuronal 
survival, precursor proliferation, neurite outgrowth and neuronal differentiation in 
certain neuronal populations (Yamashima, 2012). Some of the kinases involved in 
phosphorylating CREB at Ser133 are the MAPK and PI3K/Akt. Therefore, it is 
hypothesised that uridine present in the P. giganteus extracts could be metabolised in 
the N2a cells, and uridine along with its phosphates derivatives bind P2Y receptors and 
activates the MAPK and PI3K/Akt pathways, leading to the phosphorylation of the 
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transcription factor CREB that is able to selectively activate numerous downstream 
genes such as the growth associated protein 43 (GAP-43) and microtubules.  
There is mounting evidence supporting the fact that growing neurons express 
high levels of GAP-43 and that the up-regulation of GAP-43 mRNA and protein is 
associated with neurite outgrowth (Benowitz & Routtenberg, 1997). The results in this 
study showed that after exposure to uridine, N2a cells exhibited morphological changes 
and neurite formation along with up-regulation of GAP-43. This is consistent with 
previous findings which demonstrated that DHA significantly increased the cellular 
GAP-43 immunoactivity and GAP-43 content in N2a cells (Wu et al., 2009). 
Dishevelled (Dvl), a cytoplasmic protein involved in the Wnt-Frizzled signaling 
cascade, has also been shown to interact with the cytoskeleton through modulation of 
GAP-43, and caused neurite outgrowth in N2a cells (Fan, Ramirez, Garcia, & 
Dewhurst, 2004). Claulansine F (Clau F) is a carbazole alkaloid isolated from the stem 
of wampee, Clausena lansium (Lour) Skeels. Clau F was found to have a critical role in 
elevating GAP-43 expression, which in turn triggered neuritogenesis in PC12 cells 
promoted by Clau F. Besides, 5-hydroxy-3,6,7,8,3’,4’-hexamethoxyflavone (5-OH-
HxMF), which is found exclusively in the Citrus genus (particularly in the peels of 
sweet orange) was found to promote neurite outgrowth in PC12 cells. Accordingly, it 
was reported that there was a strong positive correlation of elevated GAP-43 expression 
with the neuronal outgrowth states (Lai et al., 2011). Further, an increase in GAP-43 
protein is associated with neuritogenesis in NGF-treated PC12 cells, potentiated by 
green tea polyphenols (Gundimeda et al., 2010). Finally, Figure 5.15 shows the 
hypothetic mechanism of uridine in promoting neurite outgrowth in differentiating N2a 
cells. 
 
 
 
118 
 
 
 
 
 
 
 
 
  
Figure 5.15: Hypothetic mechanism of uridine in promoting neurite outgrowth in 
N2a cells. Uridine could induce neurite outgrowth associated with expression of 
neuronal differentiation marker (GAP-43, tubA4a, and tubB1). Uridine stimulated 
CREB phosphorylation and neurite outgrowth mainly through activation of P2Y-
dependent pathway. MEK/ERK1/2 and PI3K/Akt/mTOR were also partly 
involved in the uridine-induced neurite outgrowth. In addition, uridine 
conversation to UTP which is further combined with phosphocholine yielding 
phosphatidylcholine, may also partially contribute to the uridine-mediated neurite 
outgrowth.         = inhibit.  increase. 
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5.5 Conclusion 
The neurite outgrowth stimulatory effect of the chemical compounds and P. giganteus 
extracts in descending order was: uridine > aqueous extract > ethanol extract > NGF > 
linoleic acid > succinic acid > benzoic acid > cinnamic acid > caffeic acid > oleic acid > 
p-coumaric acid. The findings in this study clearly demonstrate that uridine (1.66-1.80 
g/100g extract) may have potential in promoting neurite outgrowth as evidenced by the 
neurite bearing cell scores (43.09 ± 4.88%) and the chromogenic method (0.53 ± 0.02 
AU). This finding supports P. giganteus as a potential mushroom that may be used as a 
functional food for reducing the impact of neurodegenerative diseases which involve the 
decrease or absence of neurite outgrowth. Moreover, uridine may serve as a marker 
component for the standardisation of P. giganteus as a functional food. Uridine 
promoted neurite outgrowth in differentiating N2a cells in a dose-dependent manner. 
The results indicated that uridine- and P. giganteus extracts-induced neuritogenesis was 
regulated, at least in part, by cross-talk between the MEK/ERKs and PI3K/Akt/mTOR 
pathways and required the activation of the transcription factor CREB. The neuronal 
biomarkers (GAP-43, tubulin alpha 4a, and beta) in N2a cells were also significantly (p 
< 0.05) increased when treated with uridine.  
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CHAPTER VI 
PROPOSED FUTURE STUDIES AND CONCLUSIONS 
 
The following is recommended as important and promising research directions for 
developing functional food of P. giganteus and other edible mushrooms with neurite 
outgrowth activity: 
a) Additional effort is needed to determine the uridine level in different mushroom 
species as this nucleoside is clearly shown to promote neurite outgrowth.  
b) In view of the neurite outgrowth activity of P. giganteus observed in this study, 
this mushroom can become a popular functional food. It is therefore necessary to 
examine the (subacute) toxicity of the mushroom extracts in compliance with the 
guidelines from the Organization of Economic Cooperation and Development 
(OECD, 1995).  
c) Animal model studies with a dose-response design are needed to clearly 
establish the efficacy and mechanisms of action of uridine in P. giganteus in 
stimulating neurite outgrowth in vivo. Further, if P. giganteus is proposed to be a 
functional food, the animal model study should reflect this hypothesis by using 
the oral route of administration. Most importantly, the bioavailabity of uridine in 
P. giganteus extracts must be determined.  
Therapeutic strategy to stimulate neuronal cell events including neurite outgrowth 
and to some extent, neuroprotection are needed for several neurodegenerative disorders 
like dementia. Many mushrooms have been known to have health benefits, but little is 
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known about their neurite outgrowth stimulatory effects. The main findings of this study 
are: 
a. Pleurotus giganteus was identified as a potential neuritogenic mushroom species 
based on its high score in percentage of neurite-bearing N2a cells (33.4 ± 4.6%) 
which  was significantly (p < 0.05) higher than the NGF control. The mushroom 
extract also recorded mean neurite length of 116.72 ± 29.5 µm which was about 
6-time longer than cell body. The neuritic process was further confirmed by 
neurofilaments staining.   
b. It was revealed that P. giganteus extracts contained considerably high amount of 
potassium, vitamins B1, B2, and B3, as well as linoleic acid; all of which may 
contribute to the neurite outgrowth stimulatory effects. The extracts also 
exhibited antioxidant activity which was believed to potentiate neuritogenesis by 
scavenging reactive species and influent intracellular redox status.  
c. The uridine constituent (1.66-1.80 g/100g extract) present in P. giganteus was 
the most promising compound in promoting neurite outgrowth as evidenced by 
the neurite bearing cell score (43.09 ± 4.88%). Nucleoside, such as uridine, can 
cross blood-brain barrier. Uridine may work as therapeutic agent that possessed 
high neurotrophic potency and involved in numerous effects within the brain.  
d. Uridine from P. giganteus was able to stimulate neuritogenesis via its 
interactions with critical neuronal intracellular signaling pathways. The uridine-
induced neurite outgrowth involved the activation of MEK/ERK1/2, PI3k/Akt, 
and to some extends the mTOR pathways. Since uridine was the major bioactive 
constituent present in the extract, the involvement of specific P2Y receptor is 
suggested as the addition of P2Y inhibitor blocked the uridine-induced neurite 
outgrowth activity. Further, the phosphorylation of CREB may be associated 
with the neuronal function of uridine on differentiating N2a cells. Additionally, 
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uridine and P. giganteus extracts induced the accumulation of intracellular GAP-
43, tubulin A4a and tubulin B1 activities. 
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APPENDICES 
A. DATA AND STATISTICAL TABLES 
Table 1: Multiple range test: The effects of different NGF concentrations (5-100 ng/mL) on 
stimulation of neurite outgrowth 
 
Table 2: Multiple range test: The mean neurite length of N2a cells treated with different 
mushroom extracts 
 
 
 
 
 
Multiple Range Tests for Col_2 by Col_1
--------------------------------------------------------------------------------
Method: 95.0 percent LSD
Col_1          Count     Mean              Homogeneous Groups
--------------------------------------------------------------------------------
8              5         7.486             X   
7              5         78.578             X  
3              5         82.39              X  
1              5         90.576             XX 
4              5         95.564             XXX
5              5         116.722             XX
2              5         121.51               X
--------------------------------------------------------------------------------
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Table 3: Multiple range test: TPC results 
 
Table 4: Multiple range test: Total polysaccharides  
 
Table 5: Multiple range test: DPPH scavenging effects between the commercial and 
cultivated wild P. giganteus 
 
 
 
 
Multiple Range Tests for Col_2 by Col_1
--------------------------------------------------------------------------------
Method: 95.0 percent LSD
Col_1          Count     Mean              Homogeneous Groups
--------------------------------------------------------------------------------
1              3         9.57653           X   
2              3         12.1436            X  
3              3         21.6116             X 
4              3         24.0762              X
--------------------------------------------------------------------------------
Contrast                                   Difference           +/-  Limits
--------------------------------------------------------------------------------
1 - 2                                     *-2.56706             2.46052           
1 - 3                                     *-12.0351             2.46052           
1 - 4                                     *-14.4997             2.46052           
2 - 3                                     *-9.46802             2.46052           
2 - 4                                     *-11.9327             2.46052           
3 - 4                                     *-2.46463             2.46052           
--------------------------------------------------------------------------------
* denotes a statistically significant difference.
Multiple Range Tests for Col_2 by Col_1
--------------------------------------------------------------------------------
Method: 95.0 percent LSD
Col_1          Count     Mean              Homogeneous Groups
--------------------------------------------------------------------------------
4              3         2.462             X   
3              3         2.972              X  
2              3         3.22967             X 
1              3         3.862                X
--------------------------------------------------------------------------------
Multiple Range Tests for Col_2 by Col_1
--------------------------------------------------------------------------------
Method: 95.0 percent LSD
Col_1          Count     Mean              Homogeneous Groups
--------------------------------------------------------------------------------
2              3         8.10132           X  
1              3         11.2823           XX 
3              3         16.1761            XX
4              3         21.4631             X
--------------------------------------------------------------------------------
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Table 6: Multiple range test: FRAP results between the commercial and cultivated wild P. 
giganteus 
 
Table 7: Multiple range test: Lipid peroxidation inhibition results between the commercial 
and cultivated wild P. giganteus 
 
 
--------------------------------------------------------------------------------
Method: 95.0 percent LSD
Col_1          Count     Mean              Homogeneous Groups
--------------------------------------------------------------------------------
1              3         2.03596           X 
3              3         2.25992           XX
2              3         2.69474           XX
4              3         2.9864             X
--------------------------------------------------------------------------------
Multiple Range Tests for Col_2 by Col_1
--------------------------------------------------------------------------------
Method: 95.0 percent LSD
Col_1          Count     Mean              Homogeneous Groups
--------------------------------------------------------------------------------
2              3         44.406            X 
1              3         44.6145           X 
4              3         49.5831            X
3              3         49.8018            X
--------------------------------------------------------------------------------
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Table 8: Correlation table of the antioxidant activities
 
Table 9: Multiple range test: Percentage of neurite bearing cells of different chemical 
compounds from P. giganteus 
 
 
 
 
Multiple Range Tests for Col_2 by Col_1
--------------------------------------------------------------------------------
Method: 95.0 percent LSD
Col_1          Count     Mean              Homogeneous Groups
--------------------------------------------------------------------------------
1              3         9.03333           X    
7              3         10.8527           X    
11             3         16.535             X   
6              3         24.2633             X  
2              3         24.2967             X  
10             3         24.5167             X  
8              3         25.55               X  
12             3         27.5133             X  
13             3         27.6133             X  
9              3         28.1067             X  
4              3         33.3833              X 
5              3         37.03                X 
3              3         47.6873               X
--------------------------------------------------------------------------------
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Table 10: Multiple range test: Quantification of neurite using chromogenic methods  
 
Table 11: Multiple range test: The effects of different concentration of uridine on neurite 
outgrowth  
 
 
 
 
 
 
 
Multiple Range Tests for Col_2 by Col_1
--------------------------------------------------------------------------------
Method: 95.0 percent LSD
Col_1          Count     Mean              Homogeneous Groups
--------------------------------------------------------------------------------
2              3         0.0419            X     
11             3         0.119133           X    
7              3         0.12               X    
6              3         0.1371             X    
9              3         0.157133           X    
8              3         0.16               X    
5              3         0.167833           X    
10             3         0.304833            X   
3              3         0.353367            XX  
4              3         0.4088               XX 
1              3         0.459667              X 
12             3         0.567767               X
Multiple Range Tests for Col_2 by Col_1
--------------------------------------------------------------------------------
Method: 95.0 percent LSD
Col_1          Count     Mean              Homogeneous Groups
--------------------------------------------------------------------------------
1              3         9.03333           X     
5              3         21.9403            X    
2              3         23.1667            X    
3              3         29.3567             X   
4              3         34.9733              X  
7              3         43.0785               X 
8              3         45.4244               XX
6              3         49.2406                X
--------------------------------------------------------------------------------
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Table 12: Multiple range test: The effects of two specific inhibitors of P2Y receptors 
(suramin and PPADS) on neurite outgrowth 
 
Table 13: Multiple range test: GAP-43 expression 
 
 
 
 
 
 
Multiple Range Tests for Col_2 by Col_1
--------------------------------------------------------------------------------
Method: 95.0 percent LSD
Col_1          Count     Mean              Homogeneous Groups
--------------------------------------------------------------------------------
1              3         9.03333           X    
7              3         10.8527           X    
11             3         16.535             X   
6              3         24.2633             X  
2              3         24.2967             X  
10             3         24.5167             X  
8              3         25.55               X  
12             3         27.5133             X  
13             3         27.6133             X  
9              3         28.1067             X  
4              3         33.3833              X 
5              3         37.03                X 
3              3         47.6873               X
--------------------------------------------------------------------------------
Multiple Range Tests for Col_2 by Col_1
--------------------------------------------------------------------------------
Method: 95.0 percent LSD
Col_1          Count     Mean              Homogeneous Groups
--------------------------------------------------------------------------------
1              3         0.151555          X   
2              3         1.2664             X  
4              3         1.35624            X  
3              3         1.56145            X  
5              3         2.15596             X 
6              3         2.72776              X
--------------------------------------------------------------------------------
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Table 14: Multiple range test: Tubulin alpha 4a expression 
 
Table 15: Multiple range test: Tubulin beta b1 expression 
 
 
 
 
 
 
 
 
 
Multiple Range Tests for Col_2 by Col_1
--------------------------------------------------------------------------------
Method: 95.0 percent LSD
Col_1          Count     Mean              Homogeneous Groups
--------------------------------------------------------------------------------
1              3         0.291242          X   
2              3         0.489628           X  
4              3         0.623897           XX 
5              3         0.628423           XX 
3              3         0.789093            X 
6              3         1.06668              X
--------------------------------------------------------------------------------
Multiple Range Tests for Col_2 by Col_1
--------------------------------------------------------------------------------
Method: 95.0 percent LSD
Col_1          Count     Mean              Homogeneous Groups
--------------------------------------------------------------------------------
5              3         0.297333          X  
1              3         0.329333          X  
6              3         0.358             X  
2              3         0.682333           X 
3              3         0.695              X 
4              3         0.808667            X
--------------------------------------------------------------------------------
Contrast                                   Difference           +/-  Limits
--------------------------------------------------------------------------------
1 - 2                                     *-0.353               0.0998231         
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Figure 1: Calibration plot for TPC 
 
 
Figure 2: Calibration plot for total polysaccharides 
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Figure 3: Calibration plot for total flavonoids 
 
Figure 4: Calibration plot for FRAP 
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Figure 5: Calibration plot for uridine 
 
 
Figure 6: Calibration plot for GAP43 
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Figure 7: Calibration plot for Tubulin alpha A4a 
 
Figure 8: Calibration plot for Tubulin beta b1 
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Abstract
Mushrooms have long been used not only as food but also for the treatment of various
ailments. Although at its infancy, accumulated evidence suggested that culinary-medicinal
mushrooms may play an important role in the prevention of many age-associated neurological
dysfunctions, including Alzheimer’s and Parkinson’s diseases. Therefore, efforts have been
devoted to a search for more mushroom species that may improve memory and cognition
functions. Such mushrooms include Hericium erinaceus, Ganoderma lucidum, Sarcodon spp.,
Antrodia camphorata, Pleurotus giganteus, Lignosus rhinocerotis, Grifola frondosa, and many
more. Here, we review over 20 different brain-improving culinary-medicinal mushrooms and at
least 80 different bioactive secondary metabolites isolated from them. The mushrooms (either
extracts from basidiocarps/mycelia or isolated compounds) reduced beta amyloid-induced
neurotoxicity and had anti-acetylcholinesterase, neurite outgrowth stimulation, nerve growth
factor (NGF) synthesis, neuroprotective, antioxidant, and anti-(neuro)inflammatory effects.
The in vitro and in vivo studies on the molecular mechanisms responsible for the bioactive
effects of mushrooms are also discussed. Mushrooms can be considered as useful therapeutic
agents in the management and/or treatment of neurodegeneration diseases. However, this
review focuses on in vitro evidence and clinical trials with humans are needed.
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Introduction
Life expectancy of humankind had increased to 50–60 years
at the beginning of the twentieth century due to improved
medicinal, dietary, and sanitation conditions. It is, however,
foreseen that society will witness an elevated life expectancy
of 80–90 years by the twenty-first century (Candore et al.,
2006). Nevertheless, ageing is inexorable with an age-
associated decline in immune competence and the onset
of chronic inflammation leading to neurodegenerative dis-
eases including dementia, Alzheimer’s disease (AD) and
Parkinson’s disease (PD); atherosclerosis and stroke; diabetes;
sarcopenia; and cancer (Martorana et al., 2012). With the
increased lifespan of the world’s population, it is estimated
that about 80 million people will suffer from dementia by
2040 whereby AD accounted for almost 60% of dementia
cases (Bharadwaj et al., 2010).
The pathological hallmarks of AD are characterised by
amyloidogenic processing of amyloid precursor protein
(APP) and a subsequent b-amyloid cascade and tau
hyperphosphorylation (Claeysen et al., 2012). Other hypoth-
eses of AD pathogenesis include microglial activation
associated with neuroinflammation, increased level of acetyl
cholinesterase (AChE) activity, and free radical generation
(Martorana et al., 2012). Drug therapies for AD include
nicotine, melatonin, estrogens (Coˆte´ et al., 2012) cholinester-
ase inhibitors, and an N-methyl-D-aspartate receptor antag-
onist named memantine (Hong-Qi et al., 2012). However, the
current AD drug therapy is ineffective and only provides
a short-term delay progression of AD. Moreover, although
there was a close association of the use of non-steroidal anti-
inflammatory drugs (NSAIDs) and a lower incidence of AD,
patients suffered from withdrawal syndrome as a result of
gastrointestinal toxicity (Hong-Qi et al., 2012).
There has been a recent upsurge of interest in comple-
mentary and alternative medicine, especially dietary supple-
ments and functional foods in delaying the onset of age-
associated neurodegenerative diseases. As recently reviewed
by Perry & Howes (2011), phyto-chemical approach for
dementia and AD treatment includes galantamine from
Narcissus sp., lemon balm (Melissa officinalis), and periwin-
kle (Vinca minor). Other edible ‘‘brain food’’ consists
primarily of blueberry, grape seed, pomegranate, and
walnut. The polyphenol entities found in the vegetables,
Address for correspondence: Prof. Vikineswary Sabaratnam, Mushroom
Research Centre, Institute of Biological Sciences, Faculty of Science,
University of Malaya, 50603 Kuala Lumpur, Malaysia. E-mail:
viki@um.edu.my
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fruits and nuts, inhibited neuro-inflammation by preventing
APP signaling, and Ab aggregation (Essa et al., 2012).
Mushrooms offer great potential as a polypharmaceutic
drug because of the complexity of their chemical contents and
different varieties of bioactivities. Available evidence sug-
gests that mushrooms exhibit anti-oxidants, anti-tumor, anti-
virus, anti-cancer, anti-inflammatory, immune modulating,
anti-microbial, and anti-diabetic activities (Roupas et al.,
2012). In contrast to plant herbal medicines, which are
widely explored and relatively more advanced, the brain and
cognition health effects of mushrooms are in the early stages
of research. Palmitic, oleic, and linoleic acids dominate
fatty acid profiles in mushrooms (Dog˘an & Akbas¸, 2013).
These fatty acids are important nutritionally, as oleic acid
(C18:1 n-9) has been shown to promote axon generation in
the striatum during brain development (Guest et al., 2013).
Furthermore, in vitro toxicology assessment across different
mushroom extracts on embryonic fibroblast and neuroblast-
oma cell lines suggested that the extracts are safe to be
consumed even at high doses and they may be developed as a
dietary supplement to improve brain and cognitive health.
An elaborated discussion on the toxicity of various mushroom
metabolites can be found in Phan et al. (2013).
Disease prevention is better than cure especially in
neurodegenerative diseases as degeneration process is nearly
impossible to be arrested or delayed once the process has
commenced. In the present review, brain and cognition
health effects of higher Basidiomycetes are analyzed with
emphasis on dementia, AD, and PD. The review summarizes
the biodiversity of brain-health promoting mushrooms, the
chemical structure of the responsible bioactive metabolites,
their biological actions, and molecular mechanisms, i.e.
neurite outgrowth, cholinesterase inhibition, BACE1 inhib-
ition, anti-neuroinflammation and neuroprotection. The posi-
tive, as well as negative, results of experimental testing
(in vitro and in vivo) are also included.
Diversity of mushrooms with brain health
promoting effects
In mushroom biology, species boundaries are always indis-
tinct and many mushrooms are subsumed under erroneous
names (Hallenberg et al., 2012). Therefore, common names
and taxonomic descriptions of different culinary-medicinal
mushrooms, which were found to promote brain and cognitive
health, are included in Supplemental Table 1. Common names
and a morphological description of the mushroom basidio-
carps can also be found in Supplemental Table 1.
Inhibition of beta-amyloid, p-tau, and
acetylcholinesterase
Beta-amyloid 1–42 (Ab1–42), a 42-amino acid-length poly-
peptide, is a cleavage product of amyloid precursor protein
(APP) by two secretase enzymes: beta (b-) and gamma (g-)
secretases. Ab peptides self assemble into soluble oligomers
and deposit as insoluble senile plaque in the hippocampus;
causing impaired memory and cholinergic dysfunctions
in the brains of Alzheimer’s patients. Therefore, AD may be
prevented by inhibiting the production of Ab or preventing
the aggregation of Ab into amyloid plaques. Following this
hypothesis, the potential of b-secretase (b-site APP cleaving
enzyme, BACE1) inhibitor is promising (Saboticˇ & Kos,
2012). Some BACE1 (EC3.4.23.46) inhibitors such as KMI-
429, GSK188909, and PMS777 have provided new insights
for clinical application in the near future (Sathya et al., 2012).
Apart from that, the level of acetylcholine, a neurotransmitter
involved in the regulation of learning and memory functions,
decreased dramatically in the neocortex and hippocampus
in AD. Therefore, AChE inhibitors can be used to restore
acetylcholine levels and therefore cholinergic brain activity.
Ab 1–40 causes oxidative stress and inflammation in the
brain leading to the secretion of p-tau protein which is
involved in neuron damage (Bharadwaj et al., 2010). In a
study by Wang et al. (2012), the mycelium and/or fruiting
body of Antrodia camphorata were able to reverse the
damaging effects of in vivo Ab-40 infusion and in vitro Ab-40
treatment. A working memory test to evaluate short-term
memory and learning abilities of Ab brain infusion rats was
carried out. The mushroom-supplemented group displayed
better improvement in memory and learning abilities. Also,
the expression of p-tau protein in rat pheochromocytoma
(PC-12) cells was significantly decreased by the treatment
of A. camphorata. However, A. camphorata did not have
significant inhibitory effects on BACE expression. This result
was interpreted to indicate that p-tau inhibition, rather than
BACE modulation, played a vital role in AD prevention by
A. camphorata.
The effects of Hericium erinaceus on Ab25–35 peptide-
induced cognitive dysfunction in mice was investigated by
Mori et al. (2011). The powder of H. erinaceus was mixed
with a normal powdered diet and the Ab25–35 peptide was
administered by intracerebroventricular injection. The results
revealed that H. erinaceus prevented impairments of spatial
short-term and visual recognition memory induced by Ab25–
35 in mice. Human trials with H. erinaceum derivatives
also showed promising results in patients with dementia
based on Revised Hasegawa Dementia Scale (HDS-R) (Mori
et al., 2009).
Aqueous extract of Ganoderma lucidum significantly
attenuated Ab-induced synaptotoxicity and apoptosis by
preserving the synaptic density protein called synaptophysin
(Lai et al., 2008). Further, a study by Wang et al. (2004)
concluded that senescence-accelerated mice (strain SAMP8)
given a diet supplemented with Ganoderma extract exhibited
significantly lower brain amyloid and higher antioxidation
activities such as superoxide dismutase, glutathione peroxid-
ase (GPx), and glutathione reductase when compared with the
control mice. Moreover, a study by Pinweha et al. (2008)
suggested that G. lucidum mycelium extract might possess
nerve growth factor (NGF)-like properties for the processing
of APP via an enhanced NGF signaling pathway. As a result,
the increased APP expression promoted non-amyloidogenic
protein secretion (sAPP).
The mushroom Cortinarius infractus has a strong bitter
taste and an unpleasant odor due to the presence of indole
alkaloids infractine, 6-hydroxyinfractine, and infractopicrine
(Brondz, et al., 2007). Infractopicrin (1) and 10-hydroxy-
infractopicrin (2) (Supplemental Figure 1) showed AChE-
inhibiting activity with non-detectable cytotoxicity (Geissler
et al., 2010). Topological polar surface area (TPSA) of below
2 C.-W. Phan et al. Crit Rev Biotechnol, Early Online: 1–14
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70 A˚2 suggested that the compounds could pass through the
blood–brain barrier. Aggregation of Ab1–40 (fibril formation)
was also inhibited by the two alkaloids as revealed by
the thioflavin T fluorescence assay. In addition, in vitro
AChE and butyrylcholinesterase-inhibiting activities of
extracts of Tricholoma species (T. fracticum, T. imbricatum,
and T. terreum) were tested. As a result, only the hexane
extract of T. imbricatum (0.2 mg/mL) was confirmed to
inhibit AChE and butyrylcholinesterase by 71.8 ± 0.3% and
52.6 ± 1.0%, respectively (Tel et al., 2011).
According to Dai et al. (2010), hispidin (3), a class of
polyphenols is an important medicinal metabolite from
Phellinus spp. Hispidin (Supplemental Figure 1) were isolated
from the culture broth of P. linteus, and it has been shown
to be a non-competitive inhibitor of BACE1 with an IC50
value of 4.9 106 M and a Ki value of 8.4 106 M (Park
et al., 2004a). In addition, hispidin was shown to be an
efficient reactive oxygen species (ROS) scavenger (Park et al.,
2004b). Agaricus bisporus (button mushroom), Flammulina
velutipes (enoki), and Lentinula edodes (shiitake) neither
inhibited nor activated BACE1. The major polysaccharide
of button mushroom, b-D-glucan, in contrast, did not cause
BACE1 activation (Sheean et al., 2012). The results indicated
that BACE1 activity behaved differently with different
compound features. Nevertheless, the effects of button
mushrooms, enoki, and shiitake together with b-D-glucan
need to be tested further. Most recently, BACE1 activity was
shown to be inhibited by extracts of fresh basidiocarps of
Auricularia polytricha (wood ear mushroom). The BACE1
inhibitory activity was most likely due to the hispidin-derived
polyphenolics (Bennett et al., 2013b).
Stimulation of neurite outgrowth and NGF synthesis
Neurotrophic factors (neurotrophins) such as NGF, brainder-
ived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and
glia-derived neurotrophic factor (GDNF) play an important
role in differentiation, survival, and maintenance of the
neuronal cells. Insufficient neurotrophins is believed to result
in dysfunction of the nervous system, causing dementia, AD,
and PD. However, polypeptides such as NGF in therapy are
unfavorable as they are unable to cross the blood–brain
barrier. Therefore, finding small molecules that show neuro-
trophic properties and/or enhancing the action of endogenous
neurotrophic factors is important (Shi et al., 2011).
Sarcodon spp., also called ‘‘bitter tooth’’, are widely
distributed in Europe, North America, and Asia. Sarcodon
mushrooms are considered inedible due to their bitter taste.
On one hand, cyrneines A (4) and B (5) (Figure 1) isolated
from Sarcodon cyrneus stimulated neurite outgrowth in PC12
at 100 mM with no cytotoxicity as indicated by lactate
dehydrogenase (LDH) analysis (Marcotullio et al., 2006a)
(Table 1). Later, it was shown that both cyrneines A and B
promoted NGF production in 1321N1 cells (Marcotullio
et al., 2007). Neurite outgrowth activity was also observed
in NG108-15 cells, a hybrid neuronal cell line derived from
mouse neuroblastoma and rat glioma (Obara et al., 2007).
On the other hand, cyrneines C (6) and D (7) failed to induce
neurite outgrowth. In addition, glaucopine C (8), isolated
from the hexane extract of Sarcodon glaucopus
(Marcotullio et al., 2006b), did not significantly promote
neurite outgrowth in PC12 cells but induced NGF gene
expression to a lesser extent when compared with cyrneines
A and B. It seemed that the presence of the hydroxyl
cycloheptadienyl carbaldehyde system in cyrneines could
be important for neuritogenesis (Marcotullio et al., 2007).
In other words, minor differences in functional groups on
cyathane structures in cyrneines A, B, C, and D can influence
the responses in neuronal cells. Figure 1 shows the chemical
structure of different cyrneines.
Scabronine A (9) (Table 2), isolated from Sarcodon
scabrosus, showed potent inductive activity of NGF syn-
thesis in 1321N1 human astrocytoma cells (Ohta et al.,
1998). Further investigation led to the isolation of novel
cyathane diterpenoids named scabronines B–F (10–14) (Kita
et al., 1998), G (15) (Obara et al., 1999), K (16), and L (17)
(Shi et al., 2011). However, only scabronines B, C, E, and
G showed NGF-synthesis stimulating activity. It appeared
that the presence of the a,b-unsaturated aldehyde system in
the seven-membered ring could be crucial for the bioactiv-
ity. Recently, the first synthesis of scabronine G in optically
pure form has been reported, and the neurite outgrowth
activity was comparable with NGF and natural scabronine G
(Waters et al., 2005). Meanwhile, scabronine G-methyl-ester
(18) synthesized from scabronine G also potently promoted
the secretion of NGF and interleukin-6 (IL-6), another
major neurotrophic factor released from astrocytes. Most
recently, secoscabronine M (19), a hemiacetal cyathane
diterpenoid was isolated from S. scabrosus but no
neuritogenesis has been reported for this compound.
Figure 1 shows the structures of scabronine A-G, K, L,
scabronine G-methyl-ester, and secoscabronine M isolated
from S. scabrosus.
There is a possible use of Hericium erinaceus (Bull.: Fr.)
Pers. in the treatment of neurological disorders and dementia
as reported by Kawagishi & Zhuang (2008). In a study by
Wong et al. (2007), the extracts of H. erinaceus fruiting body
and mycelium induced neurite outgrowth of neuronal cells
NG108-15 in vitro (Supplemental Figure 2). Also, ethanol
extract of H. erinaceus promoted the neurite outgrowth of
PC12 cells, enhanced NGF mRNA expression, and the
secretion of NGF from 1321N1 human astrocytoma cells
(Mori et al., 2008). Further, in vivo functional recovery of
axonotmetic peroneal nerve injury in Sprague–Dawley rats
was assessed by walking-track analysis and toe-spreading
reflex (Wong et al., 2009) (Supplemental Figure 3). The
peroneal functional index (PFI) and toe-spreading reflex
improved more rapidly in the group treated with daily
administration of H. erinaceus extract. These data suggested
that H. erinaceus could promote the regeneration of nerve
injury in the early stage of recovery (Wong et al., 2010).
Although preliminary, it was demonstrated that the
H. erinaceus extract exerted neurotrophic action and
improved the myelination process in the rat brain without
affecting nerve cell growth and toxicity (Moldavan et al.,
2007). There was an attempt to isolate a polysaccharide
from the mycelium of H. erinaceus and the polysacchar-
ide (1 000 000 dalton; molar ratio of 1.5:1.7:1.2:0.6:0.9;
glucose:galactose:xylose:mannose:fructose) promoted neurite
outgrowth in PC12 cells in vitro (Park et al., 2002).
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However, it needs to be clarified that this in vitro evidence
cannot be assumed to occur in vivo and that the in vitro
activity of polysaccharides cannot be extrapolated to explain
in vivo observations.
On one hand, hericenones (benzyl alcohol derivatives)
were isolated from the fruiting bodies of H. erinaceus
(Table 2). Hericenones A (20) and B (21) were first reported
in 1990 but no neurite outgrowth activity was reported
(Kawagishi et al., 1990). Hericenones C (22), D (23), E (24),
F (25), G (26), and H (27) exhibited stimulating activity for
the biosynthesis of NGF in vitro (Kawagishi & Ando, 1993;
Kawagishi et al., 1991). On the other hand, diterpenoid
derivatives (named erinacines) were isolated from the myce-
lium of H. erinaceus. Erinacines A–I (28–36) significantly
induced the synthesis of NGF in vitro (Kawagishi et al., 1994,
1996a,b; Lee et al., 2000) and in vivo (Shimbo et al., 2005).
Figure 1. Cyrneines A (4), B (5), C (6), and D (7) from Sarcodon cyrneus; and glaucopine C (8), isolated from the hexane extract of Sarcodon
glaucopus. Scabronine A–G (9–15), K (16), L (17), scabronine G-methyl-ester (18), and secoscabronine M (19), isolated from Sarcodon scabrosus.
4 C.-W. Phan et al. Crit Rev Biotechnol, Early Online: 1–14
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Isolation of new compounds from this mushroom
continued with the discovery of erinacines J (37), K (38),
P–R (39–41), as well as erinacol (42), a novel cyathadien-
14-ol (Kawagishi et al., 2006; Kenmoku et al., 2000;
Kenmoku et al., 2002, 2004; Ma et al., 2010, 2008).
Structures of hericenones and erinacines are given in
Figure 2.
Cheung et al. (2000) reported that G. lucidum extract
reduced PC12 cell proliferation and induced neuronal differ-
entiation and neurite outgrowth via the activation of
MAP kinases and cAMP-response element binding protein
(CREB) signaling pathways. In addition, a lipophilic
fraction of G. lucidum (125 and 500 mg/L) was also shown
to induce neurite outgrowth of PC12 cells (Zhang et al.,
2005).
Mycoleptodonoides aitchisonii is a rare mushroom that
improves brain function in rats. The mycelium-containing
cultivation medium was found to bear fragrant compounds
of phenylpentane, which consists of 1-phenyl-3-pentanol and
1-phenyl-3-pentanone. The compounds improved dopamine
liberation in the brains of rats fed with the mushroom powder
or aqueous extracts (Okuyama et al., 2004a). Further, NGF
synthesis in the cerebral cortex and hippocampus of newborn
rats was also enhanced after the pregnant rats were fed
Table 2. List of hericenones and erinacines in Hericium erinaceus, some of which showed neurite outgrowth activity.
No. Compound
Mushroom
component In vitro study Neurite outgrowth activity References
20 Hericenone A F – – Kawagishi et al. (1990)
21 Hericenone B F – – Kawagishi et al. (1990)
22 Hericenone C F Mouse astroglial cells NGF " Kawagishi et al. (1991)
23 Hericenone D F Mouse astroglial cells NGF " Kawagishi et al. (1991)
24 Hericenone E F Mouse astroglial cells NGF " Kawagishi et al. (1991)
25 Hericenone F F Mouse astroglial cells NGF " Kawagishi & Ando (1993)
26 Hericenone G F Mouse astroglial cells NGF " Kawagishi & Ando, (1993)
27 Hericenone H F Mouse astroglial cells NGF " Kawagishi & Ando, (1993)
28 Erinacine A M Mouse astroglial cells
Rat (in vivo)
NGF ";
catecholamine "
in the CNS of rats
Kawagishi et al. (1994)
Shimbo et al. (2005)
29 Erinacine B M Mouse astroglial cells NGF " Kawagishi et al. (1994)
30 Erinacine C M Mouse astroglial cells NGF " Kawagishi et al. (1994)
31 Erinacine D M Mouse astroglial cells NGF " Kawagishi et al. (1996b)
32 Erinacine E M Mouse astroglial cells NGF " Kawagishi et al. (1996a)
33 Erinacine F M Mouse astroglial cells NGF" Kawagishi et al. (1996a)
34 Erinacine G M Mouse astroglial cells NGF " Kawagishi et al. (1996a)
35 Erinacine H M Rat astroglial cells NGF " Lee et al. (2000)
36 Erinacine I M Rat astroglial cells NGF " Lee et al. (2000)
37 Erinacine J M MRSA – Kawagishi et al. (2006)
38 Erinacine K M MRSA – Kawagishi et al. (2006)
39 Erinacine P M – Biosynthesis of erinacines Kenmoku et al. (2000)
40 Erinacine Q M – Biosynthesis of erinacine C Kenmoku et al. (2002)
41 Erinacine R M – – Ma et al. (2010, 2008)
42 Erinacol M – Biosynthesis of erinacine Q Kenmoku et al. (2004)
F, fruiting body; M, mycelium; –, none; NGF, nerve growth factor; CNS, central nervous system; MRSA, methicillin-resistant Staphylococcus aureus.
Table 1. Compounds isolated from mushroom Sarcodon spp. that were screened for neurite outgrowth activity.
No. Compound Sarcodon spp. In vitro study Neurite outgrowth activity References
4 Cyrneine A SC PC12; NG108–15; 1321N1 Neurite outgrowth ", NGF " Marcotullio et al. (2006a) and
Obara et al. (2007)
5 Cyrneine B SC PC12 Neurite outgrowth ", NGF " Marcotullio et al. (2006b, 2007)
6 Cyrneine C SC PC12 – Marcotullio et al. (2007)
7 Cyrneine D SC PC12 – Marcotullio et al. (2007)
8 Glaucopine C SG PC12 NGF gene expression " Marcotullio et al. (2006a) and
Marcotullio et al. (2007)
9 Scabronine A SS 1321N1 Neurite outgrowth " Ohta et al. (1998)
10 Scabronine B SS Rat astroglial cells NGF " Kita et al. (1998)
11 Scabronine C SS Rat astroglial cells NGF " Kita et al. (1998)
12 Scabronine D SS Rat astroglial cells – Kita et al. (1998)
13 Scabronine E SS Rat astroglial cells NGF " Kita et al. (1998)
14 Scabronine F SS Rat astroglial cells – Kita et al. (1998)
15 Scabronine G SS 1321N1 Neurite outgrowth " Obara et al. (1999) and
Waters et al. (2005)
16 Scabronine G-Methyl ester SS PC12 NGF and IL-6 " Obara et al. (2001)
17 Scabronine K SS PC12 – Shi et al. (2011)
18 Scabronine L SS PC12 – Shi et al. (2011)
19 Secoscabronine M SS – – Shi et al. (2012)
SC, S. cyrneus; SG, S. glaucopus; SS, S. scabrosus; –, no effect on neurite outgrowth; NGF, nerve growth factor; ", promoted/increased.
DOI: 10.3109/07388551.2014.887649 Culinary-medicinal mushrooms 5
Cr
iti
ca
l R
ev
ie
w
s i
n 
Bi
ot
ec
hn
ol
og
y 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
17
5.
14
3.
19
6.
73
 o
n 
03
/2
4/
14
Fo
r p
er
so
na
l u
se
 o
nl
y.
with either M. aitchisonii powder or its aqueous extract for 7 d
before delivery (Okuyama et al., 2004b). A recent study
concluded that M. aitchisonii aqueous extract prevented the
reduction of dopaminergic and serotoninergic neuronal
activities following brain ischemia damage in the cerebral
cortex (Okuyama et al. 2012). The concentrations of the
neurotransmitters, dopamine, and its metabolites were
increased after treatment with this mushroom. Moreover,
M. aitchisonii was shown to activate NF-E2-related factor 2
(Nrf2) and might contribute to the prevention of oxidative
stress-related diseases (e.g. Alzheimer’s) by inducing anti-
oxidative and phase II detoxifying enzyme series (Kokubo
et al., 2011).
Dictyophora indusiata is a famous edible mushroom used
in Chinese cuisine and medicine. Two eudesmane-type ses-
quiterpenes, dictyophorines A (43) and B (44) (Supplemental
Figure 4), were isolated from the mushroom and were found
to promote NGF synthesis by astroglial cells (Kawagishi
et al., 1997). It was shown that NGF secreted into the medium
in the presence of 3.3 mM of dictyophorines A was four times
higher than the negative control. Meanwhile, lysophosphati-
dylethanolamine (LPE) isolated from G. frondosa (GLPE)
was found to induce neurite outgrowth and it upregulated the
neurofilament M expression in cultured PC12 cells (Nishina
et al., 2006). This study also showed the suppressive effect of
G. frondosa on serum deprivation-induced apoptosis of the
PC12 cells.
The aqueous extract of Tremella fuciformis not only
promoted neurite outgrowth of the PC12 cells but also
significantly reversed the scopolamine- and trimethyltin-
induced memory deficit in rats, as revealed by the Morris
water maze test and choline acetyltransferase (ChAT)
immunohistochemistry (Kim et al., 2007; Park et al., 2012).
Besides, neuritogenic compounds named tricholomalides
A–C (45–47) (Supplemental Figure 4) were also isolated
from Tricholoma sp. and neurite outgrowth in PC-12 cells was
significantly induced at concentrations of 100mM
(Tsukamoto et al., 2003). Whereas for Termitomyces
Figure 2. Hericenones A–H (20–27); erinacine A–K (28–38), P–R (39–41), and erinacol (42).
6 C.-W. Phan et al. Crit Rev Biotechnol, Early Online: 1–14
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albuminosus, the cerebrosides named termitomycesphins A–
D (48–51) (Qi et al., 2000), E–F (52–53) (Qi et al., 2001),
and G–H (54–55) (Qu et al., 2012) (Supplemental Figure 4)
were identified to potentiate neuritogenesis in PC12 cells.
It is interesting that termitomycesphin with a 16-carbon-chain
fatty acid (A, C, and G) showed higher neuritogenic activity
than that of termitomycesphin with an 18-carbon-chain fatty
acid (B, D, and H), suggesting that the chain length of the
fatty acyl moiety played a determining role in neuritogenesis.
A number of new mushrooms have been reported to possess
neuritogenic effects (Sabaratnam et al., 2013). Aqueous
extract of L. rhinocerotis sclerotium (Eik et al., 2012),
L. rhinocerotis mycelium (John et al., 2013), Ganoderma
neo-japonicum (Seow et al., 2013), and Pleurotus giganteus
(Phan et al., 2012) were shown to induce neuronal differen-
tiation and stimulate neurite outgrowth of PC12 and N2a
cells. Meanwhile, a methanol extract of Cordyceps militaris
(5–20mg/mL) was able to increase primary neurite sprouting
and ChAT expression in differentiated N2a cells (Lee et al.,
2011). Administration of C. militaris also restored the
scopolamine-induced memory deficit in vivo.
Neuroprotection, anti-inflammatory, and
anti-oxidant activities
Accumulating evidence have indicated that oxidative stress
and ROS play an important role in the progression of many
chronic diseases including cardiovascular diseases, diabetes,
and neurodegenerative disorders (Chu et al., 2012). Imbalance
between ROS generation and antioxidant enzyme activities
will cause lipid peroxidation, nuclear mitochondrial DNA
damage and protein oxidation, resulting in brain damage and
amnesia (Biasibetti et al., 2013). Therefore, a drug with
antioxidant and anti-inflammatory activities may prevent
neuronal degeneration in AD. Mushrooms, known for their
potent antioxidant property, have attracted interest due to
their potential in neuroprotection, antioxidant, and anti-
inflammatory effects, in a variety of experimental models
(Gunawardena et al., 2014).
At least 140 different triterpenes have been identified in
G. lucidum and they include ganoderic, lucidenic, ganoder-
mic, ganoderenic, ganolucidic and applanoxidic acids,
lucidones, ganoderals, and ganoderols (Connolly & Hill,
2003; Smina et al., 2011; Wu et al., 2001). The total
triterpenes from G. lucidum scavenged 2,2-diphenyl-1-picryl
hydrazyl (DPPH+), 2,20-azinobis-(3-ethylbenzothiazolin-6-
sulphonic acid (ABTS+) and superoxide radicals (Smina
et al., 2011). Also, the administration of total triterpenes to
mice enhanced the superoxide dismutase (SOD), reduced
glutathione (GSH), catalase (CAT), and GPx in the blood and
liver tissues. Further, the aqueous extracts of G. lucidum
fruiting bodies were shown to prevent H2O2-induced oxida-
tive damage to cellular DNA (Shi et al., 2002). Dietary intake
of natural or synthetic products with a putative antioxidant
effect has been shown to delay the onset AD (Pratico`, 2008).
Therefore, the ability of the triterpenes of G. lucidum to
scavenge free radicals may suppress reactive oxygen damage
that leads to AD pathology.
For PD, a neuroprotective approach to salvage dopamine
neurons from progressive death in the brain (substantia nigra
region) is currently being explored. A study by Zhu et al.
(2005) has shown that rats fed with G. lucidum spores oil
ameliorated Parkinsonism induced by neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP). The number of
surviving dopamine neurons in the substantia nigra and the
level of dopamine in the striatum of MPTP-induced mice has
increased after treatment with the oil of Ganoderma spores.
Furthermore, involuntary movement of mice was also
significantly reduced. Microglia is the resident innate
immune cells of central nervous system (CNS) and it plays
a major role in the neuroinflammatory process. Activation of
microglia can trigger neurotoxicity via the production of
pro-inflammatory and cytotoxic factors including tumor
necrosis factor-(TNF)-a, nitric oxide (NO), superoxide rad-
icals, interleukin- b (IL-b), and cyclooxygenase 2 (COX2)
(Liu et al., 2006). The over-activation of microglia in the CNS
contributes to neurodegenerative processes (Brown & Neher,
2010). To test for the potential neuroprotective effect of
G. lucidum, co-cultures of 1-methyl-4-phenylpyridinium-
(MPP+)-treated dopaminergic neuronal cell line MES23.5
and LPS-activated microglia were used (Zhang et al., 2011a).
MPP+ is a metabolite of the neurotoxin MPTP. The
G. lucidum extracts significantly inhibited the production
of microglia-derived proinflammatory and cytotoxic factors
(NO, TNF-a, and IL-1b) suggesting that G. lucidum is
a promising agent in deterring inflammation-induced
Parkinson’s disease.
Ganoderic acid is a member of highly oxygenated C30
lanostane-type triterpenoids. However, its biological activity
on the nervous system is still unknown. Recently, a new
lanostanoid, 4,4,14-trimethyl-5-chol-7,9(11)-dien-3-oxo-24-
oic acid (56) was isolated from an ethyl acetate extract
of the dried fruiting bodies of G. lucidum. The
triterpenoids, together with seven other known triterpenoids,
i.e. 7-oxo-ganoderic acid Z (57), ganolucidic acid A (58),
methyl ganoderic acid A (59), methyl ganoderic acid B (60),
ganoderic acid S1 (61), ganodermic acid TQ (62) and
ganodermatriol (63) (Figure 3), have shown NGF- and
brain-derived neurotrophic factor-like neuronal survival-
promoting effects (Table 3).
The role of vitamin D2-enriched button mushrooms
(Agaricus bisporus) was studied especially for their mem-
ory improving effects in rats (Bennett et al., 2013a).
Fungi, especially the members of Basidiomycetes, are
rich in ergosterol. The ergosterol in mushrooms can be
converted to vitamin D2 following exposure to ultra violet
(UV) light. Recent research suggested that higher vitamin D
dietary intake was associated with a lower risk of
developing AD among older women (Annweiler et al.,
2012). Compound (56) has a steroidal feature resembling
cholesterol that can be converted to vitamin D by enzym-
atic pathways, in response to UV irradiation. Therefore, there
is a potential for this class of compounds to interact with
vitamin D receptors and exert bioactivity via vitamin D
mimicry.
The endoplasmic reticulum (ER) is an organelle within
fungal cells in which protein folding, lipid biosynthesis,
and calcium storage takes place (Brown & Naidoo, 2012).
The ER, by serving as quality control machinery, suppresses
protein aggregation in the cells under normal physiological
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conditions. However, with age and under stress, ER homeo-
stasis will be interrupted and brings about the ER-stress
response or the activation of the unfolded protein response,
followed by programmed cell death (apoptosis) in the brain
and/or insoluble protein fibrils formation. ER stress accom-
panies and contributes to several neurological disorders
including PD. Due to that, the demand for new protective
substances against the ER-stress-dependent cell death is
high. In this review, the protective effects of medicinal
mushrooms, namely H. erinaceus, Stropharia rugosoannu-
lata, Leccinum extremiorientale, Termitomyces titanicus,
and Mycoleptodonoides aitchisonii against age-implicated
ER stress are discussed (Table 4).
In the protection assay against ER stress-dependent cell
death, a popular cell line Neuro2a (N2a) cell is widely used.
In general, the ER stress was either induced by addition
of tunicamycin or thapsigargin. Tunicamycin is a protein
glycosylation inhibitor that induces accumulation of mis-
folded protein in the ER and ultimately causes cell death.
Thapsigargin is a non-competitive inhibitor of Ca2+ ATPase
in ER that causes Ca2+ reduction. 3-hydroxyhericenone F (64)
(Supplemental Figure 5), which was isolated from the fresh
fruiting bodies of H. erinaceus, was found to protect N2a
cells against both tunicamycin and thapsigargin toxicities
(Ueda et al., 2008). Another ER stress attenuating compound,
dilinoleoyl-phosphatidylethanolamine, was also isolated and
Figure 3. New lanostanoid (56),
7-oxo-ganoderic acid Z (57), ganolucidic
acid A (58), methyl ganoderic acid A (59),
methyl ganoderic acid B (60), ganoderic acid
S1 (61), ganodermic acid TQ (62), and
ganodermatriol (63), isolated from
Ganoderma lucidum.
Table 3. List of ganoderic acids in Ganoderma lucidum which showed neuroprotection effects in in vitro studies using NIH-3T3/TrkA and NIH-3T3/
TrkB cells.
No. Compound Neuronal surviving effect References
56 4,4,14-Trimethyl-5-chol-7,9(11)-dien-3-oxo-24-oic acid NGF " Zhang et al. (2011b)
57 7-Oxo-ganoderic acid Z BDNF " Li et al. (2006) and Zhang et al. (2011b)
58 Ganolucidic acid A BDNF " Zhang et al. (2011b)
59 Methyl ganoderic acid A BDNF " Zhang et al. (2011b)
60 Methyl ganoderic acid B NGF " Zhang et al. (2011b)
61 Ganoderic acid S1 BDNF " Zhang et al. (2011b)
62 Ganodermic acid TQ BDNF " Zhang et al. (2011b)
63 Ganodermatriol BDNF " Zhang et al. (2011b)
NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor.
Table 4. Protective effects of mushrooms from endoplasmic reticulum stress-induced neuronal cell death.
No. Mushroom Compound References
64 Hericium erinaceum 3-Hydroxyhericenone F Ueda et al. (2008)
Dilinoleoyl-phosphatidylethanolamine Nagai et al. (2006)
65 Stropharia rugosoannulata Strophasterol Wu et al. (2011, 2012)
66 Leccinum extremiorientale Ethyl 2-(N-phene-thylformamido)acetate; also Leccinine A Choi et al. (2011)
67–71 Termitomyces titanicus Termitomycamides A–E Choi et al. (2010)
72 Mycoleptodonoides aitchisonii 3-(Hydroxymethyl)-4-methylfuran-2(5H)-one Choi et al. (2009)
73 3-(10-Hydroxyethyl)-4-methyldihydrofuran-2(3H)-one
74 3-Hydroxyethyl-4-methyldihydrofuran-2(3H)-one
75 1-Hydroxy-3-pentanone
8 C.-W. Phan et al. Crit Rev Biotechnol, Early Online: 1–14
Cr
iti
ca
l R
ev
ie
w
s i
n 
Bi
ot
ec
hn
ol
og
y 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
17
5.
14
3.
19
6.
73
 o
n 
03
/2
4/
14
Fo
r p
er
so
na
l u
se
 o
nl
y.
identified from the dried fruiting bodies of H. erinaceum
(Nagai et al., 2006). A compound from S. rugosoannulata
attenuated the ER stress caused by thapsigargin, but not by
tunicamycin (Wu et al., 2011). The compound was later found
to be strophasterol (65) with a new steroid skeleton not
previously reported (Wu et al., 2012) (Supplemental
Figure 5). Similarly, leccinine A (66) (Supplemental
Figure 5) from L. extremiorientale also showed significant
protective activity against thapsigargin toxicity but not
tunicamycin (Choi et al., 2011). Meanwhile, five fatty acid
amides, termitomycamides A–E (67–71) isolated from
T. titanicus (Supplemental Figure 5), were screened for their
protective effects against tunicamycin toxicity. Only termito-
mycamides B and E showed significant protective effects,
suggesting that these compounds blocked the inhibitory action
of tunicamycin and N-linked glycosylation in ER was not
repressed. Another four compounds (72–75) (Supplemental
Figure 5) were also successfully isolated from the mushroom
M. aitchisonii and they have shown attenuating effects on ER
stress-dependant neuronal cell death (Choi et al., 2009).
Inonotus obliquus is another mushroom popular for its
antioxidative effects in neuronal cells (Jung et al., 2008). An
acid protein-bound polysaccharide from I. obliquus exhibited
notable quenching of 1,1-diphenyl-2-picrylhydrazyl (DPPH)
and hydroxyl radicals (Chen et al., 2010). Enzymatically
hydrolyzed I. obliquus by carbohydrase (Celluclast) and
protease (Protamex) showed the highest DPPH radical-
scavenging activities (Kim et al., 2011). Pepsin extracts of
I. obliquus managed to decrease generation of ROS and cell
death in PC12 cells against H2O2-induced oxidative damage.
In another study using the peroxide-treated human fibroblasts,
I. obliquus showed cytoprotective effects by scavenging
intracellular ROS and preventing lipid peroxidation and
ultimately stopping premature senescence. Most recently,
a significant cognitive enhancement was observed in amnesic
mice after orally administration of methanolic extracts of
I. obliquus (Giridharan et al., 2011). The critical metabolites
responsible for the neuroprotection were thought to be the
phenolic ingredients namely 3,4-dihydroxybenzalacetone (76)
and caffeic acid (77) (Nakajima et al., 2009) (Supplemental
Figure 6).
Armillaria mellea produces an array of different metabol-
ites, including carbohydrates, sterols, sphingolipids, fatty
acids, sesquiterpenes, non-hallucinogenic indole compounds,
peptides, enzymes, and adenosine derivatives (Muszyn´ska
et al., 2011). N6-(5-hydroxy-2-pyridyl)-methyl-adenosine
(78) (Supplemental Figure 6) from the mycelia of A. mellea
displayed an adenosine-like cerebral protecting activity
(Gao et al., 2009; Watanabe et al., 1990). Compounds of
Daldinia concentric, 1-(3,4,5-trimethoxyphenyl) ethanol (79)
and caruilignan C (80) (Supplemental Figure 6) showed
neuroprotective effects against iron-induced neurotoxicity in
mouse cortical cell cultures (Lee et al., 2002).
Five compounds were isolated from the fruiting bodies
of Antrodia camphorata (Chen et al., 2006) (Supplemental
Figure 6). The compounds, 19-hydroxylabda-8(17)-en-16,15-
olide (81), 3b,19-dihydroxylabda-8(17),11E-dien-16,15-olide
(82), 13-epi-3b,19-dihydroxylabda-8(17),11E-dien-16,15-
olide (83), 19-hydroxylabda-8(17),13-dien-16,15-olide (84),
and 14-deoxy-11,12-didehydroandrographolide (85), were
shown to protect neurons from Ab25–35 damage. In the
study, primary cultures of neonatal cortical neurons from
the cerebral cortex of Harlan Sprague–Dawley rat pups at
postnatal day 1 were used. The cell stress model for this
particular study was serum-deprived PC12 cells (Huang et al.,
2005; Lu et al., 2008). Lu et al. (2006) unraveled that the
protective effect of A. camphorata was due to adenosine (86)
(Supplemental Figure 6). The protective effect of adenosine
was found to be mediated through Adenosin-2A receptor (A2A-
R) activation on PC12 cells. A2A-R has been regarded as a
potential therapeutic target in protecting against neuronal
injury and it has been reported that A2A-R activation delayed
apoptosis in human neutrophils (Lu et al., 2006).
Mechanisms and signaling pathways of
bioactivity of mushrooms secondary metabolites
in neurodegenerative diseases
Signal transduction cascades like the mitogen-activated
protein kinase (MAPK), phosphatidylinositol-3-kinase-Akt
(PI3K-Akt), and protein kinase C (PKC) pathways play
important roles in neurons downstream of multiple signals
including neurotrophins and neurotransmitters (Martin &
Arthur, 2012). Certain mushrooms have shown NGF-like
neuritogenic effects. Therefore, it is of utmost importance to
elucidate the molecular mechanism responsible for the
activity. Essentially, the process where a cell translates an
external signal into cellular response is ‘‘signal transduction’’
(Martin & Arthur, 2012). Signal transduction begins with
the binding of an external ligand (NGF, neurotransmitter, or
mushroom compound in this case) to a specific receptor on
a cell. This ultimately causes a systematic signalling cascade
that initiates a response in a cell, for instance cell differen-
tiation and extension of neurite.
The MAPK signal cascade is known to regulate cell
growth and differentiation (Zhang & Liu, 2002). Three
MAPK families have been characterized namely extracellular
signal-regulated kinase (ERK), C-Jun N-terminal kinase/
stress-activated protein kinase (JNK/SAPK), and p38 kinase.
Small and selective molecule protein kinase inhibitor is a
powerful tool to study kinase function. Since NGF induces the
activation of MEK and phosphorylation of ERK1/2, MEK
inhibitors (U0126 and PD98059) were widely used as one of
the checkpoints to assess the MAPK cascade. As reported by
Phan et al. (2012), the induction of activation of ERK1/2 by
both NGF and P. giganteus extracts was inhibited by U0126
and PD98059. Therefore, the mushroom extracts (as well as
NGF) induced the activation of MEK1/2, resulting in neurite
outgrowth. Similar observations were reported by Cheung
et al. (2000) for G. lucidium extracts and Nishina et al. (2006),
for lysophosphatidylethanolamine from Grifola frondosa.
Interestingly, there was no direct involvement of the Trk
family of receptor tyrosine kinase, (TrkA) for the above
mushroom-potentiated neuritogenesis, as opposed by the
classical NGF. It is thus predicted that activation of TrKA
may not be necessary for NGF-independent neuritogenic
effects by mushrooms. It is widely accepted that PI3K/Akt
regulates neuritogenesis (Kimura et al., 1994). Akt is a serine/
threonine kinase essential for neurotrophin-induced cell
survival and the activation of Akt by neurotrophins is
DOI: 10.3109/07388551.2014.887649 Culinary-medicinal mushrooms 9
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mediated by phosphatidylinositol-3 kinase (PI3K). Inhibition
of PI3K/Akt by inhibitor LY294002 negatively affected
neurite outgrowth of PC12 potentiated by P. giganteus. This
finding suggested that P. giganteus induced-neurite outgrowth
is also regulated by PI3K/Akt cascade.
As for the inhibitory mechanism of G. lucidum on Ab25–
35 neurotoxicity, the levels of stress kinases, namely
phosphorylated JNK, phosphorylated c-Jun, and phosphory-
lated p38 were markedly attenuated (Lai et al., 2008).
Meanwhile, the phosphorylation levels of ERK, JNK, and
p38 were found to increase in microglia after lipopolysac-
charide (LPS) and/or interferon gamma treatment. The
methanol extracts of A. camphorata significantly inhibited
the phosphorylation of ERK and JNK, slightly inhibited
the activator of transcription (STAT-1) phosphorylation,
in the course of anti-inflammatory activity in microglia.
Another study also agreed that A. camphorata prevented
serum deprivation-induced PC12 cell apoptosis through a
PKA-dependent pathway and by suppression of JNK and
p38 activities (Lu et al., 2008). 3,4-Dihydroxybenzalacetone
(DBL) isolated from I. obliquus, inhibited H2O2-induced
apoptosis of neurons by suppressing the intracellular ROS
levels and inhibited Bax and caspase-3 activation. Treatment
of DBL significantly inhibited the H2O2-dependent phos-
phorylation of p38-MAPK, but not the ERK and JNK, since
p38 was responsible for phosphorylate p53, which ultimately
lead to apoptosis.
IL-6 is an important interleukin to promote neuronal
survival and neuronal differentiation. Scabronine
G-ME-induced neuritogenesis was mediated by PKC cas-
cades, since a selective inhibitor of PKC, GF109203X
inhibited the process (Obara et al., 2001). In contrast,
GF109203X, as well as the wortmannin (another inhibitor
of PI3K), did not inhibit neurite outgrowth of PC12 in
response to cyrneine A from the mushroom Sarcodon
cyrneus. This indicated that PKC and PI3K/Akt were not
Figure 4. Schematic model of the antioxidative, anti-inflammatory, neurite outgrowth, and neuroprotective effects of mushroom extracts/compounds.
", increased; #, decreased; , inhibited; COX, cyclooxygenase; ILs, interleukins; TNF, tumor necrosis factor; IFN-g, interferon-g; NF-kB, nuclear
factor-kB; iNOS, inducible nitric oxide synthase; Bax, BCL2-associated X; GSH, glutathione; SOD, superoxide dismutase; CAT, catalase; GPx,
glutathione peroxidase; ROS, reactive oxygen species; cAMP, cyclic adenosine monophosphate; STAT3, signal transducers and activators of
transcription 3: CREB, cAMP response element-binding; PLC-g, phosphoinositide phospholipase C-g; NO, nitric oxide; APP, amyloid precursor
protein; PARP, poly (ADP-ribose) polymerase.
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involved. However, the neurite outgrowth process was
blocked by PD98059, indicating that ERK1/2 is required for
cyrneine A-induced neuritogenesis. The activity of Rac1,
which is a GTPase protein that regulates actin, was also
increased by cyrneine A. Both scabronine G-methylester and
cyrneine A enhanced the activation of nuclear factor-kB, but
not phospho-cAMP-response element-binding protein
(CREB). In contrast to this, Tremella fuciformis (Park et al.,
2012) and G. lucidum (Cheung et al., 2000) enhanced the
neurite outgrowth of PC12 cells via activation of CREB
transcription. A. camphorata was also found to prevent serum
deprivation-induced PC12 cell apoptosis through CREB-
dependent protein kinase A (PKA) pathway (Huang et al.,
2005). The coordinated events involved in the mechanisms of
antioxidant, anti-inflammation, neurite outgrowth, and inhib-
ition of neurotoxicity are presented in Figure 4.
Conclusions
In this review, we have summarized mushrooms that have
been reported to show beneficial effects in neuronal health,
with particular emphasis on either crude extracts or isolated
metabolites. Taken as a whole, these medicinal mushrooms
have shown neurological properties such as neuronal survival
and neurite outgrowth activities, including improvement in
recovery and function in both in vitro and in vivo mammalian
nervous systems. Therefore, based on the studies discussed
in this review, including our own research over the last
decade, we propose that these medicinal mushrooms may
have therapeutic values to treat human neurological diseases.
However, any such endeavor, involving human models, must
be carried out with great care and caution as the pharmaco-
logical and negative effects of these mushrooms are not well
established even though many of these mushrooms are edible.
We hope this review will promote interest in medicinal
mushroom research in the experimental clinical neurology
area with a long-term objective of developing effective
therapies for neurological diseases.
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Different solvent extracts of Pleurotus giganteus fruiting bodies were tested for antifungal activities against Candida species responsible for human infections. 
The lipids extracted from the ethyl acetate fraction significantly inhibited the growth of all the Candida species tested. Analysis by GC/MS revealed lipid 
components such as fatty acids, fatty acid methyl esters, ergosterol, and ergosterol derivatives. The sample with high amounts of fatty acid methyl esters was 
the most effective antifungal agent. The samples were not cytotoxic to a mammalian cell line, mouse embryonic fibroblasts BALB/c 3T3 clone A31. To our 
knowledge, this is the first report of antifungal activity of the lipid components of Pleurotus giganteus against Candida species. 
 
Keywords:  Pleurotus giganteus, Candida, yeast, Antifungal, Medicinal mushroom, Fatty acid, Fatty ester methyl ester, Ergosterol. 
 
 
 
Fungal infections are problematic for human health and are 
responsible for high rates of morbidity and mortality worldwide. 
Species of Candida are the dominant cause of opportunistic 
mycoses and among them, C. albicans, C. glabrata, C. parapsilosis, 
C. tropicalis and C. krusei account for 95–97% of all Candida 
infections [1,2]. C. albicans and C. tropicalis are susceptible to 
polyenes, flucytosine, azoles and echinocandins, while C. glabrata 
is either susceptible or resistant to fluconazole[3]. Furthermore, C. 
krusei displays decreased susceptibility to amphotericin B, as well 
as fluconazole. Considering the increasing incidence of drug-
resistant Candida infections, the search for more effective anti-
Candida agents as an alternative to synthetic ones is needed. The 
interest in natural products from medicinal plants as a source of 
anti-Candida agents has grown dramatically. A wide variety of plant 
extracts have been reported to have anti-C. albicans activity. 
Examples include propolis, Punica granatum (pomegranate), 
Streblus asper (Siamese rough bush), Vitis vinifera (common grape 
vine), and tea tree oil from Melaleuca alternifolia [4].  
 
Medicinal mushrooms are relatively less researched for their 
antifungal properties. However, in the last five years, there has been 
a renewed interest in using mushrooms as antimicrobial agents. 
Lentinula edodes (shiitake), Boletus edulis (Penny bun), Pleurotus 
ostreatus (oyster mushroom), Coprinus comatus (shaggy mane), 
Astraeus hygrometricus (earthstar mushroom), and Cordyceps 
militaris were shown to exhibit antifungal activity against C. 
albicans [5–8]. Pleurotus giganteus (Zhudugu, Dabeijun, morning 
glory mushroom), a saprobic mushroom,  is one of the largest 
mushroom which grows on soil either as solitary or gregarious 
fruiting bodies [9]. This mushroom has gained popularity in China 
for its culinary properties. The medicinal properties of this 
mushroom are less known. We have previously reported the 
hepatoprotective and neuronal stimulating effects of P. giganteus 
[10,11]. In this study the antifungal activities of different solvent 
extracts of this mushroom were evaluated. The  extracts prepared 
with different solvents had different profiles of fatty acids, and fatty  
Table 1: Activity of different extracts of Pleurotus giganteus against Candida species. 
 
Candida strains Untreated
Solvent extracts (µg/mL) 
Methanol Ethyl acetate Aqueous 
25 50 100 25 50 100 25 50 100 
Candida albicans WM1172 ++++ ++++ +++ ++ + - - ++++ ++++ ++++
Candida albicans 
ATCC90028 ++++ +++ +++ + + - - ++++ ++++ +++
Candida dubliniensis ++++ ++++ +++ - + - - ++++ ++++ +++
Candida glabrata CBS138 ++++ ++++ ++ - + - - ++++ ++++ ++++
Candida glabrata 
ATCC90030 ++++ ++++ ++++ - + - - ++ +++ +++
Candida krusei ATCC6258 ++++ +++ +++ + - - - ++++ +++ +++
Candida pseudotropicalis ++++ +++ +++ ++ - - - ++++ ++++ ++++
Candida tropicalis WM30 ++++ +++ ++++ ++ + - - ++++ ++++ ++++
Strains were grown with different mushroom extracts at the concentrations shown for 
two days on YEPD media. Growth was scored from “-” to “++++”, indicating no 
growth to strong growth.  
 
acids have been shown to demonstrate antimicrobial activities 
[12].The main metabolites / components in the extracts were 
analysed by GC-MS. As a preliminary in vitro toxicity assessment, 
the P. giganteus extracts were also investigated for cytotoxicity to 
mouse embryonic 3T3 fibroblast cells. 
 
The anti-Candida activity of methanol, ethyl acetate and aqueous 
extracts of P. giganteus against all yeast species tested are 
summarised in Table 1. Candida species showed strong growth 
(denoted as “++++”) when extracts were not added to the medium. 
The aqueous extract had minimum or no inhibitory activity against 
all Candida spp. The ethyl acetate extract completely inhibited the 
growth of all Candida spp. when tested at 50 and 100 µg/mL.  
Thus, the ethyl acetate extract was fractionated to identify the active 
component/s responsible for the antifungal activity. Sub-fractions A 
to H were obtained and the minimum inhibitory concentration 
(MIC) values against all the tested yeasts are given in Table 2.    
The MIC values for all the Candida spp. tested, ranged from 2.0 ± 
1.0 to 10.3 ± 2.5 µg/mL for sub-fraction A; and 9.3 ± 2.3 to 34.3 ± 
10.8 µg/mL for  sub-fraction  B;  respectively.  The  MIC  values of  
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Table 2: Activity of the sub-fractions of ethyl acetate extracts against Candida species. 
 
Candida strains 
Sub-fractions from ethyl acetate 
extract (MICa) 
IC50 (mM) 
A B C D E F G H Fluconazole
Amphotericin 
B 
Candida albicans 
WM1172 
7.3 ± 
1.5 
16.0 ± 
6.1 
26.6 ± 
11.6 * * * * * 1.0 0.6 
Candida albicans 
ATCC90028 
7.0 ± 
1.0 
22.6 ± 
11.5 
40.6 ± 
16.6 * * * * * 2.0 0.7 
Candida dubliniensis 8.2 ± 
3.7 
31.6 ± 
7.8 
37.0 ± 
7.0 * * * * * 24.0 2.1 
Candida glabrata 
CBS138 
8.1 ± 
1.5 
12.5 ± 
2.4 
28.3 ± 
6.6 * * * * * >10.0 1.3 
Candida glabrata 
ATCC90030 
9.2 ± 
1.6 
29.4 ± 
7.0 
41.3 ± 
7.6 * * * * * >10.0 1.2 
Candida krusei 
ATCC6258 
10.3 ± 
2.5 
37.2 ± 
5.0 * * * * * * 8.0 0.4 
Candida 
pseudotropicalis 
3.8± 
1.4 
9. 3 ± 
2.3 
23.0 ± 
11.0 * * * * * 9.0 0.6 
Candida tropicalis 
WM30 
2.0 ± 
1.0 
34.3 ± 
10.8 * * * * * * <1.0 1.2 
Results were from three independent experiments performed in triplicate. aMIC is 
expressed in µg/mL. * : >50 µg/mL 
 
sub- fraction C varied from 23.0 ± 11.0 to >50 µg/mL; whereas the 
MIC values for sub-fractions D-H were all >50 µg/mL. Overall, 
sub-fraction A showed the lowest MIC value for all Candida spp. 
tested.  
 
Sub-fractions A and B were further analysed by GC-MS. Both 
samples were pale yellow-colored oils with a distinct odor. 
Constituents of sub-fractions A and B are listed in Table 3. Twelve 
compounds were identified in sub-fractions A and B. Sample A was 
characterized by high amounts of fatty acid methyl esters, namely: 
methyl palmitate, ethyl palmitate, methyl linoleate, methyl oleate, 
methyl stearate, and ethyl oleate. Sample B contained fatty acids 
(palmitic acid and oleic acid), fatty acid methyl esters (methyl 
linoleate and methyl oleate), ergosterol, ergosta-5,7,9 (11),22-
tetraen-3β-ol, ergost-5,8(14)-dien-3-ol, and γ-ergostenol.  
 
Table 3: Chemical composition of lipids in sub-fractions A and B of .P. giganteus. 
 
Constituents RT (min) Percentage (%) Quality 
Sub-fraction A    
Methyl palmitate 20.50 14.8 99 
Ethyl palmitate 21.81 1.2 98 
Methyl linoleate 23.70 19.8 99 
Methyl oleate 23.80 39.3 99 
Methyl stearate  24.26 3.3 99 
Ethyl oleate  24.99 12.3 99 
Sub-fraction B    
Methyl palmitate 20.49 0.2 95 
Palmitic acid  21.28 14.4 99 
Methyl linoleate 23.68 0.4 93 
Methyl oleate 23.79 1.0 93 
Oleic acid  24.61 31.7 99 
Ergosta-5,7,9(11),22-tetraen-3β-ol  39.83 2.2 90 
Ergosterol  40.33 24.4 98 
Ergost-5,8(14)-dien-3-ol 40.51 10.2 87 
γ-Ergostenol 41.32 3.7 94 
 
The methanol, ethyl acetate, and aqueous extracts were not toxic to 
3T3 fibroblasts cells and the IC50 values were more than 2 mg/mL 
(Fig. 1). Meanwhile, cell viability (%) decreased steadily with 
increasing concentrations of sub-fractions A and B at levels up to 
500 µg/mL. The IC50 value of sub-fraction A was 352 µg/mL and 
the R2 value was 0.9609. For sub-fraction B, the IC50 was 362 
µg/mL with the R2 value recorded at 0.9552. 
 
To our knowledge, this is the first report on the antifungal activity 
of the lipid components of P. giganteus. It has been reported that 
crude extracts of P. ostreatus and C. comatus inhibited the growth 
of C. albicans [6]. However, the MICs were much higher (up to 1 
mg/mL) when compared with this study, which recorded an MIC of  
 
 
Figure 1: Cell viability of embryonic fibroblast cells after treatment with various 
extracts of P. giganteus. 
 
100 µg/mL. The sub-fractions A and B were shown to contain 
several bioactive components. Since they are blends of fatty acids 
and fatty acid methyl esters, they do not act on specific targets in 
the fungal cells, and fungal resistance may be unlikely to occur. 
Furthermore, fatty acids and their methyl esters were reported to 
have fungicidal activity to C. albicans, C. krusei, C. tropicalis and 
C. parapsilosis [13]. The entities might play crucial roles in 
lipophilic or hydrophilic effects on the cell wall and membrane, 
hence affecting the distribution of the lipids in the cells [14]. 
Moreover, ergosterol present in the sample could disrupt the 
ergosterol biosynthesis pathway in the yeast, causing growth 
inhibition or cell death. This was further supported by a study of 
Irshad et al. [15], who reported that ergosterol-rich Cassia fistula oil 
significantly decreased the in vivo ergosterol content in the Candida 
cell wall. 
 
In this study, the sub-fractions A and B were not cytotoxic to mouse 
fibroblasts at the concentrations tested (Fig. 1).  Animal testing is 
becoming less popular and is gradually being replaced by in vitro 
methods for toxicity assessment of pharmaceutical products. In 
conclusion, P. giganteus lipids are promising natural products to be 
further explored as antifungal agents against Candida species.  
 
Experimental 
 
Mushroom: The fruiting bodies of Pleurotus giganteus (Berk) 
Karunarathna & K.D. Hyde were obtained from Nas Agro Farm, 
Selangor, Malaysia. A voucher specimen (KLU-M 1227) was 
deposited in the Herbarium in the University of Malaya. 
 
Chemicals: Fluconazole and amphotericin B were purchased from 
Sigma Co. (St. Louis, MO, USA). The stocks were prepared in 
dimethyl sulfoxide (DMSO) prior to bioassays. [3-(4,5-
Dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT), 
was also obtained from Sigma. Methanol (MeOH), ethyl acetate 
(EtOAc), n-hexane and acetone were from Merck (Darmstadt, 
Germany). 
 
Extracts preparation: The fresh fruiting bodies of P. giganteus 
were sliced, freeze-dried and ground to a fine powder (500 g). The 
mushroom powder was extracted with 80% MeOH to yield a MeOH 
extract (115 g, 23.0%). This (125 g) was further partitioned in 
EtOAc-H2O (100 mL: 100 mL) to give an EtOAc-soluble extract 
(6.96 g, 6.05%) and a H2O extract (74.2 g, 64.52%).  
 
Fractionation of extract: The EtOAc extract (5.00 g) was further 
fractionated by CC over silica gel. The extract was eluted with n-
hexane containing increasing concentrations of acetone to obtain 8 
fractions (A to H) based on similarity of spots on TLC.  
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Cell culture: Mouse embryonic fibroblasts were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 
10%, v/v, heat-inactivated fetal bovine serum (PAA), 100 U/mL 
penicillin and 100 µg/mL streptomycin. The cells were routinely 
passaged every 2-3 days and incubated at 37°C and 5%, v/v, CO2 in 
a humidified atmosphere.  
 
Cytotoxicity: The crude MeOH and fractionated EtOAc extracts 
were dissolved in DMSO (10 mg/mL) as stock solutions. The H2O 
extract (10 mg/mL) was stocked in sterilised distilled water. The 
cytotoxic effects of varying concentrations of MeOH, EtOAc and 
H2O extracts, as well as the fractions A-H in DMSO to 3T3 
fibroblast cells were tested by the established colorimetric MTT 
assay [16]. The absorbance was measured at 550 nm using a 
microplate reader. The IC50 is the concentration of extract or 
fraction that reduced fibroblast cell growth by 50%. 
 
Anti-yeast activity: Candida albicans WM1172, C. albicans 
ATCC90028, C. dubliniensis, C. glabrata CBS138, C. glabrata 
ATCC90030, C. krusei ATCC6258, C. pseudotropicalis, and C. 
tropicalis WM30 were used in this study. The yeast inhibition assay 
was performed according to the method of Macreadie et al. [17]. 
The yeast strains were grown in YEPD (1% yeast extract, 2% 
peptone, 2% glucose). If required, media were solidified by the 
addition of 1.5% agar. Yeast inocula (100 µL) with a starting 
optical density at A595 of 0.02-0.04 were added to each well of a 96-
well microplate (Orange Scientific, Braine-l’Alleud, Belgium). 
Mushroom extracts were then added as two-fold serial dilutions 
commencing with a 100 µg/mL concentration. Fluconazole (0.1 
mM) and amphotericin B (1.0 mM) were used as positive controls. 
A growth control DMSO solvent alone was also included. The 
microplate was incubated in a microplate shaker at 35ºC. After 2 h 
and 4 h incubation, the A595 was recorded using a microplate reader 
(Sunrise™, Tecan, Austria). Each sample was assayed in triplicate. 
The lowest concentration of extracts that inhibited growth of 
Candida spp. is the minimum inhibitory concentration (MIC). 
 
Gas chromatography-mass spectrometry (GCMS): GCMS analysis 
was performed on sub-fractions A and B using Network Gas 
Chromatography system (Agilent Technologies 6890N) equipped 
with an Inert Mass Selective Detector (Agilent Technologies 5975) 
(70eV direct inlet) on a HP-5ms (5% phenyl methyl siloxane) 
capillary column (30 m × 250 µm × 0.25 µm) initially set at 150ºC, 
then increased at 5ºC per min to 300ºC and held for 10 min. Helium 
was used as carrier gas at a flow rate of 1 mL per min. The total ion 
chromatogram obtained was autointegrated by chemstation and the 
constituents were identified by comparison with the accompanying 
mass-spectra database (Wiley 9th edition with NIST 11 Mass 
Spectral Library, USA) wherever possible. 
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http://www.biomedcentral.com/1472-6882/13/261RESEARCH ARTICLE Open AccessNeurite outgrowth stimulatory effects of
culinary-medicinal mushrooms and their toxicity
assessment using differentiating Neuro-2a
and embryonic fibroblast BALB/3T3
Chia-Wei Phan1,2, Pamela David1,3*, Murali Naidu1,3, Kah-Hui Wong1,3 and Vikineswary Sabaratnam1,2Abstract
Background: Mushrooms are not only regarded as gourmet cuisine but also as therapeutic agent to promote
cognition health. However, little toxicological information is available regarding their safety. Therefore, the aim of
this study was to screen selected ethno-pharmacologically important mushrooms for stimulatory effects on neurite
outgrowth and to test for any cytotoxicity.
Methods: The stimulatory effect of mushrooms on neurite outgrowth was assessed in differentiating mouse
neuroblastoma (N2a) cells. Neurite length was measured using Image-Pro Insight processor system. Neuritogenesis
activity was further validated by fluorescence immunocytochemical staining of neurofilaments. In vitro cytotoxicity
was investigated by using mouse embryonic fibroblast (BALB/3T3) and N2a cells for any embryo- and neuro-toxic
effects; respectively.
Results: Aqueous extracts of Ganoderma lucidum, Lignosus rhinocerotis, Pleurotus giganteus and Grifola frondosa; as
well as an ethanol extract of Cordyceps militaris significantly (p < 0.05) promoted the neurite outgrowth in N2a cells
by 38.4 ± 4.2%, 38.1 ± 2.6%, 33.4 ± 4.6%, 33.7 ± 1.5%, and 35.8 ± 3.4%; respectively. The IC50 values obtained from
tetrazolium (MTT), neutral red uptake (NRU) and lactate dehydrogenase (LDH) release assays showed no toxic
effects following 24 h exposure of N2a and 3T3 cells to mushroom extracts.
Conclusion: Our results indicate that G. lucidum, L. rhinocerotis, P. giganteus, G. frondosa and C. militaris may be
developed as safe and healthy dietary supplements for brain and cognitive health.
Keywords: Culinary-medicinal mushrooms, Neurite outgrowth, Cytotoxicity, Mouse neuroblastoma N2a cell,
Mouse 3T3 embryonic fibroblast, NeurofilamentBackground
Neurite outgrowth is an important event in neuronal path
finding and the establishment of synaptic connections
during development [1,2]. It is also essential in neuronal
plasticity, neuronal regeneration after injury [3,4] and
neurodegenerative conditions such as Alzheimer’s and
Parkinson’s diseases [5]. Therefore, treatments aiming at* Correspondence: rosiepamela@um.edu.my
1Mushroom Research Centre, Institute of Biological Sciences, Faculty of
Science, University of Malaya, 50603 Kuala Lumpur, Malaysia
3Department of Anatomy, Faculty of Medicine, University of Malaya, 50603
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Full list of author information is available at the end of the article
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reproduction in any medium, provided the orpromoting neurite outgrowth and preserving the neurite
network and synaptic connections are needed.
The potential use of culinary-medicinal mushrooms in
neurodegenerative diseases is being explored [6]. On-going
research in our laboratory shows that Hericium erinaceus
(Bull.: Fr) Pers. (monkey’s head mushroom, lion’s mane
mushroom and Yamabushitake) [7], Lignosus rhinocerotis
(Cooke) Ryvarden (tiger milk mushroom) [8,9], and
Pleurotus giganteus (Berk.) Karunarathna & K.D. Hyde
(morning glory mushroom, cow’s stomach mushroom)
[10] exhibit neurite outgrowth stimulatory effects in
NG108-15 and PC12 cell lines. This observation raised a
question with respect to the neurodevelopmental effects,d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have been identified as a growing social and healthcare
issue. Congenital diseases are present in 2–3% of human
newborns [11]. About 20% of the birth defects are due to
genetic anomaly and 10% are caused by environmental
factors during pregnancy [12]. Therefore, toxicological
safety assessments of food, chemicals and drugs to evaluate
the effects on reproductive health and for embryotoxicity
have become an important requirement. Thus, the aims of
the present study were (a) to evaluate neurite outgrowth
stimulatory effects of selected culinary-medicinal mush-
rooms using neuroblastoma-2a (N2a) cells and (b) to
assess the neuro- and embryotoxicity of the mushroom
extracts using N2a and 3T3 fibroblasts. The results will
enable us to select potential mushrooms for further in
depth in vivo developmental toxicity evaluation.Methods
Mushroom and plant samples
The mushrooms were authenticated by experts in the
Mushroom Research Centre, University of Malaya and
voucher specimens were deposited in the University of
Malaya herbarium at Rimba Ilmu (Table 1). Fresh fruiting
bodies of Ganoderma lucidum (Fr) P. Karst (KLU-M 1233)
and H. erinaceus (KLU-M 1232) were obtained from
Ganofarm Sdn Bhd. Pleurotus giganteus (KLU-M 1227)
was provided by Nas Agro Farm and Dong Foong Biotech.
Freeze dried powder of Cordyceps militaris (L.:Fr.) Link
and L. rhinocerotis were purchased from BioFact Life Sdn
Bhd and Ligno Biotek Sdn Bhd, respectively. Pleurotus
pulmonarius (Fr.) Quél. (KLU-M 1309) and Gingko biloba
extracts were obtained from Reishilab Sdn Bhd, Selangor.
Wild Ganoderma neo-japonicum Imazeki 1939 (KLU-M
1231) was collected from forest in Ulu Grik, Perak,
Malaysia. Ganoderma neo-japonicum was used as trad-
itional medicine by the indigenous people in Malaysia.
Grifola frondosa (Dicks.: Fr.) S.F. Gray (KLU-M 1229)
imported from Japan was obtained from supermarkets
in Selangor, Malaysia. Lycium barbarum (wolfberry),
a traditional Chinese medicine was purchased from a
Chinese medicine shop in Selangor, Malaysia and deposited
in University of Malaya herbarium. Curcumin was pur-
chased from NatXtra, Synthite Co., India.Chemicals
Phosphate buffered saline (PBS), [3-(4,5-dimethythiazol-
2-yl)-2,5-diphenyltetrazolium bromide] (MTT), dimethyl
sulfoxide (DMSO), nerve growth factor (NGF) from mur-
ine submaxillary gland, 3-amino-7-dimethylamino-2-me-
thyl-phenazine hydrochloride (neutral red), and foetal
bovine serum (FBS) were obtained from Sigma Co. (St.
Louis, MO, USA).Cell culture
Mouse neuroblastoma cells (N2a, ATCC CCL-131) and
mouse embryonic fibroblast cells (BALB/c 3T3, ATCC
clone A31) were purchased from American Type Culture
Collection (ATCC; MD, USA). N2a cells were cultured
in Eagle’s minimum essential medium (MEM) with L-
glutamine (PAA) supplemented with 10% (v/v) heat-
inactivated foetal bovine serum (PAA), 100 U/ml penicillin,
and 100 μg/ml streptomycin. 3T3 fibroblasts were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM) with L-glutamine (high glucose at 4.5 g/l)
supplemented with 10% FBS. All the cells were maintained
at 37°C and 5% CO2 in a humidified atmosphere. N2a cells
were subcultured at 3 – 4 days intervals while 3T3 cells
were routinely passaged every 2 – 3 days. For preserva-
tion, the cells were frozen at −70°C liquid nitrogen in
complete medium supplemented with 5% (v/v) dimethyl
sulfoxide (DMSO; Sigma) as a cryoprotecting agent.
Preparation of mushroom extracts
The fresh fruiting bodies of P. giganteus, P. pulmonarius,
H. erinaceus, and G. frondosa were sliced, frozen and
then freeze-dried for two days. The freeze-dried fruiting
bodies were then ground to powder and kept at 4 - 8°C.
For aqueous extraction, the freeze dried powder was
soaked in distilled water (1:20, w/v) at room temperature
and 200 rpm in a shaker for 24 h. The mixture was then
double boiled in water bath for 30 min, cooled and then
filtered (Whatman No. 4). The resulting aqueous extracts
were freeze-dried and kept at −20°C prior to use. The
process was repeated for the freeze-dried powder of C.
militaris and L. rhinocerotis sclerotia. For ethanol extrac-
tion, the freeze dried powder was soaked in 95% ethanol
at room temperature for three days and the process was
repeated three times. The solvent was then evaporated
using a rotary evaporator (Eyela N-1000, USA) to give a
brownish viscous extract.
Neurite outgrowth assay
N2a cells were seeded in 24-well culture plate at an initial
density of 5,000 cells per well containing complete growth
medium (1 ml/well) and incubated overnight. Concentra-
tions of NGF ranging from 5–100 ng/ml (w/v) were tested
to determine the optimum concentration that stimulates
maximum neurite outgrowth. The optimum concentra-
tion was then used as a positive control throughout the
subsequent assays. Aqueous and ethanol mushroom ex-
tracts were stocked at 10 mg/ml and were subsequently
dissolved in sterile distilled water or DMSO, to the appro-
priate concentrations. The final concentration of DMSO
in the assays was 0.1 - 0.25%. To induce cell differenti-
ation, the complete medium was carefully replaced with
5% serum medium before exposure to mushroom extracts
at 10–50 μg/ml. Cells with medium only served as a
Table 1 Medicinal mushrooms used in this study, their common names, and culinary nature
Mushroom species Voucher
number
Common
names
Local names
(in Malay)
Part used Edible/ Wild/ Medicinal properties References
culinary cultivated
Pleurotus giganteus KLU -M 1227 Zhudugu, cow’s stomach
mushroom
Cendawan seri pagi
(morning glory), perut
lembu (cow’s stomach)
Fruiting body Culinary Cultivated Antioxidant, neurite
outgrowth simulation
[10,13]
Pleurotus pulmonarius KLU-M 1309 Grey oyster mushroom Cendawan tiram kelabu
(grey oyster)
Fruiting body Culinary Cultivated Antioxidant, anti-diabetic [14]
Lignosus rhinocerotis Purchased from
Ligno Biotek Sdn
Bhd
Tiger milk mushroom, Cendawan susu rimau Sclerotium and
mycelium
Non-culinary but
edible
Cultivated Anticancer, anti-inflammatory,
neurite outgrowth stimulation
[8,15]
(tiger’s milk)
Hericium erinaceus KLU-M 1232 Monkey’s head mushroom,
lion’s mane mushroom,
Yamabushitake
Cendawan bunga kubis Fruiting body Culinary Cultivated Anti-ulcer, neurite outgrowth
stimulation
[7,16-18]
(cauliflower)
Ganoderma lucidum KLU-M 1233 Lingzhi, reishi Cendawan merah
(red mushroom)
Fruiting body Non-culinary but
edible
Cultivated Anticancer, neuroprotection [19]
Ganoderma
neo-japonicum
KLU-M 1231 Purple reishi Cendawan senduk
(cobra mushroom)
Fruiting body Non-culinary but
edible
Wild Antioxidant, antihepatoxic,
neurite outgrowth stimulation
[9,20]
Cordyceps militaris Purchased from
BioFact Life Sdn
Bhd
Winter worm summer
grass, caterpillar fungus
- Fruiting body
(ascocarp)
Non-culinary but
edible
Cultivated Anti-inflammatory, anticancer,
relief respiratory disorders
[21]
Grifola frondosa KLU- M 1229 Maitake, hen of the
woods
Cendawan maitake Fruiting body Culinary Cultivated Anti-inflammatory,
anti-cholesterol
[22]
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at 37°C, 95% air and 5% CO2 to observe neuritogenesis
activity, if any. Curcumin, G. biloba and L. barbarum
extracts were also tested to compare the neurite outgrowth
activities with those of mushroom extracts.
Quantification of neurite bearing cells
Five random fields (100 – 200 cells/well) were exam-
ined in each well by using a phase contrast microscope
(20× magnifications) equipped with QImaging Go-3
camera (QImaging, Canada). Neurite length was measured
in at least 30 cells in randomly chosen fields by using image
processor system Image-Pro Insight (MediaCybernetics,
MD). The number of neurite outgrowths, defined as axon-
like extensions that were double or more than the length of
the cell body diameter was recorded. The percentage of
neurite bearing cells (%) is the number of neurite bearing
cells divided by the total number of cells in a field and
then multiplied by 100%. At least three independent
experiments were conducted and results were expressed
as mean ± standard deviation (S.D).
Fluorescence immunocytochemistry study
The axon-like extensions were confirmed as neurite out-
growth by immunofluorescence study. N2a cells were
seeded in 12-well μ-dishes (ibidi, Martinsried, Germany)
and were exposed to treatments for 48 h. The cells were
fixed with 4% paraformaldehyde in PBS (pH 7) for 20 min.
After two washes with PBS, the cells were incubated with
rabbit anti-neurofilament 200 polyclonal antibody (1:80 in
10% sheep serum as blocking buffer) for 1 h. The cells
were washed and then incubated in a mixture of fluores-
cein isothiocyanate (FITC)-conjugated secondary antibody
and sheep anti-rabbit IgG (1:160 in blocking buffer) for
2 h at room temperature in the dark. The cells were
then washed three times. 4'-6-diamidino-2- phenylindole
(DAPI) was used to counter stain the nuclei. Images were
observed under a fluorescent microscope (Nikon Eclipse
80i microscope).
Evaluation of embryo- and/or neurotoxic effects
of mushroom extracts
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] assay
N2a and 3T3 cells (1 × 104) per well were seeded in 96-well
plates. After incubation for 24 h, different concentrations
of mushroom extracts (0 – 5 mg/ml) dissolved in phenol
red free culture medium were added to each well. The
samples were incubated for 24 h at 37°C under humidified
atmosphere of 5% CO2 and 20 μl MTT (5 mg/ml) was
added to each well. The crystal dyes which were up-taken
by the cells were then dissolved with DMSO. Absorbance
was measured at 570 nm in a microplate reader (Tecan,
Austria) using 630 nm as a reference wavelength. Allmeasurements were done in triplicates, and at least
three independent experiments were carried out. To
calculate IC50 values which estimated the concentra-
tion of mushroom extract that caused 50% inhibition
of proliferation (viability) in N2a and 3T3 cells, Probit
analysis was conducted using SPSS 17.0 (SPSS Science
Inc., Chicago, IL).Neutral red uptake assay
Neutral red medium (40 μg/ml) was prepared fresh before
use by diluting the neutral red stock (4 mg/ml) with
phenol red free culture medium. Neutral red medium
was centrifuged at 1800 rpm for 10 min to remove any
precipitated dye crystals before use. After cell seeding
and treatment (0 – 5 mg/ml), the medium was discarded
and replaced with equal amount of neutral red medium to
each well of the plate. The plate was then incubated for
2 h. The neutral red medium was then removed and
the cells were washed quickly with adequate amount of
PBS. A total of 100 μl of neutral red solubilising solution
(1% acetic acid in 50% ethanol) was added to each well
and allowed to stand for 10 minutes at room temperature
until the neutral red extracted from the cells reached a
homogeneous solution. The absorbance at a wavelength
of 540 nm with 690 nm of background absorbance was
spectrophotometrically measured (Tecan, Austria). The
experiment was repeated at least three different times.Lactate dehydrogenase (LDH) release assay
After cell seeding and treatment with mushroom extracts
(0 – 5 mg/ml), the culture plates were centrifuged at 1500
rpm for 5 minutes and 50 μl of supernatant was then
transferred to a new plate for LDH analysis according to
manufacturer instruction (Sigma). To each well, 100 μl of
LDH mixture solution comprising of LDH assay substrate,
dye and cofactor was added and incubated at room
temperature for 30 min. The reaction was stopped by
adding 10 μl of 1 N HCl to each well. Absorbance was
spectrophotometrically measured at 490 nm with back-
ground absorbance at 690 nm. Triton X-100 (0.5%,
Scharlau) was used as a positive control and was thus
set to 0% viability representing a 100% cell death.Statistical analysis
All the experimental data are expressed in mean ± standard
deviation (S.D). Statistical differences between groups
were analysed and calculated by one-way analysis of
variance (ANOVA) from at least three independent
experiments. This was followed by Duncan's multiple
range tests. P < 0.05 was considered to be significant
between groups.
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The effects of NGF on neurite outgrowth activity in
N2a cells
Nerve growth factor induced neurite outgrowth of N2a
in a dose-dependent manner (Figure 1). After 48 h of
NGF stimulation, the percentage of neurite bearing cells
increased significantly (p < 0.05) to 26.1 ± 1.8% in N2a
cells treated with 50 ng/ml NGF when compared to
negative control (7.6 ± 2.5 %). At 60 ng/ml of NGF, the
percentage of neurite bearing cells significantly decreased
to 12.2 ± 2.1% (p < 0.05). Based on these findings, the
optimised concentration of NGF (50 ng/ml) was selected
for the following experiments as a positive control.
The effects of different mushroom extracts on neurite
outgrowth activity in N2a cells
The positive control (NGF) recorded 26.4 ± 3.6% of
neurite-bearing cells (Figure 2). The extraction yield of
extracts from the mushrooms are summarised in Table 2.
The percentage of neurite bearing cells after treatment
with aqueous extracts of G. lucidum (38.4 ± 4.2%),
L. rhinocerotis (38.1 ± 2.6%), and ethanol extract of
C. militaris (35.8 ± 3.4%)were significantly higher (p < 0.01)
than NGF control by approximately 1.45-, 1.44- and
1.35-fold, respectively. Aqueous extracts of G. frondosa
(33.7 ± 1.5%) and P. giganteus (33.4 ± 4.6%) were also
shown to induce significantly (p < 0.05) higher neurite
bearing cells compared to the NGF control. Meanwhile,
the aqueous extracts of L. rhinocerotis mycelium,
H. erinaceus, G. neo- japonicum, P. pulmonarius, as
well as ethanol extracts of H. erinaceus, P. pulmonarius
and P. giganteus showed varied neurite outgrowth stimula-
tory effects with average neurite bearing cells ranging from
26.4 ± 5.4% to 29.6 ± 2.2%. Further, these extracts showed
no significant difference when compared to NGF control
(p > 0.05). Among the plant extracts tested, wolfberryFigure 1 Effects of different NGF concentrations (5 – 100 ng/ml)
on stimulation of neurite outgrowth using differentiating N2a
cells as an in vitro model. The results shown represent the
mean ± SD; n = 3. Means not sharing a common letter were
significantly different at p < 0.05.extract did not show any neurite outgrowth activity.
The percentage of neurite bearing cells obtained after
treatment with 20 μg/ml of ethanol extract of G. biloba
(30.3 ± 2.5%) was better than curcumin which gave
26.4 ± 5.4% at 20 μg/ml. The five different mushroom
extracts (G. lucidum, L. rhinocerotis, P. giganteus,
G. frondosa and C. militaris) each at 20 μg/ml were
selected for neurofilament staining.
The mean diameter of N2a cell body was found to be
19.45 ± 0.72 μm (Figure 3). To qualify as a “neurite”, the
axon-like extension needs to be double or more than the
cell body length of N2a. The average neurite length of
NGF-stimulated cells was 78.58 ± 18.6 μm, which is
approximately 4-time longer than the cell body. Cells
treated with aqueous extract of G. lucidum were found to
develop the longest mean neurite length i.e. 121.51 ± 28.6
μm (6.25-time longer than cell body), followed by aqueous
extract of P. giganteus which recorded mean neurite
length of 116.72 ± 29.5 μm (5.99-time longer than cell
body). Figure 4 shows the morphology of differentiat-
ing N2a cells with neurites after 48 h of treatment
with 50 ng/ml NGF (a) and 20 μg/ml of aqueous ex-
tracts of G. lucidum (b), L. rhinocerotis (c), P. giganteus
(d) and G. frondosa (e); as well as ethanol extract of
C. militaris (f ).Immunofluorescence staining of neurofilament
Neurofilament belongs to a class of intermediate filament
found in neuronal cells that provides specific support
for axons. There is a direct relationship between neurite
outgrowth and neurofilament expression as neurofilament
protein levels increase with differentiation of cell lines
[23]. Figure 5 shows the immunocytochemical labeling of
neurons. The expression of neurofilament protein during
neurite outgrowth was stained green while nuclei were
stained blue.The cytotoxic effects of mushroom extracts on 3T3 and
N2a by using MTT, NRU and LDH release assay
Table 3 shows the results of cytotoxicity screening of
mushroom and plant extracts to N2a cells and 3T3
fibroblasts. The cytotoxicity determination are expressed
as IC50 values, which is the concentration resulting in
50% inhibition of cell growth and proliferation after 24 h
exposure. All the extracts of mushrooms and plants did
not show cytotoxic effects to the two tested cell lines
(IC50 ≥ 1 mg/ml in all cases). Three cytotoxicity endpoints
were used in this experiment, which were MTT, NR
uptake assay and LDH release assay. Interestingly, IC50
determined by NRU test and LDH test was higher than
that of MTT. In general term, the ethanol extracts
showed lower IC50 too.
Figure 2 Percentage of neurite bearing cells after treatment of different mushroom and plant extracts. * p < 0.05, ** p < 0.01 versus the
positive control (NGF). (S) = sclerotium, (M) = mycelium.
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Eight species of medicinal mushrooms were investigated
and categorised into two groups: culinary and non-
culinary. The former group represents mushrooms that
can be used for culinary purposes like preparing meal
and cooking, especially from the fruiting bodies. This
group (culinary-medicinal mushrooms) comprised of
P. giganteus, P. pulmonarius, H. erinaceus, and G.
frondosa. Medicinal mushrooms of no culinary properties
are appreciated for their pharmacological merits and areTable 2 Extraction yield of aqueous and ethanol extracts
from the studied mushrooms
Mushrooms Extract Yield (%, w/w)
Lignosus rhinocerotis (S) Aqueous 3.56
Lignosus rhinocerotis (M) 4.65
Hericium erinaceus 8.56
Ganoderma lucidum 3.67
Ganoderma neo-japonicum 5.75
Grifola frondosa 3.54
Pleurotus pulmonarius 3.60
Pleurotus giganteus 6.70
Hericium erinaceus Ethanol 4.50
Cordyceps militaris 3.45
Pleurotus pulmonarius 6.70
Pleurotus giganteus 5.30
Lycium barbarum (wolfberry) Aqueous 9.76
Gingko biloba Ethanol n.d
(S) = sclerotium, (M) = mycelium. n.d. = not determined.not cooked as a meal. The fruiting bodies or sclerotia are
often handpicked, ground to powder and subjected to
various extraction methods before being used as a trad-
itional medication [24]. L. rhinocerotis, G. lucidum, G.
neo-japonicum, and C. militaris are non-culinary medi-
cinal mushrooms.
Ganoderma lucidum (also known as Lingzhi in Chinese
or Reishi in Japanese) has been widely investigated for its
potential therapeutic benefits and longevity. Our results
showed that aqueous extract of G. lucidum promoted
neuritogenesis in N2a cells with 38.4 ± 4.2% of neuriteFigure 3 The mean neurite length of N2a treated with different
mushroom extracts at 20 μg/ml. The results shown represent the
mean ± SD; n = 3. Means not sharing a common letter were
significantly different at p < 0.05. S = sclerotium, aq = aqueous,
EtOH = ethanol.
Figure 4 Phase-contrast photomicrographs showing the effects of (a) NGF, (b) G. lucidum, (c) L. rhinocerotis, (d) P. giganteus, (e)
G. frondosa, and (f) C. militaris on the morphology of differentiating N2a cells after 48 h. Untreated cells serve as control (g) and only
contained 5% FBS as vehicle. Arrows indicate typical neurites of N2a. Scale bar represents 20 μm. Photomicrographs of representative
microscope fields were taken with a 20× objective.
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[25] who showed that Ganoderma extract contained NGF-
like compounds that mediated the neuronal differentiation
and elongation of rat pheochromocytoma (PC12) cells.
The Ganoderma neuroactive constituents that accounted
for neurite outgrowth activity are triterpenoids, such as
lucidenic acid [26], 7-oxo-ganoderic acid Z, ganolucidic
acid A, methyl ganoderic acid A, ganoderic acid S1,
and 4,4,14α-trimethyl-5α-chol-7,9(11)-dien-3-oxo-24-
oic acid [27]. Further, the water-soluble polysaccharides
of G. lucidum were shown to significantly (p < 0.05)
reduce neuronal cell death and apoptosis of rat primary
cortical neurons (model of brain cerebral ischemia) induced
by oxygen/glucose deprivation treatment [19]. Ganoderma
extracts may also provide mitigation to Parkinson’s disease
as it was shown to prevent dopaminergic neuron degener-
ation by attenuating the pro-inflammatory response of
microglial cells [28].
The tiger milk mushroom, L. rhinocerotis has been
described as the national treasure of Malaysia as thisFigure 5 Immunocytochemical staining of neurofilament in N2a cells
P. giganteus, (e) G. frondosa, and (f) C. militaris, and untreated cells as
200 kD labeled with FITC stains neuronal cells green. Scale bar represents 2
representative microscope fields were taken with a 20× objective.macrofungus is rare and is often used as folk remedy to
treat a variety of diseases. Consistent with our previous
study [8], the sclerotia of L. rhinocerotis improved
neurite outgrowth in N2a. Interestingly, in the present
study, the sclerotial extract (38.4 ± 4.2% of neurite
bearing cells) performed better than the mycelial extract
(27.2 ± 2.9%). However, the active components in L.
rhinocerotis that play the role in neurite outgrowth activity
need further investigation. Lee et al. [15] highlighted that
the protein or carbohydrate/protein complex of the cold
water scerotial extract (4°C) is responsible for the anti-
proliferative activity against human breast and lung car-
cinoma. In this study, a hot water extraction approach was
employed and we hypothesise that polysaccharides or
triterpenoids rather than peptides are involved in the
neurite outgrowth stimulatory activity of L. rhinocerotis.
Wild Pleurotus giganteus has been reported to be
consumed by the indigenous tribes of Semai, Temuan,
and Jakun in Malaysia [29]. This wild mushroom has been
successfully domesticated for large scale production and istreated with (a) NGF, (b) G. lucidum, (c) L. rhinocerotis, (d)
control (g). DAPI stains for nuclei blue, while anti-neurofilament
0 μm. Arrows indicate neurite outgrowth. Photomicrographs of
Table 3 IC50 values obtained by using different cytotoxicity assays- MTT, NRU and LDH release
Mushroom/Plant Species Extracts Neuroblastoma 2a cells 3T3 embryonic fibroblast
IC50 (mg/ml) after 24 h IC50 (mg/ml) after 24 h
MTT NRU LDH MTT NRU LDH
Culinary/medicinal
mushroom
Pleurotus giganteus Aqueous 4.07 ± 0.67e 6.95 ± 1.00g - 2.16 ± 0.05c 2.67 ± 0.47d -
Pleurotus pulmonarius 2.85 ± 0.06cd 2.13 ± 0.87cdef - 1.75 ± 0.14bc 2.60 ± 0.55d -
Lignosus rhinocerotis
(sclerotium)
3.27 ± 0.77d 2.72 ± 0.65ef - 5.63 ± 0.06e 5.93 ± 0.05f -
Lignosus rhinocerotis 2.43 ± 0.12c 1.75 ± 0.18abc - 5.23 ± 0.17e 5.60 ± 0.1f -
(mycelium)
Hericium erinaceus 2.60 ± 0.52cd 2.85 ± 0.56e - 3.43 ± 0.29d 3.53 ± 0.06e -
Ganoderma lucidum 1.35 ± 0.03a 1.52 ± 0.17ab 2.20 ± 0.52ab 1.19 ± 0.06ab 1.35 ± 0.02ab 1.50 ± 0.08a
Ganoderma
neo-japonicum
1.17 ± 0.006a 1.11 ± 0.03a 2.00 ± 0.53ab 1.47 ± 0.37ab 1.78 ± 0.56bc 1.58 ± 0.44a
Grifola frondosa 2.72 ± 0.08cd 4.60 ± 1.10f - 6.67 ± 0.87f 7.60 ± 0.1g -
Pleurotus giganteus Ethanol 2.43 ± 0.10c 2.81 ± 0.15e 5.8 ± 0.10c 1.66 ± 0.56bc 1.96 ± 0.42c 1.73 ± 0.48a
Pleurotus pulmonarius 2.30 ± 0.72bc 2.64 ± 0.16def 2.53 ± 0.96bc 1.27 ± 0.06ab 1.48 ± 0.05abc 1.67 ± 0.12a
Hericium erinaceus 2.47 ± 0.50c 1.61 ± 0.51ab 2.10 ± 0.72ab 1.31 ± 0.03ab 1.84 ± 0.57bc 1.47 ± 0.31a
Cordyceps militaris 1.65 ± 0.015ab 1.81 ± 0.10abcd 2.37 ± 0.21b 1.02 ± 0.08a 1.10 ± 0.02a 1.40 ± 0.29a
Medicinal plant Lycium barbarum Aqueous 4.37 ± 1.00e 6.96 ± 0.73g - 8.40 ± 0.72g 7.86 ± 0.06g -
Gingko biloba Ethanol 1.56 ± 0.08ab 1.66 ± 0.11ab 1.43 ± 0.39a 1.56 ± 0.58abc 1.37 ± 0.07ab 1.78 ± 0.07a
Curcumin Compound 1.13 ± 0.01a 1.15 ± 0.01a 1.30 ± 0.16a 1.16 ± 0.06ab 1.23 ± 0.03ab 1.60 ± 0.22a
The data represent the mean ± SD of three determinations. Means not sharing a common letter were significantly different at p < 0.05.
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erties of P. giganteus are comparatively little as compared
to P. pulmonarius (grey oyster mushroom). Recently
P. giganteus (synonyms: Lentinus giganteus and Panus
giganteus) was shown to have in vivo hepatoprotective
effect in rat [13] and in vitro neuritogenic effects in
PC12 cells [10]. On-going studies aimed at isolating and
identifying the chemical constituents of the P. giganteus
fruiting bodies indicate the presence of phenolics (caffeic
acid and cinnamic acid), organic acid (succinic acid) and
triterpenoids (unpublished data). The compounds may
work synergistically and accounted for neuritogenesis.
Cordyceps militaris is a parasitic fungus that colonises
moth larvae (Lepidoptera) and has been valued in Trad-
itional Chinese Medicine for more than 2000 years. The
major bioactive components in C. militaris include adeno-
sine, cordycepin and polysaccharides [30]. Our finding is
in agreement with the work by Lee et al. [21] where
methanol extract of C. militaris was shown to significantly
reverse the scopolamine-induced deficit in memory of rat
and improve neurite outgrowth in N2a. Similar to our
results, lysophosphatidylethanolamine isolated from G.
frondosa (Maitake) was also reported to induce neuronal
differentiation in PC12 cells, causing up-regulation of
neurofilament M expression of PC12 cells [22].
It is well known that N2a cells, upon the withdrawal
of serum, differentiate and elaborate neurites [31,32].This well-defined neuronal model is often employed for
studies relating to neuronal differentiation [33]. It is also
a popular cell line in studying neurotoxicity as the brain
is a first target in situations such as ageing and neurode-
generative diseases [34]. NGF is the most appropriate
positive control in neurite outgrowth assays as its role in
neural development have been characterised extensively
as supported by Sofroniew et al. [35]. The therapeutic
application of neurotrophins like nerve growth factor
(NGF) is not possible as NGF cannot penetrate the
blood–brain barrier. Studies indicate that lower-molecular-
weight molecules may be a promising alternative for
therapeutic intervention, for example, α-phenyl-N-tert-
butylnitron [36]. However, most of the experiments testing
natural products have been conducted in vitro, and few
studies evaluated these compounds in the brain in vivo.
Our previous study showed that aqueous extract of P.
giganteus induced neuronal differentiation of PC12 cells
via the activation of extracellular signal-regulated kinase
(ERK) and phosphatidylinositol-3-kinase-Akt (PI3K/Akt)
signaling pathways [10]. In fact, the most studied path-
way controlling the consolidation of neurites involves
signaling through neurotrophin receptors to a Ras-
dependent, mitogen-activated protein kinase (MAPK)
cascade [33]. At present, the precise neuritogenic signal
transduction pathway involved in the actions of NGF,
serum withdrawal, and the mushroom extracts is yet to be
Phan et al. BMC Complementary and Alternative Medicine 2013, 13:261 Page 9 of 10
http://www.biomedcentral.com/1472-6882/13/261elucidated. It is anticipated that mushroom extracts (com-
prising of neuroactive polysaccharides or triterpenoids)
under certain condition (serum deprivation) participate in
triggering NGF signals, hence activating the downstream
neuronal responses to axonal growth [37].
It is important that functional and health food remedies
recommended for the prevention or treatment of diseases
undergo safety assessment. Today, a number of natural
products with potential biomedical application are being
launched, although some could be potentially toxic when
ingested at high doses or in combination with other medi-
cations [38]. Our results indicated that no cytotoxicity was
detected for the concentrations tested. Notably, ethanol
extract of C. militaris showed the lowest IC50 (p < 0.05)
value against 3T3 fibroblast. Similarly, curcumin although
was reported beneficial in neuroprotection [39], the IC50
value detected against N2a was the lowest by means of
MTT, NRU and LDH assays. Elsewhere, in vivo toxicity
evaluation of Ganoderma boninense (Pat.) was carried out
[40] and a significant toxicity (IC50 = 640 μg/ml) against
Artemia salina (brine shrimp) was demonstrated after 24
h. However, Ganoderma extract is granted safe on short-
term exposure. Conversely, in vivo toxicity profiling of
total triterpene fraction from G. lucidum against Swiss
albino mice showed that ganoderma triterpenes did
not possess significant toxicity [41] and administration
of G. lucidum β–glucan (2000 mg/kg body weight/day)
to Sprague Dawley rats did not cause toxicological
abnormality [42]. Mutagenicity studies by means of
Salmonella typhimurium also did not reveal any geno-
toxicity. Meanwhile, sub-acute toxicity study of the
sclerotial powder of L. rhinocerotis by using rat model
showed no treatment-related toxicity at 1000 mg/kg
[43]. Taken together, beneficial mushroom extracts
hardly exert any significant toxicity.
We have chosen more than one cytotoxicity assay
namely MTT, NRU and LDH release assay to determine
in vitro cell viability in order to increase the reliability of
the results obtained and also to avoid over- or underestima-
tion of the mushroom or plant toxicity. The mechanisms of
the chosen assays are different. While MTT is based on the
enzymatic conversion of MTT in the mitochondria, NRU
assay is based on the dye uptake capability by lysosomes
[44]. Both served as colorimetric assays, whereby viable and
uninjured cells stain blue and red, for MTT and NRU
assays, respectively. LDH release assay, on the other hand
is based on the release of the enzyme into the culture
medium after the disruption of cell membrane [45]. It is
noteworthy that the toxicity profiles detected by the three
different assays generally followed a similar trend although
some results were not in agreement. For instance, no IC50
values were recorded for some mushroom extracts by
using LDH assays, suggesting that LDH may be the least
sensitive method among the three.Conclusions
The extracts of G. lucidum, L. rhinocerotis, P. giganteus,
G. frondosa and C. militaris showed potential in promot-
ing neurite outgrowth of differentiating N2a cells. The
synergism of the various active entities in these mushroom
extracts may be responsible for the neurite outgrowth
activity and further experiments are warranted to isolate
and identify the compounds. The signaling pathways
involved is yet to be elucidated but based on our previous
results, among other possibilities, phosphorylation and
activation of the ERK and Akt may be involved. This study
also showed the absence of embryotoxic and neurototoxic
effects of the various mushroom extracts in 3T3 and N2a
cells, respectively.
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Hyde: Nutritional value and in vitro neurite
outgrowth activity in rat pheochromocytoma cells
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Background: Drugs dedicated to alleviate neurodegenerative diseases like Parkinson’s and Alzheimer’s have always
been associated with debilitating side effects. Medicinal mushrooms which harness neuropharmacological
compounds offer a potential possibility for protection against such diseases. Pleurotus giganteus (formerly known as
Panus giganteus) has been consumed by the indigenous people in Peninsular Malaysia for many years.
Domestication of this wild mushroom is gaining popularity but to our knowledge, medicinal properties reported for
this culinary mushroom are minimal.
Methods: The fruiting bodies P. giganteus were analysed for its nutritional values. Cytotoxicity of the
mushroom’s aqueous and ethanolic extracts towards PC12, a rat pheochromocytoma cell line was assessed by
using 3-[4,5-dimethythiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Neurite outgrowth stimulation assay
was carried out with nerve growth factor (NGF) as control. To elucidate signaling mechanisms involved by
mushroom extract-induced neurite outgrowth, treatment of specific inhibitor for MEK/ERK and PI3K signalling
pathway was carried out.
Results: The fruiting bodies of P. giganteus were found to have high carbohydrate, dietary fibre, potassium,
phenolic compounds and triterpenoids. Both aqueous and ethanolic extracts induced neurite outgrowth of PC12
cells in a dose- and time-dependant manner with no detectable cytotoxic effect. At day 3, 25 μg/ml of aqueous
extract and 15 μg/ml of ethanolic extract showed the highest percentage of neurite-bearing cells, i.e. 31.7 ± 1.1%
and 33.3 ± 0.9%; respectively. Inhibition treatment results suggested that MEK/ERK and PI3K/Akt are responsible for
neurite outgrowth of PC12 cells stimulated by P. giganteus extract. The high potassium content (1345.7 mg/100 g)
may be responsible for promoting neurite extension, too.
Conclusions: P. giganteus contains bioactive compounds that mimic NGF and are responsible for neurite
stimulation. Hence, this mushroom may be developed as a nutraceutical for the mitigation of
neurodegenerative diseases.
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Neurodegenerative diseases are on the rise. The most
common form of neurodegenerative disease is Alzhei-
mer's disease, which causes thinking and memory to be-
come seriously impaired due to neuronal loss in brain
[1]. The second most common neurodegenerative syn-
drome, Parkinson's disease is characterised by the classic
symptoms of tremors, rigidity and gait impairment [2].
Medications to alleviate these neurodegenerative dis-
eases can only provide benefits for several years but are
not effective as the diseases progress [3]. Some un-
desired side effects associated with these drugs include
hallucinations, dyskinesia, nausea and constipation [2,3].
In this regard, complementary and alternative medicine
which is now gaining momentum may be a promising
way for prevention and protection against such neurode-
generative diseases [4].
Mushrooms are largely consumed not only in Asian
countries but across Western countries. Mushrooms are
of considerable interest because of their organoleptic
merit, medicinal properties and economic significance.
We have documented the effects of an edible mushroom
Hericium erinaceus (Bull.:Fr.) Pers. (also known as mon-
key’s head, lion’s mane, and yamabushitake) on neurite
outgrowth and peripheral nerve regeneration both
in vitro and in vivo [5-7]. More recently, the aqueous
extracts of Lignosus rhinoceros (Cooke) Ryvarden (tiger’s
milk mushroom) was reported to induce neurite out-
growth with or without the trigger of nerve growth fac-
tor (NGF) [8]. The cocktail of bioactive compounds
present in these mushroom extracts exhibits NGF-like
properties and play important roles in the growth, differ-
entiation and survival of neuronal cells [9-11].
Formerly known as Panus giganteus (Berk) Corner,
Pleurotus giganteus (Berk.) Karunarathna & K.D. Hyde is
a culinary mushroom that is gaining popularity for its
organoleptic properties and commercial prospects. In
fact, consumption of this used-to-be wild mushroom has
long been a tradition in the indigenous villages in Penin-
sular Malaysia [12]. A variety of P. giganteus from China
is now being cultivated in Malaysia and the common
commercial name in Malay language for P. giganteus is
“Seri Pagi” (morning glory). In China, P. giganteus is
widely referred as “Zhudugu” (swine’s stomach) [13]. It
is noteworthy to mention that the “Panus-Pleurotus-
Lentinus” complex has long existed and has resulted in
the confusion of nomenclature and taxonomy of these
three species. Briefly, Panus giganteus (Polyporaceae,
Polyporales) is characterised by its unbranched skeletal
hyphae that usually grow on buried woody substrates
[14]. While Pegler [15] has merged Panus as a subgenus
within Lentinus, Corner [14], has grouped the genus
Panus to species with skeletal hyphae and separated
those species with ligative hyphae in Lentinus. Hence,Lentinus giganteus is regarded as synonym for Panus
giganteus and Lentinus giganteus should be used if
recommendation of Pegler is ever adopted [13,16]. How-
ever, Karunarathna and colleagues have revisited this
issue and concluded that Panus/Lentinus giganteus
should be unified and positioned in Pleurotus as sup-
ported by molecular evidences [17].
Cell cultures derived from nervous system tissue have
proven to be powerful tools for elucidating cellular
mechanisms of nervous system function [18]. The effect
of chemicals, drugs, natural products or even growth
factors on neurite outgrowth can be quantified by enu-
merating the number of cells that bear neurites using
in vitro cell line model [19]. Neurite refers collectively to
“axons and dendrites extended by primary cells growing
in culture, or processes extended by neuronal cell lines,
which are neither definitive axons, nor dendrites”
[19,20]. Pheochromocytoma (PC12) cells, originated
from a rat adrenal medullary tumour (pheochromocy-
toma) have been widely employed as a model of neur-
onal differentiation and neurite outgrowth [21]. PC12
cells respond to NGF and when triggered, cease prolif-
eration, extend neurites, and become electrically excit-
able [22].
There is, however, minimal information on the medi-
cinal properties of P. giganteus. The aqueous and etha-
nolic extracts of P. giganteus have shown antioxidant,
genoprotection (unpublished data) and liver protection
properties [23]. To our knowledge, there are no reports
on the nutritional composition of P. giganteus and its
benefits on neurite outgrowth stimulation, if any. In
the present study, aqueous and ethanolic extracts of
P. giganteus fruiting bodies were investigated for their
effects in neurite outgrowth of rat pheochromocytoma
(PC12) cells. Prior to this, the cytotoxicity of the extracts
was determined by using [3-[4,5-dimethythiazol-2-yl]-
2,5-diphenyltetrazolium bromide] (MTT) assay. The hy-
pothesis that MEK/ERK and PI3K/Akt are required for
the neuronal differentiation and neurite outgrowth of
PC12 cells was also tested using specific inhibitors.
Methods
Materials and chemicals
The fruiting bodies of P. giganteus were obtained from
Nas Agro Farm, Sepang, Selangor, Malaysia. Rat pheo-
chromocytoma (PC-12) cell line was purchased from
American Type Culture Collection (ATCC; Rockville,
MD, USA; Catalogue Number: CRL-1721.1TM). [3-[4,5-
dimethythiazol-2-yl]-2,5-diphenyltetrazolium bromide]
(MTT), phosphate buffered saline (PBS), dimethyl sulf-
oxide (DMSO), F-12 K medium (Kaighn’s Modification
of Ham’s F-12 Medium), NGF-7 S from murine submax-
illary gland, MEK inhibitor (U0126, PD98059), and PI3K
inhibitor (LY294002) were obtained from Sigma Co. (St.
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serum (HS) were purchased from PAA Laboratories
(Cölbe, Germany).
Cultivation condition of mushrooms
Pleurotus giganteus (KUM61102) was maintained on po-
tato dextrose agar (PDA) at 4 - 10 °C and regularly sub-
cultured. The substrate formulation for the cultivation
of P. giganteus is similar to that for oyster mushroom
cultivation, i.e. 89 - 94% (w/w) rubber wood sawdust, 5 -
10% (w/w) rice bran and 1% (w/w) calcium carbonate.
Polypropylene bags are used for substrate bagging and
the moisture content in the substrate was kept at 60% -
65%. The temperature for mycelia growth, spawn run,
and fruiting body formation is 26 - 32 °C. Relative hu-
midity of 70% and 80 - 90% during mycelia growth and
fruiting; respectively, should be maintained. Direct illu-
mination should be avoided as it has been reported to
inhibit the fruiting body formation. A 20-day cycle after
complete colonization of the artificial log is needed for
each harvest and about four harvests (a total yield of
280 g) can be obtained from each bag of 900 g (Nas
Agro Farm, personal communication).
Cell culture
The PC12 cells (adherent variant, PC-12Adh) from
ATCC were maintained in F-12 K medium (Sigma) sup-
plemented with 2.5% (v/v) heat-inactivated fetal bovine
serum (PAA) and 15% (v/v) horse serum (PAA) with
final pH 6.8 - 7.2. All incubations were performed at
37 °C in a humidified environment of 5% CO2 and 95%
air. The cells were maintained in the logarithmic phase
of growth and were subcultured at 2–3 day intervals.
For storage, the cells were frozen at −70 °C liquid nitro-
gen in complete medium supplemented with 5% (v/v) di-
methyl sulfoxide (DMSO) (Sigma) as a cryoprotectant.
Extraction of P. giganteus fruiting bodies
The fresh fruiting bodies were sliced, weighed and
freeze-dried (Christ, Germany) for 1–2 days. The freeze-
dried fruiting bodies were then ground using a blender.
The resulting dried powder was weighed and kept in 4 -
8 °C. Aqueous extraction method was according to Eik
et al. [8]. Briefly, the freeze dried powder was soaked in
distilled water (1:20 ratio, w/v) and was left overnight at
room temperature and 200 rpm in a shaker. The mix-
ture was double boiled in water bath for 30 min and fil-
tered (Whatman Grade 4) after cooling. The resulting
aqueous extract was freeze-dried and kept at −40 °C
prior to use. For ethanol extraction, the freeze dried
powder was soaked in 95% ethanol at room temperature
for three days and the process was repeated three times.
The ethanol solvent was evaporated using a rotaryevaporator (Eyela N-1000, USA) to give a brownish vis-
cous extract.
Nutritional composition of freeze dried fruiting bodies
of P. giganteus
Fifty grams sample of P. giganteus fruiting bodies was
sent to Consolidated Laboratory (M) Sdn. Bhd. for nutri-
tional analysis.
Cell viability and cytotoxicity assay
Cell viability and proliferation was determined by MTT
assay [24]. Approximately 12,000 cells per well were
seeded on a 96-well plate and incubated at 37 °C over-
night in a humidified environment of 5% CO2 and 95%
air. Fresh medium were then replaced and the cells were
exposed to 0 to 1000 μg/ml of aqueous or ethanolic ex-
tract of P. giganteus for 48 hours. Subsequently, 20 μl of
sterilized MTT (5 mg/ml) in phosphate buffered saline
(PBS) buffer (pH 7.4) was spiked into each well and
incubated at 37 °C for 4 hours. The supernatant was
then carefully removed, and 200 μl of dimethyl sulfoxide
(DMSO) was added into each well to dissolve the MTT
formazan (blue colour) at the bottom of the wells. After
15 min, the absorbance at 540 nm with 690 nm as back-
ground absorbance was measured with an ELISA micro-
plate reader (Sunrise, Tecan, Austria). The complete
growth medium was the blank, and cells incubated in
medium only without mushroom extracts were denoted
as positive control.
Neurite outgrowth stimulation activity
Neurite outgrowth stimulation assay was according to
Eik et al. [8] with some modifications. The cells were
seeded in a 6-well plate at an initial density of 5,000 cells
per well in 2 ml complete growth medium with different
concentrations of aqueous and ethanolic mushroom
extracts. For freeze dried aqueous extract, a stock solu-
tion of 10 mg/ml was prepared freshly each time prior
to assay. The stock solution was then diluted five times
in sterile distilled water to final concentrations ranging
from 5–100 μg/ml (w/v). For ethanolic extract, 10 mg/
ml of stock solution in DMSO was prepared freshly. The
solution was also diluted five times with sterile distilled
water. In positive control experiments, cells were
induced to differentiate by the addition of 50 ng/ml (w/
v) NGF extracted from murine submaxillary gland
(Sigma). Cells in complete growth medium only served
as a negative control. All the cells were incubated for
five days at 37 °C, 95% air and 5% CO2 to observe any
neuronal differentiation activity.
Quantification of neurite bearing cells
A cell was scored positive if it bears a thin neurite exten-
sion that was double or more the length of the cell body
Table 1 The breakdown of nutritional content of
Pleurotus giganteus freeze-dried fruiting bodies
Test Parameter Result * Recommended daily
allowance (RDA)
Total Fat 3.7 65 g
• Saturated fat 0.97 -
• Monosaturated fat 1.97 -
• Polyunsaturated fat 0.77 -
• Trans fat N.D (<0.01 g/100 g) -
Energy in Kilo Calorie 364 kcal/100 g -
Protein 15.4 50 g
Cholesterol N.D (<0.001 mg/100 g) 300 mg
Carbohydrate 67.2 300 g
Dietary fibre 33.3 25 g
Sodium (as Na) 5.7 2400 mg
Calcium (as Ca) 5.78 1000 mg
Magnesium (as Mg) 67.64 0.4 g
Iron (as Fe) 1.85 18 mg
Zinc (as Zn) 2.68 15 mg
Phosphorus (as P) 526.45 700 mg
Potassium (as K) 1345.7 3500 mg
Copper (as Cu) 0.59 2.0 mg
Manganese (as Mn) 0.41 2.0 mg
Selenium (as Se) N.D (<0.02 mg/kg) 70 μg
* g or mg/100 g of freeze-dried fruiting bodies; test method was according to
AOAC (Association of Analytical Communities/Association of Official
Agricultural Chemist); ND: Not detectable.
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examined under an inverted microscope (Nikon Eclipse
TS100). The cells were photographed using a Nikon
DS-Fi1 camera and processed with a Nikon’s Imaging
Software, NIS-Elements D. The percentage of neurite-
bearing cells were quantified by scoring the number of
neurite-bearing cells over the total number of viable
cells in 10 microscopic fields with average of randomly
chosen 200 to 300 cells per well.
Treatment with specific inhibitors of signaling pathways
Stock solution (10 mM) of MEK inhibitor (U0126,
PD98059) and PI3K inhibitor (LY294002) were prepared
in DMSO and stored in −20 °C in the dark. Each inhibi-
tor i.e. 10 μM for U0126 [25], 10–50 μM of LY294002
[26]; and 40 μM for PD98059 [27] was then prepared by
diluting in medium just before use. PC12 cells were ei-
ther incubated with or without the treatment of inhibi-
tors for 1 hour. All the cells were then stimulated with
25 μg/ml of P. giganteus aqueous extract for three days
prior to scoring neurite bearing cells.
Statistical analysis
Results were expressed as the means ± standard devi-
ation (SD). Data comparison between groups was per-
formed using one-way analysis of variance (ANOVA).
P< 0.05 was considered to be significant between groups
by using Duncan's multiple range tests (DMRT).
Results
Nutritional composition of freeze dried fruiting bodies
of P. giganteus
The nutritional components of P. giganteus fruiting bod-
ies are shown in Table 1. Pleurotus giganteus contains
67.2 g/100 g of carbohydrate, 15.4 g/100 g of protein
and 33.3 g/100 g of dietary fibre. It is rich in minerals
like magnesium (67.64 mg/100 g) and potassium
(1345.7 mg/100 g).
The effects of aqueous and ethanolic extracts of
P. giganteus on PC12 cell viability
MTT assay was performed to determine the degree of
cytotoxicity of P. giganteus extracts in PC12 cell. The
cell viability and cell proliferation was denoted as 100%
for the positive control i.e. cells in complete growth
medium without mushroom extracts. It was shown that
the growth of PC12 cell decreased with the increasing
concentrations of the mushroom extracts. Figure 1a and
the negative region of Figure 1b and 1c indicates that
treatment with 10–200 μg/ml of aqueous extract and
10 μg/ml of ethanolic extract induced cell proliferation
significantly (p< 0.05) as compared to control after a
48 h incubation. Upon challenge with a threshold dosage
(500 μg/ml for aqueous extract and 200 μg/ml forethanolic extract), the number of viable cells decreased
significantly (p< 0.05) to 13.9% and 37.1%, respectively.
At a concentration of 1000 μg/ml, the different extracts
inhibited the cell proliferation to 75.65 ± 5.8% for aque-
ous extract, and 85.67 ± 5.3 for ethanolic extract. The
IC50 which is the concentration at which 50% of cell
growth inhibition occurs for aqueous extract and etha-
nolic extract were 806.39 ± 48 μg/ml and 309.46 ± 46 μg/
ml, respectively. Hence, ethanolic extract is more
toxic compared to aqueous extract, as the IC50 of etha-
nolic extract was 2.6-fold higher than that of aqueous
extract.
The effects of aqueous and ethanolic extracts of
P. giganteus on neurite outgrowth of PC12 cells
All concentrations of mushroom extracts tested were
non-cytotoxic to the cells, as determined by MTT assay.
Aqueous extract of P. giganteus induced neurite out-
growth of PC12 cells in both a time- and dose-
dependent manner (Figure 2a). On the second day,
the percentage of neurite-bearing cells increased signifi-
cantly (p< 0.05) to 18.8% after treatment with 25 μg/ml
of aqueous extract when compared to time-matched
negative control (9.5%). After stimulation with aqueous
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Figure 1 The effects of aqueous and ethanolic extracts of P. giganteus on PC12 cell viability. (a) Effect of aqueous extract and ethanolic
extract on the cell proliferation of PC12 cells. The mean absorbance obtained using medium with cells only was designated 100%. Results shown
represent the mean± SD; n= 3. *,¥ p< 0.05 for aqueous extract and ethanolic extract, respectively compared to the control 100%. (b) & (c): IC50
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not shown).
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http://www.biomedcentral.com/1472-6882/12/102extract, the percentage of neurite-bearing cells signifi-
cantly increased (p< 0.05) until the effect reached a plat-
eau after day 3. Therefore, day 3 was selected for further
studies as the neurite scoring for all concentrations were
the highest. Similarly, ethanolic extract induced neurite
outgrowth of PC12 cells in a time- and dose-dependent
manner and the number of neurite-bearing cells
remained constant after day 3, as shown in Figure 2(b).
Figure 2c and 2d give the percentage of neurite-
bearing cells for aqueous extract and ethanolic extract,
respectively, on day 3. As shown in Figure 2c, aqueous
extract at 25 μg/ml had a significant (p< 0.05) effect
(31.7 ± 1.1%) in stimulating neuronal differentiation
compared to NGF (28.3 ± 0.4%). On day 3, 15 μg/ml ofethanolic extract induced 33.3 ± 0.9% of neurite-bearing
cells (Figure 2d). There was no significant difference
(p> 0.05) in the percentage of neurite-bearing cells
at 25 μg/ml of aqueous extract and 15 μg/ml of
ethanolic extract. However, both the extracts per-
formed better than NGF (p< 0.05). It was obvious
for ethanolic extract, that 50 μg/ml, 75 μg/ml and
100 μg/ml did not significantly (p> 0.05) trigger
neuronal differentiation and neurite outgrowth of
PC12 as compared to aqueous extract for the same
concentrations. Figure 3 shows the morphology of
PC12 cells with neurites at day-3 of treatment with
50 ng/ml NGF (a), 25 μg/ml of aqueous extract (b),
and neither of them (c).
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Figure 2 The effects of aqueous and ethanolic extracts of P. giganteus on neurite outgrowth of PC12 cells. (a) & (b) Time- and
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Figure 3 Phase-contrast photographs of PC12 neurites at day 3. (a) Treatment with 50 ng/ml NGF (b) Treatment with 25 μg/ml of aqueous
extract, and (c) Negative control, treatment of nither of (a) and (b). Scale bar = 20 μm. Arrows indicate neurite extentions.
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extracts of P. giganteus
It was shown that neurite outgrowth induced by NGF
and aqueous extract of P. giganteus was markedly inhib-
ited (p< 0.05) by MEK inhibitors U0126 and PD98059
(Figure 4a and 4b). In fact, in PC12 cell treated with
aqueous extract combined with either 10 μM of U0126
or 40 μM of PD98059, the decrease in the number of
neuritic processes was significant (p< 0.05). On the con-
trary, an inhibitor of PI3K/Akt pathway, LY294002, did
not inhibit aqueous extract- and NGF-induced neurite
outgrowth at the concentration of 10 μM and 20 μM
(p> 0.05). LY294002 at the concentration of 30 μM
started to cause inhibition effects on PC12 in a
concentration-dependent manner. At 30 μM of
LY294002, the number of elongated PC12 cells with neur-
ites doubled the cell diameter decreased significantly, by
49.6% and 63.5%, for NGF- and aqueous extract-treated
cells; respectively (Figure 4c). At 50 μM, all the cells pre-
treated with the inhibitor showed no difference (p> 0.05)
to the negative controls, with differentiated cells bearing
neurites ranging only from 3.2 – 5.3%. From this result,
we proposed that aqueous extract induced neurite out-
growth on PC12 cells via the activation of ERK1/2 cascade
and PI3K/AKt pathways.
Discussion
There is a vast amount of nutritional studies of wild and
cultivated mushrooms across the world. However, rela-
tively little data exist in the literature on the nutrient
content of Pleurotus giganteus. Herein, it was intended
to compare only the highly appreciated and most culti-
vated culinary-medicinal mushrooms, for example the
Pleurotus genus and Agaricus genus. Generally, mush-
rooms have high (19 – 35%) protein contents [28]. In
Brazil, it was reported that the fruiting bodies of Pleuro-
tus ostreatus and Pleurotus sajor-caju presented protein
content ranging from 13.1% to 18.4%, depending on the
substrates used [29]. The present study showed that theprotein level of P. giganteus is 5.3-time lower than that
of Agaricus bisporus (white button mushroom) with
reference to a study from Portugal [30]. On the other
hand, the carbohydrate content in P. giganteus is 4-, 6-,
7.2-, 7.5-, 8-, 11-time higher than that of Lentinula
edodes, shiitake (17.12 g/100 g), Flammulina velutipes,
golden needle mushroom (10.57 g/100 g), Pleurotus
ostreatus, oyster mushroom (9.30 g/100 g), Pleurotus
eryngii, king oyster mushroom (8.95 g/100 g), Agaricus
bisporus white button mushroom (8.25 g/100 g) (30),
and Agaricus bisporus brown mushroom (5.98 g/100 g)
[31]. This suggested that carbohydrates (glucose, manni-
tol, trehalose, oligosaccharide groups, and reserved poly-
saccharide like glycogen) account for the prevailing
component of P. giganteus fruiting body. Reports related
to the nutritional evaluation of Pleurotus genus carried
out by other researchers from different regions (Japan,
India, Bangladesh, Turkey, Finland, and Italy) can be
retrieved from [32–37], respectively. Nevertheless, the
differences between the nutrient values may be attribu-
ted to the type of mushroom, strain of mushroom, envir-
onmental factors, and composition of growth media
[37].
MTT assay is by far the most convenient colorimetric
assay based on the metabolic activity of a viable cell
[24,38]. Basically, only viable cell has the mitochondrial
dehydrogenase system that can cleave the yellow MTT
tetrazolium salt and yield MTT formazan which is blue
in colour. Thus, the optical density of the amount of
solubilised MTT formazan is quantitatively correlated to
the percentage of cell viability. The present study
showed that cytotoxic effect of P. giganteus aqueous and
ethanolic extracts towards PC12 cells were concentra-
tion dependant. This is consistent with the finding by
Cheung et al. [39] whereby viability of PC12 cells was
dose-dependently decreased by increasing Ganoderma
lucidum extracts.
On-going studies show that the aqueous extract of P.
giganteus contains bioactive secondary metabolites like
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pounds are reported to have neutrophic NGF-like
properties and caused neurite outgrowth activity in
PC12 cells [40]. We have shown for the first time that
P. giganteus extract can stimulate neurite outgrowth
by using PC12 cell line model. It was shown that
25 μg/ml of aqueous extract and 15 μg/ml of ethanolic
extract induced the highest percentage of neurite out-
growth in PC12 cells at day 3. The number of neurite
bearing cells was significantly higher than that of NGF.
The mushroom extracts may contain bioactive com-
pounds either mimic NGF or trigger the production of
NGF, hence resulting in neurite outgrowth. Further, the
potassium level in P. giganteus was 1345.7 mg/100 g and
according to Kalac [41], potassium level in fruiting bodies
is between 20- and 40-fold higher than in the substrates
used for mushroom cultivation. In the study by Cohen-
Cory et al. [42], the cell number of Purkinje cells, the
major efferent neurons of the brain cerebellum increased
by 40% when treated with potassium. Besides, potassiumalone or potassium coupled with NGF markedly
increased the cell survival, cell differentiation and neurite
outgrowth. In this study, the potassium present in P.
giganteus extracts may be involved in the regulation of
the morphological differentiation of PC12 cells by acting
as a depolarising agent.
The present study extends recent findings that some
mushroom extracts can have neuritogenesis effects. Prior
studies by our group have shown that 0.2% (v/v) aqueous
extract of freeze dried fruiting bodies from Hericium eri-
naceus caused maximal stimulation of neurite outgrowth
(17.3% of neurite bearing cells and 88.2% increase com-
pared to control) in NG108-15 cell line after 24 hours of
incubation [5]. Besides, freeze drying was found to be
the best approach to preserve the bioactive compounds
in mushroom as compared to oven-dried method [43]. It
had been reported that PC12 cells responded well to
water extract of sclerotium of Lignosus rhinocerus
(Cooke) Ryvarden [8]. It was found that synergistic ef-
fect, i.e. 42.12% of neurite bearing PC12 cells was
Phan et al. BMC Complementary and Alternative Medicine 2012, 12:102 Page 9 of 11
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water extract combined with 30 ng/ml of NGF. Some
other medicinal mushrooms that induced neurite out-
growth included Grifola frondosa (Maitake) [10], Tricho-
loma sp [44], Termitomyces albuminosus [45,46],
Dictyophora indusiata [47], Tremella fuciformis [48], and
Ganoderma lucidium (Lingzhi) [39].
The involvement of the MAPK/ERKs signaling path-
way in neuronal differentiation by mushroom extracts
has been reported. Neuroprotective and neuritogenesis
effect of Ganoderma lucidium extracts on PC12 was sti-
pulated to be mediated via the MAPK/ERK signalling
pathway [39]. Besides, lysophosphatidylethanolamine
from Grifola frondosa induced activation of ERK1/2 of
PC12 cells thus stimulated neurite outgrowth and inhib-
ited serum withdrawal-induced apoptosis [10]. Neuro-
trophins like NGF are mostly mediated by the Trk
family of receptor tyrosine kinase, TrKA. However, dis-
crepancy did occur in the case of Ganoderma lucidium
extracts, whereby there was no direct involvement of
TrkA [39]. Similarly, α-Phenyl-N-tert-butylnitron was
also found to induce neurite outgrowth in PC12 inde-
pendent of TrkA [49]. It is thus predicted, based on the
ability of P. giganteus extract to stimulate neurite out-
growth of PC12 without NGF, that activation of TrKA
receptor tyrosine kinase may not be necessary. Accord-
ing to Sweatt [50], the mitogen-activated protein kinase
(MAP kinase, MAPK) cascade is a superfamily of signal-
ling cascade and is a vital regulator of cell division and
differentiation. Recently, MAPK was specified as the
extracellular signal-regulated kinase (ERK) comprising
ERK 1 and 2, or as ERK1/2. It has been demonstrated
that ERK-cascade was necessary and sufficient enough
for NGF-induced neuronal differentiation of PC12 cells.
In the present study, upon inhibition by MEK-selective
inhibitor U0126 and PD98059, the percentage of neurite
outgrowth decreased significantly. This suggested that
ERK1/2 phosphorylation was affected and this indirectly
implied that activation of ERK1/2 is necessary for P.
giganteus-mediated neuritogenesis. Inhibition of PI3K/
Akt signalling by LY294002 also negatively affected
neurite outgrowth of PC12. This finding suggested that
neurite outgrowth potentiated by P. giganteus in PC12
cells is also regulated by PI3K/Akt signaling pathway.
However, it was noted that PI3K/Akt inhibitor did not
markedly affect the activities of ERK [51], therefore
neurite extension of PC12 still could be observed at
lower concentrations of LY294002. According to Naidu
et al. [52], phospho-Akt and phospho-MAPK were
expressed during neurodevelopment and nerve regener-
ation following sciatic nerve crush on rats. Collectively,
these results demonstrated that P. giganteus-induced
neurite extension is regulated at least by part between
MEK/ERK and PI3K/Akt pathways. For the future work,confirmation by immunoblot analysis to detect the phos-
phorylation of TrKA, ERK, and Akt, is necessary.
Conclusions
To our knowledge, this is the first evidence on the
effects of Pleurotus giganteus aqueous and ethanol
extracts on neuronal differentiation and neurite out-
growth. The high potassium level in the fruiting bodies
and the presence of bioactive compounds (mainly triter-
penoids) could be responsible for the neuroactivity.
Work is in progress to determine and identity the bio-
active compound/s responsible for the activity. Our
results suggested that neurite outgrowth stimulated by
P. giganteus is mediated via the “cross-talk” between
MEK/ERKs and PI3K/Akt pathways. However, further
immunoblot analysis is required.
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Two strains of Pleurotus giganteus (commercial and wild) were tested for their ability to induce neurite outgrowth in rat
pheochromocytoma (PC12) andmouse neuroblastoma-2a (N2a) cells. Treatment with the mushroom extracts resulted in neuronal
differentiation and neuronal elongation, but not nerve growth factor (NGF) production. Linoleic acid (4.5–5.0%, w/w) which is
a major fatty acid present in the ethanol extract promoted NGF biosynthesis when augmented with low concentration of NGF
(5 ng/mL). The two strains of mushroom were found to be high in protein (154–192 g kg−1), total polysaccharides, phenolics, and
flavonoids as well as vitamins B1, B2, and B3. The total phenolics present in the mushroom extracts were positively correlated to
the antioxidant activity (free radical scavenging, ferric reducing power, and lipid peroxidation inhibition). To conclude, P. giganteus
could potentially be used in well-balanced diet and as a source of dietary antioxidant to promote neuronal health.
1. Introduction
Neurite outgrowth is a critical process in neuronal formation
and development. Malfunction of this event will lead to
demolition of synaptic connections and extended series of
neuronal dysfunctions like Alzheimer’s disease (AD) [1]. As
AD progresses, programmed apoptotic neuronal death is
triggered as a result of nerve growth factors (NGFs) depletion
and oxidative stress exerted by reactive oxygen species (ROS)
[2]. Therefore, strategies aimed at preserving and restoring
the neurite network might be beneficial in treating AD.
Dietary intake of antioxidants is also important to improve
the intrinsic antioxidant mechanisms (superoxide dismutase,
catalase, and glutathione peroxide) to avoid an environment
where prooxidant species overwhelm antioxidant species.
Functional food plays a significant role in preventing or
reducing severity of lifestyle diseases and improving physical
and mental well-being of consumers. Edible and medicinal
mushrooms are gaining recognition as preventative agents
for age-related diseases including neurodegenerative diseases
such as AD, Parkinson’s disease, and dementia [3]. At the
current stage, medications are prescribed for mild, moder-
ate, to severe Alzheimer’s disease to help delay or prevent
behavioral symptoms, but that, too, is only for a limited time.
Trials with NGF for Alzheimer’s disease had gained some
degree of success, but the high molecular weight of the NGF
protein seems to suggest that it could not cross the blood-
brain barrier [4]. Considering the limitation of the existing
preventive methods, intervention strategy using mushrooms
as functional food is of utmost importance. Edible andmedic-
inalmushrooms are packedwith awide array of bioactive and
nutritional components that could scavenge reactive oxygen
species (ROS) and exert neuroprotective effects and promote
neuritogenesis and neuroregeneration.
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There are ample studies available in the literature regard-
ing the chemical composition of different mushroom species
from all over the world. However, such information on
Pleurotus giganteus (Berk.) Karunarathna & K.D. Hyde, a
popular edible mushroom in China, Thailand, and Sri Lanka
is scanty. In Malaysia, the mushroom is also consumed as
a delicacy by the indigenous communities. Studies on P.
giganteus include domestication and cultivation [5], liver
protection [6], and anti-Candida activities [7]. It has been
shown that extracts of this mushroom exhibited neurite
outgrowth activity in rat pheochromocytoma (PC12) and
mouse neuroblastoma-2a (N2a) cells [8, 9]. In this study, the
neuritogenic effects of the commercial strain of P. giganteus
were compared to that of the wild domesticated strain. The
nutritional components including vitamins, fatty acids, and
amino acids as well as the phenolic, flavonoid contents, and
antioxidant activities were also evaluated and compared.
2. Materials and Methods
2.1. Mushroom Species. Fresh basidiocarps of P. giganteus
(commercial strain KLU-M 1227) were collected from Nas
Agro Farm andDong Foong Biotech.WildP. giganteus (KLU-
M 1228) was collected from Ayer Hitam Forest Reserve,
Puchong, Malaysia. The mushroom identity (molecular fin-
gerprinting) was authenticated by Dr. Yee-Shin Tan from
Mushroom Research Centre, University of Malaya. Voucher
specimens were deposited in the Herbarium of University
of Malaya. Domestication of the wild strain was carried out
as previously reported [8]. The substrate formulation for
basidiocarp formation of both commercial and domesticated
strains was similar and consisted of rubber wood sawdust,
rice bran, and calcium carbonate.
2.2. Chemicals. Gallic acid, rutin, 2,2-diphenyl-1-picrylhyd-
razyl (DPPH), L-ascorbic acid, ABTS [2,2󸀠-azino-bis-(3-
ethylbenzothiazoline-6-sulfonic acid) diammonium salt],
phosphate buffered saline (PBS), nerve growth factor (NGF),
and dimethyl sulfoxide (DMSO) were purchased from Sigma
(St. Louis, MO, USA). All other chemicals and solvents were
of analytical grade and purchased from Merck (Darmstadt,
Germany).
2.3. Proximate Analysis of Basidiocarps. The freeze-dried
powder of basidiocarps of P. giganteus was analyzed for
the nutritional components using the standard American
Oil Chemists’ Society (AOCS) procedures [10]. Total fat,
dietary fiber, and protein content were analyzed using AOAC
989.05, AOAC 985.25, and Kjeldahl method with boric acid
modification, respectively. Carbohydrates were calculated
using the formula carbohydrates (g) = 100 − (protein + fat +
ash). Energy was calculated using the formula energy (kcal) =
4 × (protein + carbohydrate) + 9 × (fat) [10].
2.4. Determination of Free Sugars, Minerals, Vitamins, Fatty
Acids, and Amino Acids. Free sugars and amino acids
were analyzed by high performance liquid chromatogra-
phy (HPLC). Minerals were determined using inductively
coupled plasma optical emission spectrometry ICP-OES
following the AOAC 985.01 and 922.02, as well as American
Association of Cereal Chemists (AACC 40–70) procedures.
Vitamin C was determined by the AOAC 967.21 method.
Preparation of methyl esters of long-chain fatty acids was
carried out based on AOCS Ce-2-66 test for further analysis
by gas chromatography (GC). Omega-3 and Omega-6 fatty
acids were analyzed using AOCS 1d-91 methods by capillary
gas-liquid chromatography (GLC).
2.5. Preparation of Mushroom Extracts. Crude aqueous and
ethanol extracts were prepared as previously described [8].
For aqueous extract, the freeze-dried basidiocarps powder
was soaked in distilled water (1 : 20, w/v) for 24 h at room
temperature and 200 rpm in a shaker. After double-boiling
in a water bath at 100∘C, the mixture was filtered (Whatman
No. 4). The filtrate was then freeze-dried and kept at −20∘C
prior to use. To obtain crude ethanol extract, the freeze-dried
powder was soaked in 95% (v/v) ethanol at room temperature
for three days.The solvent was then evaporated using a rotary
evaporator (Eyela N-1000, USA) and a brownish viscous
extract was obtained.
2.6. Determination of Total Polysaccharides. The total poly-
saccharide content of the aqueous and ethanol extracts was
determined using the phenol-sulphuric acid method with
d-glucose as a reference [11]. Briefly, 1mL of 5% phenol
was added to 1mL of sample solution, followed by 5mL
of concentrated H
2
SO
4
. The absorbance was measured after
10min at 497 nm.
2.7. Determination of Total Phenolic Contents (TPC) in Mush-
room Extracts. The total phenolic contents in the mushroom
extracts, expressed as gallic acid equivalents (GAEs), were
determined by the Folin-Ciocalteu method [12]. Fifty micro-
liters of sample was mixed with an equal volume of Folin-
Ciocalteu phenol reagent. After 3min, 100 𝜇L of Na
2
CO
3
(10%) was added to the mixture. The reaction was kept in
the dark for 90min, after which the absorbance was read
at 750 nm using a spectrophotometer. A calibration curve
was prepared with different concentrations of gallic acid (0–
100 𝜇g/mL) as standard. TPC was expressed as mg GAE/g of
extract.
2.8. Determination of Total Flavonoids in Mushroom Extracts.
Total flavonoids in the mushroom extract were estimated
by using the aluminum calorimetric method as previously
described [13]. Mushroom extract of 150 𝜇L was mixed
with an equal volume of AlCl
3
(2%). After 10min, the
absorbance of the supernatant was measured at 435 nm
by using an ELISA microplate reader (Sunrise, Austria).
The total flavonoid content of the mushroom extract was
expressed as rutin equivalents inmicrogram per gram extract
(mg RE/g extract).
2.9. Evaluation of Antioxidant Activity of Mushroom Extracts
2.9.1. DPPH Scavenging Activity Assay. The DPPH free
radical scavenging activity was determined as previously
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described [14]. Mushroom extracts of various concentra-
tions (5 𝜇L) were mixed with 195 𝜇L of DPPH reagent.
The reduction of the DPPH radical was determined by
measuring the absorption at 517 nm using a microtiterplate
reader (Tecan, Austria). The radical scavenging activity was
calculated using the following equation: % radical scavenging
activity = [(AbsBlank − AbsSample)/AbsBlank × 100%], where
AbsSample is the absorbance of the sample whereas AbsBlank
is the absorbance of the DPPH solution. The antioxidant
property of the extracts was expressed in terms of IC
50
value,
that is, the concentration to quench 50% of available DPPH
content. L-ascorbic acid (0–25 𝜇M) was used as standard and
butylated hydroxytoluene (BHT) was used as control.
2.9.2. FRAP (Ferric Reducing Antioxidant Power) Assay. The
reducing power of mushrooms extracts was determined
by the ferric reducing antioxidant potential (FRAP) assay
as previously described [15]. To prepare FRAP reagent,
2.5mL of FeCl
3
⋅6H
2
O solution (20mM in 40mM HCl)
was mixed with 2.5mL of 2,4,6-tri(2-pyridyl)-1,3,5-triazine
(TPTZ) (10mmol/L in 300mmol/L acetate buffer). Then,
10 𝜇L of mushroom extract was added to 300𝜇L of the FRAP
reagent after which the absorbance of the product of the
reaction between Fe2+ and TPTZ was measured at 593 nm
against a blank for each sample. Ferrous sulfate (FeSO
4
) of
concentrations 0–20mM was used as standard and BHT as
control. The FRAP value was expressed as 𝜇M of FeSO
4
equivalents/g mushroom.
2.9.3. Inhibition of Lipid Peroxidation. The assay was based
on the thiobarbituric acid reaction method [16]. Mush-
room extracts of different concentrations (0–20mg/mL)were
mixed with 0.5mL of egg yolk suspension and 0.5mL of
FeSO
4
. The mixture was incubated at 37∘C for an hour after
which 0.5mL of 20% trichloroacetic acid (TCA) and 1mL of
0.8% thiobarbituric acid (TBA) were added.Themixture was
then heated in boiling water for 15min and centrifuged at
3500 rpm for 20min. The absorbance of thiobarbituric acid
reactive substances (TBARS) present in the supernatant was
measured at 532 nm using a microtiterplate reader (Tecan,
Austria). Result was expressed as percentage inhibition of
lipid peroxidation at extract concentration of 10mg/mL. BHT
was used as a control in this assay.
2.10. Effect of Mushroom Extracts on Neuritogenesis
2.10.1. Cell Culture. Mouse neuroblastoma (N2a, CCL-131)
and rat pheochromocytoma cells (adherent variant, PC-
12Adh) were purchased from American Type Culture Col-
lection (ATCC; MD, USA). N2a cells were cultured in
Eagle’sminimumessentialmedium (MEM)with L-glutamine
(PAA) supplemented with 10% (v/v) heat-inactivated fetal
bovine serum (PAA), 100U/mL penicillin, and 100 𝜇g/mL
streptomycin. PC12 cells were maintained in F-12K medium
(Sigma) supplemented with 2.5% (v/v) heat-inactivated fetal
bovine serum (PAA) and 15% (v/v) horse serum (PAA). All
plates were incubated at 37∘C in a humidified environment of
5% CO
2
and 95% air. The cells were routinely passaged every
2-3 days.
2.10.2. Neurite Outgrowth Assay. N2a and PC12 cells were
seeded at a density of 5 × 103 cells in growth medium per well
in 24-well culture plates and incubated overnight.Mushroom
extracts (0–50 𝜇g/mL) were added to the cells and further
incubated for 3 days. For N2a cells, the cells were induced
to differentiate by replacing the growth medium with 5%
serummedium. Nerve growth factor (50 ng/mL) was used as
a positive control. After 3 days, the cells were then examined
using an inverted light microscope (Nikon Eclipse TS100).
Five random fields (200–300 cells/well) were examined in
each well. The number of axon-like processes, defined as
extensions longer than twice the cell body diameter, was
recorded. The mean number of neurite-bearing cells was
quantified by scoring the total number of neurite-bearing
cells over the total number of viable cells per field. At least
three independent experiments were conducted.
2.10.3. Measurement of NGF. TheNGF level in the PC12 cul-
ture medium was performed following the ChemiKine NGF
sandwich enzyme-linked immunosorbent assay (ELISA) kit
procedure (Merck Millipore, Germany). After treatment,
the culture medium was added into a microplate precoated
with anti-mouse NGF polyclonal antibody. Anti-mouse NGF
monoclonal antibody was then added. After 2 h, horseradish
peroxidase- (HRP-) conjugated donkey anti-mouse IgG poly-
clonal antibody was added to react with TMB substrate
solution. The color intensity of the sample was measured at
450 nm. The level of NGF was determined from a standard
curve plotted with known concentrations of NGF.
2.11. Statistical Analysis. Results were expressed as mean ±
standard deviation (SD) (𝑛 = 3). Analysis of variance
(ANOVA) followed by Duncan’s test was performed to test
for differences between means by employing Statgraphics
Plus (Statistical Graphics Corp., Herndon, VA). Correlations
between total polysaccharides, TPC, and antioxidant activ-
ities were determined by Pearson’s correlation coefficient (𝑟)
with the statistical program SPSS ver. 17.0 (SPSS Inc., Chicago,
IL, USA). The statistical significance of mean differences was
based on 𝑃 value of <0.05.
3. Results
3.1. Proximate Analysis of Mushroom Basidiocarps. The prox-
imate nutritional components of commercial P. giganteus
(KLU-M 1227) and domesticated wild P. giganteus (KLU-M
1228) are shown in Table 1. The commercial strain presented
a significantly higher (𝑃 < 0.05) carbohydrate, dietary fiber,
total fat, and monosaturated fat content compared to the
domesticated wild strain by 3.7, 2.7, 16, and 2.1%, respectively.
Both strains showed no difference in the gross energy
value and saturated fat contents. However, the wild strain
presented a significantly higher (𝑃 < 0.05) crude protein and
polyunsaturated fat content.
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Table 1: Chemical compositions, sugars, macro- and microele-
ments, and vitamins of commercial Pleurotus giganteus (KLU-M
1227) and wild P. giganteus (KLU-M 1228).
Parameter
Pleurotus giganteus
(commercial
strain)
Pleurotus
giganteus
(wild strain)
Carbohydrate (g kg−1) 672 ± 0.0a 647 ± 0.0b
Protein (g kg−1) 154 ± 0.0c 192 ± 0.0d
Energy (kcal kg−1) 3640 ± 0.00e 3640 ± 0.0e
Dietary fiber (g kg−1) 333.5 ± 0.07f 324.5 ± 0.07g
Total fat (g kg−1) 37.0 ± 0.0h 31.0 ± 0.0i
Saturated fat 9.7 ± 0.0j 9.5 ± 0.0j
Monosaturated fat 19.7 ± 0.0k 13.2 ± 0.0l
Polyunsaturated fat 7.8 ± 0.0m 8.3 ± 0.0n
Trans fat ND ND
Cholesterol (g kg−1) ND ND
Free sugars (g kg−1)
Fructose 7.2 ± 0.2a 10.6 ± 0.4b
Glucose 31.4 ± 0.7c 39.7 ± 0.2d
Sucrose ND ND
Lactose ND ND
Maltose ND ND
Maltotriose ND ND
Macroelements (g kg−1)
Potassium (as K) 13.46 ± 0.0a 11.71 ± 0.32b
Phosphorus (as P) 5.27 ± 0.39c 4.01 ± 0.04d
Magnesium (as Mg) 0.67 ± 0.00e 0.65 ± 0.00f
Calcium (as Ca) 0.058 ± 0.00g 0.087 ± 0.01h
Sodium (as Na) 0.058 ± 0.07g 0.047 ± 0.00i
Microelements (g kg−1)
Iron (as Fe) 0.019 ± 0.04a 0.014 ± 0.00b
Zinc (as Zn) 0.027 ± 0.01c 0.042 ± 0.00d
Manganese (as Mn) 0.041 ± 0.01e 0.043 ± 0.00e
Copper (as Cu) (mg kg−1) 0.60 ± 0.01f 0.228 ± 0.00f
Selenium (as Se) (mg kg−1) ND ND
Vitamins (g kg−1)
Vitamin B1 0.004 ± 0.01a 0.002 ± 0.00b
Vitamin B2 0.009 ± 0.00c 0.009 ± 0.00c
Vitamin B3 0.09 ± 0.10d 0.06 ± 0.02e
Vitamin C 0.003 ± 0.00a 0.001 ± 0.01f
Each value is expressed as mean ± SD (𝑛 = 3). In each row, the different
letters represent significant differences between samples (𝑃 < 0.05). ND: not
detectable.
3.2. Determination of Sugars, Minerals, and Vitamins. The
sugar composition of P. giganteus basidiocarps is given in
Table 1. Glucose and fructose were detected in the basidio-
carps of both strains. The glucose and fructose content of the
domesticated wild strain was approximately 47% and 26%
higher (𝑃 < 0.05) than that of the commercial strain. For
macroelements composition, potassium in the basidiocarps
of commercial strain (13.46 ± 0.0 g kg−1) was significantly
higher (𝑃 < 0.05) than the domesticated wild strain (11.71 ±
0.32 g kg−1). On the other hand, the calcium level in the
domesticated wild strain (0.087 ± 0.01 g kg−1) was higher
than that of the commercial strain (0.058 ± 0.0 g kg−1). The
vitamin profiles showed similarity, but the concentrations in
the two strains were different. Vitamin C (ascorbic acid) in
the wild strain was almost 3.9-fold higher than that of the
commercial strain (Table 1). Vitamin B3 (niacin) is the most
abundant vitamin found in this mushroom with 0.09 ± 0.10
and 0.06 ± 0.02 g kg−1 in the commercial and domesticated
wild strain, respectively.
3.3. Determination of Amino Acids and Fatty Acids. All
the essential amino acids (threonine, valine, methionine,
isoleucine, leucine, phenylalanine, tryptophan, lysine, histi-
dine, and arginine) were detected in this mushroom with
the exception of tryptophan (Table 2). Among the essential
amino acids, leucine (commercial strain 20.4 ± 0.10 g kg−1;
domesticated wild strain 19.4 ± 0.0 g kg−1) was found to be
the largest constituent, followed by phenylalanine and his-
tidine. The methionine, isoleucine, and valine were present
in small amounts ranging from 0.31 to 0.80% for both
the P. giganteus strains. In particular, P. giganteus had the
highest concentration of glycine, which is categorized as the
nonessential amino acid. Also, the wild strains exhibited
higher amount of glutamine, alanine, and asparagine as
compared to the commercial strains.
Table 3 presents the fatty acid profile of basidiocarps of
P. giganteus. Among the saturated fatty acids, palmitic acid
(C16:0) was predominant with 3.8 ± 0.01 and 3.3 ± 0.0 g kg−1
in the commercial strain and wild strain, respectively.
Amongst the polyunsaturated fatty acids, oleic acid was the
predominant fatty acid in this species. Oleic acid (C18: 1n9c)
in the commercial strain (10.3±0.06 g kg−1) was significantly
(𝑃 < 0.05) higher than that in thewild strain (8.9±0.0 g kg−1).
Linoleic acid was also present in significant quantities (4.5–
5.0 g kg−1) in P. giganteus. The medium chain fatty acid,
caprylic acid (C8:0), and the long chain fatty acid, stearic acid
(C18:0), were also present. Capric, undecanoic, palmitoleic,
and eicosadienoic acids were detected in trace amounts in P.
giganteus.
3.4. Determination of Total Polysaccharides, Total Phenolic,
and Total Flavonoids Compound. The total polysaccharides
of the commercial andwildP. giganteuswere comparable.The
aqueous extract had the highest amount of polysaccharides
as shown in Table 4. Notably, the total polysaccharides in
aqueous extract of the wild strains (17.91 ± 0.05%, w/w)
were significantly (𝑃 > 0.05) higher than those of the
commercial strain (14.93 ± 0.04%). On the other hand, the
total phenolic content in the ethanol extracts was higher.
The quantity of phenolics in the mushrooms extracts was in
descending order: commercial strain ethanol extract > wild
strain ethanol extract> commercial extract aqueous extract>
wild strain aqueous extract. There was also a significant
difference (𝑃 < 0.05) in the total flavonoids between the
basidiocarps of the commercial and wild strains. The wild
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Table 2: Amino acid content (g kg−1 protein) of Pleurotus giganteus
KLU-M 1227and KLU-M 1228.
Amino acids Pleurotus giganteus(commercial strain)
Pleurotus giganteus
(wild strain)
Asp 6.9 ± 0.0c 7.0 ± 0.0c
Glu 15.7 ± 0.0jk 17.2 ± 0.1l
Ser 11.1 ± 0.01e 11.0 ± 0.01e
His∗ 15.4 ± 0.04ji 15.1 ± 0.05j
Gly 29.0 ± 0.11p 29.5 ± 0.04p
Thr∗ 5.3 ± 0.01b 5.2 ± 0.00b
Arg∗ 11.4 ± 0.04ef 12.1 ± 0.00fg
Ala 11.1 ± 0.01e 13.5 ± 0.00h
Tyr 5.8 ± 0.06b 5.9 ± 0.00b
Cys ND ND
Val∗ 8.0 ± 0.01d 7.1 ± 0.00c
Met∗ 3.1 ± 0.01a 3.1 ± 0.00a
Phe∗ 16.4 ± 0.09kl 16.5 ± 0.00kl
Ile∗ 7.7 ± 0.02cd 7.3 ± 0.00cd
Leu∗ 20.4 ± 0.10n 19.4 ± 0.00m
Lys∗ 14.5 ± 0.01i 12.8 ± 0.00gh
Asn 15.2 ± 0.07ij 24.6 ± 0.00o
Gln ND ND
Nva ND ND
Trp∗ ND ND
Asp: aspartate; Glu: glutamate; Ser: serine; His: histidine; Gly: glycine; Thr:
threonine; Arg: arginine; Ala: alanine; Tyr: tyrosine; Cys: cystine; Val: valine;
Met:methionine; Phe: phenylalanine; Ile: isoleucine; Leu: leucine; Lys: lysine;
Asn: asparagine; Gln: glutamine;Nva: norvaline; Trp: tryptophan. Each value
is expressed as mean ± SD (𝑛 = 3). In each row, the different letters represent
significant differences between samples (𝑃 < 0.05). ND: not detected.
∗Essential amino acids.
Table 3: Fatty acids (g kg−1 dry weight) detected in the basidiocarps
of Pleurotus giganteus.
Fatty acid
Pleurotus giganteus
(commercial
strain)
Pleurotus
giganteus
(wild strain)
C8:0 Caprylic 1.3 ± 0.0a 1.1 ± 0.0ab
C10:0 Capric 0.4 ± 0.0c 0.4 ± 0.0c
C11:0 Undecanoic 0.8 ± 0.0b 0.8 ± 0.0b
C16:0 Palmitic 3.8 ± 0.0d 3.3 ± 0.0e
C16:1 Palmitoleic 0.1 ± 0.0c 0.1 ± 0.0c
C18:0 Strearic 1.1 ± 0.03ab 0.8 ± 0.0b
C18:1n9c Oleic∗∗∗ 10.3 ± 0.06g 8.9 ± 0.0h
C18:2n6c Linoleic∗∗ 5.0 ± 0.01f 4.5 ± 0.0f
C20:2 Eicosadienoic∗∗ 0.3 ± 0.01c 0.3 ± 0.0c
C22:0 Beheric 0.1 ± 0.0c 0.1 ± 0.0c
C24:0 Lignoceric 0.4 ± 0.01c 0.4 ± 0.0c
∗∗Omega-6 PUFAs; ∗∗∗Omega-9 PUFAs. Each value is expressed asmean±
SD (𝑛 = 3). In each row, the different letters represent significant differences
between samples (𝑃 < 0.05).
P. giganteus had approximately 2.09% higher flavonoids than
the commercial strains.
3.5. Evaluation of Antioxidant Activity of Mushroom Extracts
3.5.1. DPPH Scavenging Activity Assay. The scavenging effect
of the mushroom extracts on DPPH radicals increased with
sample concentration, depending on the extraction solvent
and strain type. In general, the ethanol extracts showed
higher scavenging activity, hence lower IC
50
(mg/mL) when
compared to the aqueous extracts (Table 5). The scavenging
activity obtained in descending order was wild strain ethanol
extract > commercial strain ethanol extract > wild strain
aqueous extract > commercial strain aqueous extract.
3.5.2. FRAP (Ferric Reducing Antioxidant Power) Assay.
In the ferric reducing power assay, the reducers present
in the mushroom extracts lead to the reduction of the
Fe3+/ferricyanide complex to the ferrous form. The reducing
capacity of the mushroom extract serves as an index of
antioxidant activity. The reducing ability of the different
extracts was in the range of 1.17–3.88 𝜇M FeSO
4
⋅7H
2
O/g
mushroom (Table 5). The antioxidant activity obtained in
descending order was commercial strain ethanol extract ≥
wild strain ethanol extract ≥ commercial strain aqueous
extract ≥ commercial strain aqueous extract.
3.5.3. Inhibition of Lipid Peroxidation. The study of lipid per-
oxidation (LPO) inhibition is based on the measurement of
malondialdehyde (MDA) generated by the polyunsaturated
fatty acid peroxides upon decomposition. As a result of LPO,
destruction of cellular components occurs and brings about
oxidative stress in biological systems. As shown in Table 5,
there was no significant difference (𝑃 > 0.05) in terms of
lipid peroxidation inhibition between the commercial and
domesticated wild mushroom extracts. However, the ethanol
extracts of both the strains showed significantly higher (𝑃 <
0.05) lipid peroxidation inhibitory ability (49.58–49.80%)
when compared to the aqueous extracts (44.41–44.61%).
Therefore, the means of extractions instead of mushroom
strains played a more prevailing role in lipid peroxidation
inhibition.
3.6. Correlation between Total Polysaccharides, TPC, and
Antioxidant Parameters. The TPC in the mushroom extract
was positively correlated to the DPPH scavenging capacity
(𝑟 = +.827) and FRAP reducing power (𝑟 = +.820).
This indicated that the antioxidant effects increased with
increasing concentrations of the total phenolics present in the
mushroom extracts. However, a weak correlation was found
between the lipid peroxidation inhibition activity and the
TPC (𝑟 = +.321). Nevertheless, the DPPH scavenging capac-
ity, FRAP reducing power, and lipid peroxidation inhibition
showed a strong positive correlation (𝑟 = +.806 to +.820)
between each antioxidant activity.
3.7. Neurite Outgrowth Assay. The mean value of neurite-
bearing cells in NGF treated cells (positive control) was
22.67 ± 6.67% as shown in Figure 1(a). The ethanol extracts
of the commercial and wild P. giganteus (20𝜇g/mL) caused
a significant (𝑃 < 0.05) increase in neurite-bearing cells
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Table 4: Total polysaccharides, phenolics, and flavonoids present in the crude aqueous and ethanol extracts of basidiocarps of Pleurotus
giganteus.
Pleurotus giganteus (commercial strain) Pleurotus giganteus (wild strain)
Aqueous Ethanol Aqueous Ethanol
Extraction yield (%, w/w) 15.60 ± 2.20a 12.00 ± 1.00b 13.77 ± 1.68ab 6.67 ± 1.06c
Total polysaccharides (%, w/w) 14.93 ± 0.04a 11.31 ± 0.16b 17.91 ± 0.05c 13.72 ± 0.04d
Total phenolic content (mg GAE/g) 12.14 ± 1.89a 24.08 ± 1.04b 9.58 ± 0.18c 21.61 ± 1.47d
Total flavonoids (mg RE/g) ND 2.94 ± 0.00a ND 6.14 ± 0.01b
In each row, the different letters represent significant differences between samples (𝑃 < 0.05). ND = not detected.
Table 5: Antioxidant activities of the aqueous and ethanol extracts from the commercial strain of Pleurotus giganteus (KLU-M 1227) and the
wild strain (KLU-M 1228).
Antioxidant properties Test method Positive control (BHT)
Pleurotus giganteus Pleurotus giganteus
(commercial strain) (wild strain)
Aqueous Ethanol Aqueous Ethanol
Free radical scavenging DPPH (IC50; mg/mL) 0.09 ± 0.01 21.46 ± 6.95
a 11.28 ± 3.54bc 16.18 ± 1.76ab 8.10 ± 2.15c
Reducing power FRAP (𝜇M FeSO4⋅7H2O/ g) 780.29 ± 13.4 2.26 ± 0.29
ab 2.99 ± 0.14b 2.04 ± 0.32a 2.69 ± 0.71b
Lipid peroxidation
inhibition
Inhibition of lipid peroxidation
at extract concentration of
10mg/mL (%)
79.07 ± 2.25 44.41 ± 1.00a 49.58 ± 1.87b 44.61 ± 1.42a 49.80 ± 3.27b
In each row, the different letters represent significant differences between samples (P < 0.05).
by 3.98- and 4-fold, respectively, when compared to the
control cells with medium only. Additionally, in order to
verify the neuritogenic activity of these mushroom extracts,
PC12 cells, which only extend neurite upon NGF activation,
were employed. Incubation of PC12 with 20𝜇g/mL of ethanol
extracts resulted in a significant increase (𝑃 < 0.05) in
neurite-bearing cells compared to cells treated with NGF
alone. Phase-contrast micrographs of neurite-bearing cells
were shown in Figure 1(b). The two most abundant fatty
acids in the investigated extract were oleic acid and linoleic
acid (Table 3).Therefore, the neuronal cells were treated with
linoleic acid and oleic acid and the neurite outgrowth activity
was examined. Linoleic acid enhanced the neuritogenic
activity of PC12 and N2a cells significantly (𝑃 < 0.05) but
not oleic acid (Figure 1(a)).
3.8. NGF Measurement. We measured the level of NGF in
the culture medium after PC12 cells were cultivated in the
presence of P. giganteus extracts and linoleic and oleic acids
for 3 days. Linoleic acid significantly (𝑃 < 0.05) augmented
NGF secretion by 1.4 times (Figure 2). On the other hand,
oleic acid had a lower potency in promoting NGF secretion
(255 pg/mL), as compared to linoleic acid (323 pg/mL). In
contrast to the fatty acids, the extracts had a weak stimulatory
effect on NGF secretion.
4. Discussion
The nutritional components found in the present work are
in accordance with the literature. A study in Italy showed
that the protein content in Pleurotus ostreatus (grey oyster
mushroom) was 1.61 ± 0.02 g/100 g, which is lower than
the protein content of P. giganteus in this study [17]. Pleu-
rotus giganteus also showed a higher protein content when
compared to Pleurotus sajor-caju (13.0–18.4 g/100 g) [18]. The
protein content of mushrooms is dependent on the strain,
substrate chemical composition, pileus size, and cultivation
time [19, 20]. In this study, rice bran supplementation may
have increased the soluble protein content present in both
strains as the protein content in rice bran is about 10–15% of
the total weight of the mushroom growth substrate [21].
Pleurotus ostreatus was composed mainly of glucose
(14.29 g kg−1) and mannose (10.55 g kg−1) [22]. While fruc-
tose was not detected in P. ostreatus, 27.81 g kg−1 of glucose
was detected in P. eryngii with trace amounts of ribose
and xylose. Pleurotus spp. in particular are rich in calcium,
potassium, magnesium, iron, and phosphorus [23]. Pleurotus
sajor-caju, P. platypus, and P. citrinopileatus were reported
to contain 16.3 ± 0.22, 11.2 ± 0.3, and 10.3 ± 0.2 g kg−1
of potassium, respectively. The concentrations of vitamin
B3 in mushrooms were highly species dependent and they
vary from 34 to 109mg/100 g dry weight for P. ostreatus
[24]. Mushrooms contain higher vitamin B2 (riboflavin) as
compared to vegetables. Some varieties of Agaricus bisporus
(white buttonmushroom) have also been reported to contain
vitamin B2 levels as high as those found in eggs and cheese
[25]. In our study, vitamin B1 (thiamin) was higher in the
commercial strain by 1.9-fold, while vitamin B2 level was
not significantly different when compared to that of the wild
strain.
The free amino acids in P. giganteus were comparable
with reported literature values. Tanzanian wild mushrooms
Lactarius sp. (milky cap), Boletus pruinatus (Matt Bolete
mushroom), and Boletinus cavipes were reported to have
leucine as high as 15.9%, 10.6%, and 8.40%, respectively
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Figure 1: (a) Neurite-bearing cells (%) after 3-day incubation with
NGF, mushroom extracts, linoleic acid, and oleic acid. AE: aqueous
extract; EE: ethanol extract. Data are expressed as mean ± SD of
three experiments. Different letters represent significant differences
between samples (𝑃 < 0.05). (b) Phase-contrast photomicrographs
showing the effects of NGF, ethanol extract, and linoleic acid on
the morphology of PC12 and differentiating N2a cells after 3 days.
Untreated cells serve as control and only contained 5% FBS as
vehicle. Arrows indicate neurite extension and scale bar corresponds
to 20 𝜇m.
[26]. The fresh P. ostreatus was found to have 2.74, 1.76, and
1.43 g kg−1 of glutamine, asparagine, and arginine, respec-
tively [27]. Similar to our findings, other edible mushrooms
also contained high levels of oleic acid (% total fatty acid
methyl esters): Auricularia polytricha (27.1), Lentinus sajor-
caju (23.5), Lentinus squarrosulus (5.8), Pleurotus djamor
(28.8), P. sajor-caju (16.4), and Russula brevipes (39.2) [28].
The presence of caprylic and capric acids in mushrooms
is rare. Calocybe gambosa (St. George’s mushroom) and
Clitocybe odora (Aniseed funnel mushroom) were reported
to have 0.25 ± 0.02 and 0.03 ± 0.00% of caprylic acid, respec-
tively, while Coprinus comatus (shaggy mane mushroom)
registered 0.09 ± 0.00% of capric acid [29].
Extraction with boiling water is used to obtain extracts
with high molecular weight compounds, such as polysac-
charides which play an important medicinal role in mush-
rooms [30]. Low molecular weight compounds, such as
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Figure 2: The effects of mushroom aqueous and ethanol extracts
on the stimulation of NGF secretion by neurite-bearing PC12 cells
in the presence or absence of NGF. NGF (50 ng/mL) was used as
the positive control. Values are mean ± SD from three indepen-
dent experiments. Different letters represent significant differences
between samples (𝑃 < 0.05). ∗𝑃 < 0.05 represents a significant
difference from the control, that is, 50 ng/mL of NGF.
phenolic compounds, were usually from ethanol extraction
[29]. Although flavonoid was not detected in P. sajor-caju
[31], its concentration ranging from 0.24 to 0.32mg/g was
reported in P. ostreatus [32]. Flavonoids were also present in
other mushroom species like Clitocybe gibba (3.56mg chate-
quin/g extract) and Boletus armeniacus (8.59mg chatequin/g
extract) [33]. The rubber wood sawdust which is rich in
lignin could have been depolymerized by the lignocellulosic
enzymes of mushrooms into phenolic units and further
dimerized or polymerized, creating flavonoids [34].
DPPH radical scavenging effects of the mycelia extracts
of Pleurotus spp. (P. citrinopileatus, P. djamor, P. eryngii, P.
flabellatus, P. florida, P. ostreatus, and P. sajor-caju) have
been reported [32, 35]. The methanol and hot water extracts
(10mg/mL) of P. eous were found to scavenge DPPH radical
by 85.19% and 70.21%, respectively [36]. The higher DPPH
scavenging ability of ethanol extracts might be due to more
hydrogen-donating components including phenolic com-
pounds extracted from the mushroom. The higher phenolic
content of ethanol extracts might account for the better
results found in reducing power as compared to the aqueous
extract [37].When comparing the FRAP values of P. giganteus
with P. sajor-caju, FRAP values of aqueous extract of P.
giganteus were lower than those of P. sajor-caju (35.06 ±
0.86𝜇M FeSO
4
⋅7H
2
O/g mushroom) [31]. The higher pheno-
lic content in the ethanol extractsmight contribute to a higher
inhibitory effect on lipid peroxidation. Pleurotus florida was
reported to display 57%of lipid peroxidation inhibition,while
P. flabellatus, P. cystidiosus, P. eryngii, and P. sajor-caju showed
50%, 49.8%, 48%, and 43% of lipid peroxidation inhibition,
respectively [38]. Meanwhile, P. ostreatus at a concentration
of 10mg/mL inhibited LPO activity in rat liver homogenate
by 56.20% [39]. In accordance with the present results,
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Dubost et al. [34] had demonstrated a positive correlation
between the TPC in themushroom extracts ofP. ostreatus and
P. eryngii and the antioxidant capacity.
It has been reported that tiger’s milk mushroom, Lignosus
rhinocerotis, demonstrated neuritogenic effects on PC12 cells
[40]. The aqueous extract of Ganoderma neo-japonicum
(50𝜇g/mL) was found to trigger a maximal stimulation of
PC12 neurite outgrowthwith 14.22± 0.43%of neurite-bearing
cells [41]. Extension of neurites from neuronal cell body is
an important step in neuronal development and requires the
generation of additional plasmamembrane [42]. Polyunsatu-
rated fatty acids like linoleic, linolenic, docosahexanoic, and
arachidonic acids promoted basal and nerve growth factor-
(NGF-) induced neurite extension of the PC12.This suggested
that linoleic acid which was present in abundance in the
extracts of P. giganteusmay play a key role in neuritogenesis.
In contrast, studies showed that monounsaturated fatty acids
and saturated long-chain fatty acids like oleic, stearic, and
palmitic acids caused little or no effects in neurite outgrowth
[43]. Studies have shown that cyathane diterpenes from the
mushroom Sarcodon cyrneus, namely, cyrneines A, B, C, and
D, and glaucopine C increased the NGF gene expression
in 1321N1 astrocytoma cells [44]. Hericenones C, D, and
E isolated from the basidiocarps of Hericium erinaceus
exhibited stimulating activity for the biosynthesis of NGF in
vitro. In the presence of hericenones C, D, and E at 33 𝜇g/mL,
mouse astroglial cells secreted 10.8 ± 0.8, 23.5 ± 1.0, 13.9 ±
2.1, and 45.1 ± 1.1 pg/mL of NGF into the culture medium,
respectively [45].
Long-chain polyunsaturated fatty acids (LCPUFA) are
essential nutrients in the development and functioning of
the brain and central nervous system. The most abundant
LCPUFA in the brain are docosahexaenoic acid (DHA)which
is mainly derived from fish and arachidonic acid (ARA)
from meat and eggs [46]. The desaturation and elongation
of linoleic acids and alpha-linolenic acids to ARA and
DHA, respectively, are very crucial for the infant’s brain
development. Since the percentage of ARA decreases in the
brain during prenatal development, the balance in the dietary
ratio of linoleic acid is very crucial to the brain development
in preterm infant [47]. Apart from that, many studies have
demonstrated the importance of LCPUFA as potent neuro-
protectant. Linoleic acid was found to protect mouse cortical
neurons against glutamate excitotoxicity [48]. Linoleic acid
and its derivatives also prevented sodium nitroprusside-
induced cell death of cultured rat cerebral cortical neurons
[49]. However, to date, limited information is available on
the role of polyunsaturated fatty acid as a stimulator of NGF
synthesis in neuronal cells.
5. Conclusion
In conclusion, we report for the first time the chemical
compositions of the commercial and domesticated wild
strains of P. giganteus. The extracts of both the strains
showed distinctive antioxidant activities due to the differen-
tial distributions of total phenolics and flavonoids. Aqueous
extracts did not contain flavonoids and had a lower phenolic
content, hence explaining its lower antioxidative capacity.
Our study demonstrates that the ethanol extract and itsmajor
constituent, linoleic acid, induced neurite outgrowth and
increased NGF biosynthesis. These findings provide support
for the possible role of P. giganteus as a functional food to
maintain neuronal differentiation and neuritogenesis, as well
as a healthy NGF supply in central and peripheral nervous
system.
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